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The complement system 
The complement system is part of the humoral innate immune system and consists of 
several plasma and cell surface-associated proteins (Figure 1). It can be activated via three 
distinct pathways, the classical, lectin and alternative pathway (AP). The classical pathway is 
initiated by cell surface- or immune complex-associated antibodies, whereas the lectin 
pathway is induced by pathogen-associated carbohydrates, which are recognized by lectins 
or ficolins. The AP in turn activates indistinctively on invading pathogens as well as host 
tissues (1). AP activation is initiated by complement component C3, which undergoes a 
spontaneous structural transition to form C3(H2O). C3(H2O) then associates with 
complement factor B, enabling factor B cleavage into Bb and Ba fragments by complement 
factor D, resulting in a fluid-phase C3 convertase complex (C3(H2O)Bb) (2). C3 convertase 
cleaves C3 to yield C3b, which structurally resembles C3(H2O), but can attach covalently to 
surfaces of surrounding cells and tissues (3), where it associates with factor B to form 
additional C3 convertases and locally amplify complement activation. All pathways 
ultimately result in the assembly of a C5 convertase complex (C3bBbC3b for AP activation), 
which cleaves C5. The resulting C5b fragment then initiates formation of a pore consisting of 
complement components C5b-9, which lyses affected cells (4). Additionally, inflammatory 
cell-attracting peptide fragments called anaphylatoxins C3a and C5a are released from C3 
and C5 during activation (5). The feed-forward loop of C3 activation, which also plays an 
essential role in the amplification of the classical and lectin pathway, needs to be tightly 
controlled on host tissues to prevent excessive complement activation and tissue damage 
(6). 
 
Regulation of complement activation by complement factor H 
Host cells regulate the C3 feed-forward loop by recruiting the plasma protein complement 
factor H (FH) to the cell surface (Figure 2), where it binds to C3b and dissociates the C3 
convertase complex (decay acceleration) (7). Additionally, FH acts as a cofactor for the serine 
protease complement factor I (FI; cofactor activity), which cleaves C3b into inactive iC3b, 
preventing further C3 convertase assembly (8). Properdin, the only positive regulator of the 
C3 feed-forward loop, binds to and stabilizes C3 convertases (9), counteracting complement 
inhibition by FH. Inactivation of C3b by FH and FI also contributes to the immunologically 
silent clearance of apoptotic cell debris, which is recognized by phagocytes through 
complement receptors specific for C3b degradation products (10, 11). Next to FH-mediated 
complement regulation, host cells are protected from excessive complement activation 
through the expression of membrane-associated complement inhibitors, including 
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membrane cofactor protein (CD46) (12) and decay-accelerating factor (CD55) (13), which 
share the cofactor and decay-accelerating activity with FH. 
 
 
Figure 1 – Schematic overview of complement activation. Three distinct pathways activate the complement 
system, either in response to antibodies (Complement component C1), pathogen-associated carbohydrates 
(lectins including mannose-binding lectin (MBL)) or by spontaneous conversion of C3 to C3(H2O). All pathways 
culminate in the proteolytic cleavage of C3 to C3b, which covalently attaches to cells, including cell surface 
carbohydrate layers (Glycocalyx), and tissues and recruits factor B. Factor B is cleaved by factor D to form a C3 
convertase complex (C3bBb), which catalyses further conversion of C3 to C3b. Ultimately, complement 
activation results in assembly of a C5 convertase complex, which cleaves C5 into C5b, triggering the formation 
of a lytic pore by complement components C5b-9. Both C3 and C5 cleavage releases pro-inflammatory peptides 
C3a and C5a. 
 
FH consists of twenty homologous domains with distinct functions called complement 
control protein (CCP) domains (also named short complement regulator or short consensus 
repeat (SCR) domains) (Figure 3) (14). The complement-regulating activity is localized to the 
four N-terminal domains CCP1-4 (15), which together with the two C-terminal domains 
CCP19-20 bind to C3b (16, 17). FH differentiates between host cells and pathogens by 
binding to glycan ligands on host tissues, including sialic acid and the glycosaminoglycan 
heparan sulfate (HS) with CCP20 (17–19). A second HS binding site has been described in 
CCP7 (17, 20). Interactions between FH and several other ligands involving CCP7 and CCP19-
20 have been described, including von Willebrand factor (21), C-reactive protein (22) and 
malondialdehyde epitopes (23). Certain pathogens, e.g. Streptococcus pneumoniae or 
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Neisseria gonorrhoeae, recruit FH using bacterial proteins homologous to endogenous FH 
ligands as well as sialic acid to prevent complement activation and avoid detection by the 
immune system (24).  
 
 
Figure 2 - Complement regulation by the factor H protein family. Complement factor H (FH) specifically 
inhibits complement activation on host tissues by recognizing carbohydrate ligands including heparan sulfate 
(HS) in the host cell glycocalyx. FH binds to C3b and dissociates Bb, destabilizing C3 convertases, and acts as 
cofactor for factor I, which cleaves C3b into inactive iC3b. Five factor H-related proteins (FHRs) compete with 
FH for C3b and carbohydrate ligands, counteracting the inhibitory activity of FH. While FHR deregulation on 
pathogen surfaces is beneficial, it can also occur on host cells and tissues, leading to complement-mediated 
diseases. 
 
The FH protein family 
Several structurally related plasma proteins constitute the FH protein family and participate 
in complement regulation (25). Factor H-like protein 1 (FHL-1), an alternative splice variant 
of FH, contains the seven most N-terminal CCP domains, i.e. the complement-regulating 
CCP1-4 and the N-terminal HS binding site in CCP7, and inhibits complement activation in 
the fluid-phase and on host tissues (26, 27). In contrast, five factor H-related proteins (FHR1-
5) have been identified which lack the regulatory CCP domains, but contain domains with 
high homology to CCP7 and CCP19-20 of FH (Figure 3). Accordingly, FHR proteins bind to 
C3b, and certain FHR proteins, such as FHR1 and FHR5, are able to compete with FH for 
binding to C3b, leading to complement deregulation (28, 29). Competition between FHR 
proteins and FH for C3b and other ligands on pathogen surfaces can prevent the pathogen 
from evading complement activation (30). Furthermore, FHR1, FHR3 and FHR5 have been 
described to bind to heparin (31–33), a model ligand for the glycosaminoglycan HS, 
suggesting that competition between FH and FHR proteins could also take place in the 
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context of host tissues. Aside from their ability to deregulate complement activation, some 
FHR proteins have also been described to directly inhibit complement activation in vitro. 
However, the observed inhibition was generally weak compared to FH and might occur in 
vivo only under specific conditions (29). Therefore, FHR proteins have been proposed to fine-
tune FH-mediated complement regulation on healthy and pathologically altered host tissues 
as well as pathogen surfaces (30). 
 
 
Figure 3 – The factor H protein family. Factor H (FH) consists of 20 homologous complement control protein 
(CCP) domains. CCP1-4 bind to C3b and inhibit complement activation, while CCP19-20 provide an additional 
binding site for C3b (bars). CCP7 and CCP20 interact with carbohydrate ligands on host tissues including 
heparan sulfate (orange). An alternative splice variant of FH, called factor H-like 1 (FHL1), has been described, 
which consists of the seven N-terminal CCPs. The FH protein family furthermore contains five factor H-related 
(FHR) proteins of 4-9 CCPs with high homology to HS and C3b binding domains in FH (FHR4 is expressed as two 
splice variants FHR4A and FHR4B containing nine and five CCPs, respectively). Numbers above CCP domains 
express the percentage identity with the corresponding domains in FH. 
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Heparan sulfate 
HS is particularly important for host-pathogen discrimination by FH (34), since it is expressed 
on all host cells, but is absent on invading pathogens. It belongs to the family of sulfated 
glycosaminoglycans, i.e. linear polysaccharides which are expressed in extracellular matrices 
as well as the glycocalyx, a cell surface carbohydrate layer which is particularly prominent on 
endothelial cells. The glycocalyx consists of core protein-linked glycosaminoglycans including 
HS, chondroitin sulfate and dermatan sulfate, and the soluble and non-sulfated hyaluronan. 
Glycoproteins with smaller, branched oligosaccharide chains including sialic acid contribute 
to the glycocalyx as well (35). While HS in the endothelial glycocalyx has many different 
functions (35), recruiting FH is highly important for protecting blood vessels from 
complement activation, as endothelial cells are continuously subjected to spontaneous 
activation of the alternative pathway in plasma (36). HS is synthesized as a linear 
polysaccharide from up to 200 repeating N-acetylglucosamine-glucuronic acid disaccharides, 
which are then extensively modified by N- and O-sulfation and C5 epimerization of 
glucuronic acid to iduronic acid (Figure 4) (37, 38). Depending on the sequence of structural 
modifications along the carbohydrate backbone, HS can act as ligand for a variety of proteins 
(39, 40), including growth factors, cytokines, chemokines, but importantly also complement 
regulators including FH, FHL-1, specific FHR proteins and properdin (41). The interaction 
between FH and HS contributes to complement regulation on host tissues, and is especially 
relevant in the context of extracellular matrices, which lack cell membrane-associated 
complement inhibitors (42). 
 
 
Figure 4 – Structural features of heparan sulfate. Heparan sulfate (HS) is synthesized as a linear polysaccharide 
from up to 200 repeating N-acetylglucosamine-glucuronic acid disaccharides. The carbohydrate backbone can 
be modified extensively through sulfation (R: H or sulfate; R’: Acetyl, H or sulfate), as well as C5 epimerization 
of glucuronic acid to iduronic acid. HS plays an important role in the regulation various biological processes, as 
the sequence of modifications along an HS chain generates binding sites for many different proteins, including 
members of the factor H protein family. 
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FH-associated diseases 
Failure to properly regulate complement activation on host tissues can result in disease. The 
kidneys and eyes appear to be particularly susceptible to AP-mediated damage following loss 
of complement regulation by FH. The kidney contains ~1 million functional units called 
nephrons, which filter toxic molecules from blood and recover water and non-toxic solutes 
from urine. Blood is filtered in the glomerulus, the part of the nephron containing the 
glomerular filtration barrier consisting of the endothelial glycocalyx, glomerular 
endothelium, the glomerular basement membrane (GBM) and finally the slit diaphragm 
formed by specialized epithelial cells called podocytes (Figure 5a). Notably, the healthy 
glomerular filtration barrier prevents leakage of cells and larger proteins into the urine.  
 
 
Figure 5 – The glomerulus and the macula are anatomically similar. a) In the glomerulus, blood is filtered 
through the capillary filter consisting of the endothelial glycocalyx (Glx), fenestrated glomerular endothelium 
(GE), the glomerular basement membrane (GBM) and specialized visceral epithelial cells called podocytes (P), 
which form tight slit diaphragms using their foot processes (FP). b) The macula structurally matches the 
anatomy of the capillary filter, as nutrients are transported from blood through the endothelial glycocalyx, 
fenestrated choriocapillary endothelium (CE) and the underlying basement membrane, called Bruch’s 
membrane (BM), where they are consumed by retinal pigment epithelium (RPE). In dense deposit disease and 
age-related macular degeneration, complement-containing deposits (arrowheads) accumulate in the basement 
membranes underlying the microvascular endothelium, i.e. the GBM and BM, respectively, suggesting a 
susceptibility to complement activation based on the tissues’ unique anatomy. 
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In atypical hemolytic uremic syndrome (aHUS), unregulated AP activation on the endothelial 
cell surface damages the glomerular microvasculature, with local coagulation leading to a 
loss of filtration function, proteinuria and fragmentation of red blood cells as they are forced 
through the damaged capillaries (43). aHUS is strongly associated with autoantibodies 
against and mutations in FH domains CCP19-20 (44, 45), which have been described as the 
primary host recognition site for glomerular tissues (46). Mutations frequently alter FH 
binding to C3b, as well as HS and glomerular endothelial cell surfaces (47–49). Additionally, 
aHUS can be caused by rearrangements between FH and FHR genes, generating fusion 
proteins in which the host recognition domains of FH are exchanged for the corresponding 
FHR CCPs and vice versa. The result is increased competition and complement deregulation 
on host cell surfaces (30, 43). Contrary to aHUS, C3 glomerulopathy (C3G) is associated with 
deregulation of AP activation in the fluid phase, primarily by C3 convertase-stabilizing 
autoantibodies called C3 nephritic factors, resulting in the accumulation of complement 
activation products within the glomerulus (50). The presence of both C3 convertase- and FH-
specific autoantibodies in C3G and aHUS, respectively, has recently been linked to 
monoclonal gammopathy (51, 52). C3G has been classified into two subsets, i.e. dense 
deposit disease (DDD) and C3 glomerulonephritis (C3GN), based on specific morphological 
features (53): DDD is defined by the accumulation of ribbon-like, electron-dense deposits 
containing AP proteins in the GBM, whereas C3GN is associated with more diffuse 
glomerular deposits along the capillary walls, as well as within the mesangium. In both cases 
the result is intense glomerular inflammation followed by mesangial expansion and 
hypercellularity as well as thickening of the glomerular capillary walls and ultimately loss of 
renal function. Similarly to aHUS, dysfunction of the FH protein family contributes to C3G 
development, as this disease manifestation has been associated with FH deficiencies and 
mutations in FHR proteins (54–56). FHR1, FHR2 and FHR5, classified as type 1 FHRs, normally 
occur in plasma as dimers, connected by two N-terminal dimerization domains (57). FHR 
gene rearrangements generate fusion proteins with multiple dimerization domains, resulting 
in FHR oligomers with increased competitive ability (58). Both aHUS and C3G are rare renal 
diseases, with an estimated annual incidence of ~1-2 per million individuals (54, 59), but can 
develop during early childhood and severely impact the patient’s quality of life. 
Aside from renal disease manifestation, changes in complement regulation by FH, FHL-1 and 
FHR proteins has also been associated with an ocular disease called age-related macular 
degeneration (AMD), which is the major cause of blindness in the elderly (60). AMD shares a 
similar pathogenesis with DDD, as complement-containing deposits called drusen 
accumulate in Bruch’s membrane. Analogous to the GBM in the glomerular filtration barrier, 
Bruch’s membrane is a basal membrane separating the microvasculature of the 
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choriocapillaris, including the choroidal endothelial glycocalyx, from the retinal pigment 
epithelium underlying the neural retina, the sensory layer of nerves required for vision 
(Figure 5b) (61, 62). The resulting inflammation can cause retinal atrophy and choroidal 
neovascularization, leading to a loss of central vision. A common FH polymorphism (Y402H) 
in CCP7, which has been described as the primary host recognition site for Bruch’s 
membrane (46), has been associated with an increased risk of developing AMD (54, 63). In 
turn, a deletion of FHR1 and FHR3 (ΔCFHR3-1) protects against disease development, 
underlining the importance of the FH protein family in the pathogenesis of AMD (55). While 
FH and FHR proteins are strongly implicated in disease pathogenesis, other causes of AP 
deregulation, such as mutations in FI or C3, have been described as well for aHUS, C3G and 
AMD (54, 64–66). 
The reason for the increased susceptibility of glomerular and ocular host tissues to AP 
deregulation remains elusive. However, the observation that many aHUS-associated 
mutations and the AMD-associated Y402H polymorphism localize to FH CCP domains 
containing HS binding sites suggests a functional role of HS in disease development. 
Furthermore, the extent and nature of HS modifications differs between different host 
tissues and has been proposed to provide a “ZIP-code” for different FH host recognition sites 
in different tissues (67). 
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Scope and outline of this thesis 
The aim of this thesis is to address the role of HS in the endothelial glycocalyx in 
complement regulation by the FH protein family. Research focuses on the pathogenic effects 
of FH mutations in the glomerular endothelial microenvironment and characterization of HS 
modifications which mediate the interaction between HS and FH as well as FHR proteins to 
identify novel treatment targets. Additionally, experimental tools for studying complement 
deregulation due to dysfunction within the FH protein family are developed, in the form of 
novel assays as well as in vitro models.  
 
HS as determining pathogenic factor in FH-associated disease 
Chapter 2 constitutes a literature review of the current knowledge on the interaction 
between FH and HS, and the described and proposed effects of FH binding to HS on 
complement regulation. Particular attention is given to HS as a tissue-specific determinant of 
disease development to explain the peculiar restriction of AP-mediated damage to renal and 
ocular host tissues. 
 
Functional effects of aHUS-associated FH mutations on complement regulation on 
glomerular endothelial cell surfaces 
Previous research has shown that aHUS-associated FH mutations alter FH binding to HS and 
mouse glomerular endothelial cells (49). In chapter 3, the interaction between the C-
terminus of FH and glycosaminoglycans on mouse glomerular endothelial cells, including HS, 
is investigated. Furthermore, the effect of C-terminal, aHUS-associated FH mutations on 
complement regulation is determined using a novel patient serum-independent complement 
activation assay in context of the clinically affected cells, i.e. glomerular endothelium. 
 
Protocol refinement for the isolation of glycosaminoglycans from cell cultures 
To further investigate the interaction between FH and glomerular endothelial HS without 
interference from other FH ligands expressed by glomerular endothelium, an extraction 
protocol was adapted from the literature (68) to purify glycosaminoglycans from glomerular 
endothelial cells without non-glycocalyx impurities (Chapter 4). 
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Identification of HS modifications which mediate FH and FHR protein binding to the 
glomerular endothelial glycocalyx 
FHR proteins contain CCP domains with high homology to HS-binding domains in FH, 
suggesting that they can compete for glycan ligands on host cell surfaces. Deregulation of 
the alternative pathway by type 1 FHR proteins on human glomerular endothelial cells is 
investigated in chapter 5. HS modifications which mediate FH, FHR1 and FHR5 binding to the 
glomerular endothelial glycocalyx are determined by RNA interference and competition with 
selectively desulfated heparin. Furthermore, the therapeutic potential of 2-O-desulfated 
heparin (oligosaccharides) for reversing FHR-mediated AP deregulation on glomerular 
endothelium is evaluated. 
 
Conditional immortalization and characterization of a choroidal endothelial cell line 
Most of the studies presented in this thesis focus on glomerular complement regulation by 
FH, FHR proteins and HS, i.e. on human and murine glomerular endothelial cells, for which 
conditionally immortalized cell lines are available. However, failure to properly regulate 
complement in the macula of the retina has been strongly implicated in the pathogenesis of 
AMD and further investigation of interactions between FH and HS is required in context of 
the affected host tissue. Chapter 6 describes the generation and characterization of a human 
choroidal endothelial cell line, which was then applied to study binding of FH in the context 
of the AMD-associated polymorphism Y402H. 
 
Summary and future perspectives 
In chapters 7 and 8, the findings of this thesis are summarized and future perspectives on 
the investigation and treatment of FH-associated diseases are discussed. 
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Abstract 
Complement factor H (FH) systemically inhibits excessive complement activation in the 
microenvironment of host cells, but for instance not on microbes. This self-recognition is 
mediated by two binding sites that recognize distinctly sulfated heparan sulfate (HS) 
domains. The interaction with HS not only concentrates FH on host cells, but directly affects 
its activity, evoking novel models of conformational activation. Genetic aberrations in the 
HS-binding domains systemically disturb the protective function of FH, yet the resulting loss 
of complement control affects mainly ocular and renal tissues. Recent results suggest that 
the specific expression of HS domains in these tissues restricts the interaction of HS to a 
single binding site within FH. This lack of redundancy could predispose eyes and kidneys to 
complement-mediated damage, making HS a central determinant for FH-associated 
diseases. 
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The complement system 
The complement system is a group of proteins that forms a central part of the innate 
immunity. It labels microbes and cell debris for detection and clearance by the innate and 
adaptive immune system and acts as an effector mechanism for the adaptive immune 
response. Three distinct pathways, the classical, lectin and alternative pathway (AP), can 
initiate complement activation and converge at the proteolytic cleavage of complement 
component C3 to C3b. The complement response peaks in the formation of the membrane 
attack complex, a protein complex that disrupts cell membranes, thus lysing the targeted 
cell. 
While the classical and lectin pathway recognize antibody deposits and bacterial 
carbohydrates, respectively, the AP is activated by spontaneous hydrolysis and covalent 
attachment of C3b to adjacent cell surfaces (1,2). Unlike most pathogens, host cells express 
membrane-bound complement inhibitors to prevent their destruction by the complement 
system (3). 
 
Complement factor H – structure and function 
The most important plasma inhibitor of the complement system is factor H (FH), which both 
regulates complement activation in solution and specifically binds to and protects host cells 
(4). It is a linear, ~155 kDa glycoprotein and consists of twenty globular domains called 
complement control protein (CCP) or short consensus repeat (SCR; alternatively, short 
complement regulator) domains (5). FH inhibits the complement cascade by blocking 
activating binding sites in C3b and acting as cofactor for factor I, a serum protease that 
cleaves and inactivates C3b (6,7). 
The N-terminal domains of FH, CCP1-4, bind to C3b and contain the primary complement-
regulating activity, while a second major binding site for C3b has been mapped to CCP19-20 
(8). Flexible peptide linkers between the CCPs allow the protein chain to fold back on itself. 
This enables FH to bind a single C3b molecule with both the N- and C-terminus, thereby 
increasing the avidity of the interaction (9). Furthermore, FH contains two heparan sulfate 
(HS)-binding sites, one localized to CCP7 and another to CCP19-20 (8). HS are linear, sulfated 
polysaccharides of the glycosaminoglycan (GAG) family that are present on host cell surfaces 
and in basement membranes, but absent on microbes (10). Their recognition by FH is 
assumed to be the principal mechanism for host-pathogen differentiation (4). Interactions 
with HS in basement membranes, such as the glomerular basement membrane in the kidney 
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or Bruch’s membrane in the eye, are particularly important for complement control due to 
the absence of membrane-bound complement inhibitors.  
Aside from C3b and HS, interactions of FH with various other ligands have been described 
(Table 1) and recently reviewed in great detail (11), including self-association of two or more 
FH molecules. In humans, complement regulation by FH is further influenced by the 
presence of the structurally similar FH-like protein 1 and FH-related proteins 1-5. FH-like 
protein 1 is generated through alternative splicing and includes the seven N-terminal 
domains of FH, thus containing both the CCPs with regulatory activity and the ligand binding 
sites in CCP7 (12). FH-related proteins resulted from gene duplication events and consist of 
four to nine CCPs with high homology to CCP6-9 and CCP19-20 of FH. Except for FH-related 
protein 5, they lack a direct regulatory function (13). However, FH-related proteins 3 and 4 
have been found to enhance the cofactor activity of FH, whereas FH-related protein 1 is 
believed to compete with FH for cell surface ligands (14). Detailed description of these 
proteins is beyond the scope of this review and has been done previously (15). 
 
Table 1 – Factor H ligands and their corresponding binding sites  
Ligand Binding site Reference 
C3b CCP1-4/CCP19-20 (8) 
Heparin/Heparan sulfate 
(GAGs) 
CCP7/CCP19-20 (8) 
Zinc CCP6-8 (16) 
Malondialdehyde CCP7/CCP18-20 (17) 
Factor H (self-association) CCP6-8/CCP16-20 (11) 
C-reactive protein CCP6-8/CCP16-20 (11) 
Von Willebrand Factor CCP6-8/CCP19-20 (18) 
 
FH-associated diseases – a tissue-specific pathology? 
The importance of FH-mediated complement control becomes evident in diseases that are 
associated with genetic variations in FH. These include age-related macular degeneration 
(AMD), atypical hemolytic uremic syndrome (aHUS) and dense deposit disease (DDD) 
(19,20). Accordingly, the deletion of FH-related proteins 1 and 3 is associated with an 
increased risk for aHUS (21), while acting protective in AMD (22). aHUS and DDD are rare, 
rapidly progressing nephropathies that lead to renal failure at an early age (19), whereas 
AMD is the major cause of blindness in elderly patients (23). Strikingly, complement damage 
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appears restricted to kidneys and eyes, even though FH systemically controls complement 
activation. aHUS is associated with mutations in CCP19-20, which were long believed to be 
the primary site for HS-mediated self-recognition (19). Many of the mutations affect the 
interaction between FH and HS, potentially exposing the glomerular endothelium to 
complement damage (24). However, recent results suggest that the principal self-recognition 
domain could be tissue-dependent, since CCP7 binds stronger to ocular tissues than CCP19-
20 (25). In contrast, most DDD-associated FH mutations disturb the protein structure or 
secretion (19). Therefore, aHUS is hypothesized to result from loss of complement control on 
specific cell surfaces, whereas DDD follows a systemic loss of FH activity. However, variations 
that do not affect plasma concentrations (26), such as the CCP7-Y402H polymorphism, have 
also been associated with an increased risk for DDD (27).  
This polymorphism is particularly interesting since it is also a major risk factor for AMD (28). 
Patients present with complement-containing deposits, called drusen, in Bruch’s membrane 
within the macula, followed by an increased neovascularization of choroidal endothelium 
that ultimately leads to blindness (29). Interestingly, similar deposits are observed in the 
glomerular basement membranes of DDD patients (30). The age of disease manifestation 
however is fundamentally different. 
Although the disease association of genetic variations in FH is well established, a pathogenic 
mechanism that explains both the difference in age of disease onset and the tissue-specific 
phenotype remains elusive. Therefore, early treatments have focused on systemically 
restoring complement control by plasma exchange or liver transplantation, whereas novel 
approaches include inhibition of complement activation and aberrant neovascularization by 
monoclonal antibodies (31,32). However, these treatments are expensive, confer risks for 
opportunistic infections and globally affect physiologically relevant pathways (33,34). Thus, 
development of more specific drugs is required. This review proposes a HS-dependent 
pathology that could explain the tissue specificity and other peculiar characteristics of FH-
associated diseases. 
 
The “heparan sulfate code” 
To fully appreciate the importance of FH-HS interactions, one has to understand the 
structural characteristics and physiological functions of HS, especially compared to heparin, 
a popular model molecule for sulfated GAGs. Both are synthesized as linear chains of 
alternating glucuronate β14 N-acetyl-glucosamine α14 disaccharide building blocks that 
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can be modified by sulfation as well as epimerization of glucuronate to iduronate (35). 
Theoretically, these modifications can result in 48 structurally distinct disaccharides.  
However, heparin is synthesized exclusively by mast cells and consists primarily of tri-
sulfated IdoA2S-GlcNS6S disaccharides. HS, on the other hand, is expressed on virtually all 
cells and has a more diverse disaccharide composition. It contains large regions of non-
sulfated, N-acetylated disaccharides (NAc domains) with N-sulfated building blocks 
clustering into domains with increased sulfation (NS domains) (35,36). The exact sequence of 
modified disaccharides within an HS chain, the “HS code”, gives rise to structural domains 
that specifically bind a large variety of different proteins (37). Importantly, HS structures and 
modifications have repeatedly been shown to differ between different tissues (38,39). HS 
induces receptor-ligand interactions, determines the localization of proteins in the cellular 
microenvironment and acts as scaffolding molecule, thereby regulating various biological 
processes including inflammation, morphogenesis and cell differentiation (40,41). 
 
Novel insights into FH-HS interactions 
Interactions between FH and HS are assumed to form the principal mechanism for host-
pathogen differentiation. They concentrate FH in the microenvironment of host cells, 
thereby concentrating the inhibitory activity on self-surfaces containing HS structures with 
affinity for CCP7 and CCP19-20 (Figure 1a) (4). However, there is accumulating evidence that 
the effects of HS on FH function go beyond simply localizing FH to host cells. 
FH activity is strongly affected by the presence of polyanions in the immediate vicinity of C3b 
(43) and recent experiments provide further evidence for this hypothesis using HS and 
heparin. Kelly et al. (44) measured the effect of various GAG preparations on FH cofactor 
activity in the fluid phase, thus independent of surface-binding effects. Addition of HS from 
bovine kidneys significantly increased FH cofactor activity, whereas HS from porcine 
intestinal mucosa had no effect, possibly due to the absence of activating HS domains. 
Heparin, on the other hand, inhibited FH activity both in the fluid phase and on cell surfaces. 
These observations have two important consequences: First, they suggest that the 
interaction between FH and heparin might represent a mode of binding that is interfering 
with complement inhibition. Therefore, results obtained from binding and functional studies 
with heparin or modified heparins could deviate from results obtained using HS, the 
protective cell-surface ligand. Indeed, structural models based on analytical 
ultracentrifugation and X-ray scattering data of HS and heparin oligosaccharides (dp24 and 
dp36, respectively) indicate major differences between these two ligands (45). Heparin 
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appears conformationally restricted due to electrostatic repulsion along its highly sulfated, 
negatively charged backbone. The NAc domains of HS in turn favor increased structural 
variability in solution, which could be required for determining FH cofactor activity through 
interactions with CCP7 and CCP19-20. Even if HS is chosen as model ligand, the observations 
could still be dependent on the origin of HS preparation. Second, even if a disease-
associated form of FH shows no difference in affinity for HS, the mutation could still disturb 
HS-induced changes in FH cofactor activity. Consequently, activity measurements should 
always be included when evaluating the potential pathogenic effects of genomic variations 
in FH. 
 
 
Figure 1 – Potential functional effects of FH-HS interactions. (a) Host cells express the correct HS recognition 
domains and therefore accumulate FH on their cell surface. (b) Interactions between HS and surface-accessible 
amino acid residues induce sterical changes in individual CCPs that influence FH activity. (c) Binding of HS 
through CCP7 and/or CCP19-20 (orange) activates FH by breaking charge-based intramolecular interactions 
(red dotted lines) that normally stabilize the protein in a latent conformation (42). Indicated interactions 
between individual CCPs are arbitrary, since intramolecular binding sites have not yet been mapped. (d) HS 
induces oligomer formation of FH. However, the functional effects of FH oligomerization on complement 
regulation are still unknown. 
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Despite several structural studies on the interactions between HS/heparin and FH, there is 
still no consensus about how these GAGs evoke the observed changes in FH activity. The 
simplest hypothesis is derived from established activity-regulating HS-protein interactions: 
HS could induce activating sterical changes in individual CCPs, as observed for the interaction 
between HS and antithrombin III (46) (Figure 1b). Since HS is only expressed on host cells, FH 
would only be activated in their microenvironment, thus conferring further specificity to 
complement control. Accordingly, a recombinant protein encompassing CCP6-8 has been 
shown to transition from a bent back to an extended solution structure upon binding to 
heparin (47). While the latter observation suggests that HS could impose sterical changes on 
CCP7, the potential functional effects of this transition have yet to be evaluated. 
Another recently proposed functional model postulates the existence of latent and active FH 
conformations (42). It offers an explanation for the differential affinities of FH for C3b 
compared to its inactivated fragments and the relatively small increase in affinity when both 
the N- and C-terminus cooperatively interact with C3b compared to the affinities of the 
individual binding sites. In this model, FH-HS interactions become even more relevant. 
Charge-based intramolecular interactions would stabilize FH in the latent conformation, 
which has a relatively weak affinity for C3b. The latter conformation is disrupted by binding 
the correct HS domains, which significantly increases the affinity for C3b (Figure 1c). 
Structural models for FH indicate that the protein folds back on itself, bringing the N- and C-
terminus in close proximity and theoretically allowing for intramolecular binding (9). 
Evidence for such interactions is provided by Okemefuna et al. (48), who measured FH 
dimensions in solutions of increasing salinity or pH using analytical ultracentrifugation. At a 
concentration of 250 mM sodium chloride or pH 9.4, FH transitions from a compact to a 
more elongated molecule. This suggests that intramolecular interactions favor a compact 
structure under physiological conditions, which is at least partially stabilized by histidines 
(48). The conformational change in response to high salt concentrations was shown to be 
reversible, indicating that FH could return to the latent conformation after dissociation from 
HS. Recent models of FH bound to heparin oligosaccharides showed only minor structural 
transitions compared to the unbound protein, contradicting a larger HS-induced 
conformational change (49). However, the oligosaccharides used in the heparin study were 
significantly shorter (maximum of 12 nm for heparin dp36) than physiological HS chains, 
which can consist of up to 200 disaccharides and be 160 nm in length (40). If the CCP7 and 
CCP19-20 binding sites were positioned at the correct distance along the carbohydrate 
backbone of HS, cooperative binding of the HS chain could provide sufficient energy to 
impose an activating structural transition. Recently, an interaction between FH and Von 
Willebrand Factor (VWF) has been described that, like HS, involves CCP6-8 and CCP19-20 and 
35 
 
increases the cofactor activity of FH (46). VWF is released from endothelial cells and 
megakaryocytes and assists coagulation at the sites of endothelial damage (50). The 
interaction with FH is proposed to favor complement control in the inflammatory 
environment of damaged blood vessels. Despite being structurally very distinct molecules, 
both HS and VWF interact through the same FH domains and induce functional activation. 
While it is possible that they induce activating sterical changes by interacting with the same 
amino acids in FH, they could equally well break a latent conformation by (partially) 
occupying intramolecular binding sites in FH. 
Finally, HS has been shown to induce FH oligomerization (Figure 1d), which could further 
accumulate FH on cell surfaces where other FH molecules are already bound to C3b (11). But 
oligomerization of FH could result in direct functional activation as well, potentially through 
destabilization of intramolecular binding sites. HS-mediated activation through 
oligomerization has been described for other systems, such as fibroblast growth factor 
receptor signaling (51). Unfortunately, the effect of FH self-association on its inhibitory 
activity is difficult to investigate. While techniques such as analytical ultracentrifugation 
readily reveal changes in self-association in presence of physiological ligands (49), assays 
that simultaneously evaluate the regulatory activity depending on the degree of self-
association have yet to be described. An observed HS-dependent increase in inhibitory 
potential therefore cannot be attributed to either changes in FH oligomerization or more 
direct functional effects such as changing to a more active conformation. 
 
The potential role of HS in tissue-specific disease development  
HS in the endothelial glycocalyx, a carbohydrate layer that covers the inside of all blood 
vessels (52), is particularly important for FH-mediated complement control, since endothelial 
cells are continuously exposed to AP activation in the plasma. Accordingly, complement-
mediated damage to glomerular and aberrant neovascularization of choroidal endothelium 
define the phenotypes of aHUS and AMD, respectively (19). However, the endothelium in 
tissues other than the glomerulus and retina appears unaffected by the loss of FH function, 
suggesting a tissue-specific pathogenicity. Particularly interactions with HS could explain the 
peculiar disease manifestations. Most clinically relevant variations cluster in CCPs that 
contain binding sites for HS (53) and many CCP19-20 mutations alter the interaction with 
heparin and glomerular endothelial cell surfaces (24). The CCP7-402H risk variant affects the 
heparin affinity of a recombinant CCP6-8 protein as well (54), but appears to be 
compensated by the C-terminal HS binding site in the context of full-length FH (25). It has 
also been shown that binding of C1q, the initiator of the classical pathway, to glomerular 
36 
 
endothelium in vitro is partially mediated by HS (55), further underlining the impact of HS on 
renal complement control. The potential role of FH-HS interactions in renal (56) and ocular 
(57) diseases has recently been reviewed. However, a direct comparison of the exact HS 
composition within the glomerulus and retina and evaluation of the functional consequences 
for complement control have yet to be performed. 
Recent competition experiments by the Day group support the hypothesis that tissue-
specific HS structures determine disease manifestation (25). FH appeared to bind retinal 
tissues primarily through the HS structure that is recognized by CCP7, whereas in renal 
tissues binding was mostly mediated via CCP19-20. This could explain why genetic variations 
in CCP7 lead to an ocular phenotype, whereas mutations in CCP19-20 cause complement 
dysregulation in the glomerulus. If HS domains in other tissues are recognized by both CCP7 
and CCP19-20, loss of one interaction could be compensated by the other, conferring 
additional protection to these tissues (Figure 2). In that scenario, interactions with HS 
through one of the binding sites would be sufficient to activate FH. Furthermore, loss of one 
of the FH-binding HS domains due to pathogenic alterations in HS structure could account 
for the relatively large group of patients that have no known genetic predisposition in 
complement proteins. This theory does not explain the renal disease association of the 
CCP7-Y402H polymorphism. However, the fact that most AMD patients do not develop DDD 
suggests that additional pathogenic factors are required for the manifestation of the renal 
phenotype. It is possible, though speculative, that glomerulus-specific HS structures bind the 
CCP7-402H variant of FH in a way that interferes with complement regulation, as observed 
for heparin (44). 
While the tissue-specific expression of FH-binding HS domains could explain why the disease 
is restricted to the kidneys and eyes, it does not account for the delayed age of disease onset 
in AMD. Interestingly, the structure of HS in many different tissues in the body, including the 
kidney, has been shown to change with increasing age (58,59). These changes involve a 
decrease in both chain length and sulfation. The CCP7-402H risk variant has previously been 
reported to have an increased susceptibility to the removal of sulfates from immobilized 
heparin (54). Binding of the normal CCP7-402Y variant on the other hand is less affected. 
Recently, a direct comparison between HS extracts from the eyes of young and old donors 
(average 32 vs 82 years) revealed a significant decrease in chain length and sulfation in 
Bruch’s membrane during aging (60). These changes were not observed in the adjacent 
neurosensory retina, which further underlines the tissue-specific differences in HS, even 
within the same organ. Although the age-related changes in HS decreased binding of both 
CCP7-402 variants, the effect was significantly larger for the disease-associated CCP7-402H 
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polymorphism. These novel observations could explain both the delayed disease onset in 
AMD and the disease association of the CCP7-402H variant. 
 
 
Figure 2 - Potential mechanism for the tissue-specific manifestation of Factor H (FH)-associated diseases. 
Recent models suggest that FH binding to and subsequent inactivation of C3b increases greatly through 
interactions with specific heparan sulfate (HS) structures. Tissues that are not affected by FH-associated 
diseases express HS domains that activate FH through both CCP7 and CCP19-20 (orange). The macula and 
glomerulus however express only HS domains that activate FH through interactions with CCP7 and CCP19-20, 
respectively. Therefore, loss of one interaction, either due to genetic variations in the protein or pathogenic 
alterations in HS metabolism, results in a loss of complement control. 
 
While HS is a particularly promising candidate for causing the tissue-specific disease 
manifestation, the pathogenicity of genetic variations in FH remains extremely complex. 
Many CCP19-20 mutations also affect the affinity with C3b (24) and pathogenic mechanisms 
that include ligands other than HS should still be considered. Furthermore, being 
homozygous for a risk allele and even carrying multiple disease-associated polymorphisms 
does not necessarily lead to disease development (19). Additional genetic predispositions, 
environmental factors and insults like infections might be required for disease development. 
Smoking, which is a major risk factor for AMD development (61), is particularly interesting, 
since it directly affects HS expression and metabolism (62,63). 
In conclusion, although FH-associated diseases are most likely multifactorial and the amount 
of known FH ligands has been increasing, HS remains one of the most promising pathogenic 
factors. Disturbed interactions with HS are observed for many of the pathogenic FH variants 
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and could greatly affect complement regulation, especially considering the potential 
functional effects on FH activity. The presence of tissue-specific HS modifications and their 
differential recognition by the two binding sites in FH in eyes and kidneys offers the first 
explanation for the tissue-specific manifestation of FH-associated diseases. Therefore, 
comparison of HS within the affected tissues, particularly its effect on FH activity, could 
provide novel insight in the role of HS as determining factor for disease development.  
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Abstract 
Complement factor H (FH) inhibits complement activation and interacts with glomerular 
endothelium via its complement control protein domains 19 and 20, which also recognize 
heparan sulfate (HS). Abnormalities in FH are associated with the renal diseases atypical 
hemolytic uremic syndrome and dense deposit disease and the ocular disease age-related 
macular degeneration. Although FH systemically controls complement activation, clinical 
phenotypes selectively manifest in kidneys and eyes, suggesting the presence of tissue-
specific determinants of disease development. Recent results imply the importance of 
tissue-specifically expressed, sulfated glycosaminoglycans (GAGs), like HS, in determining FH 
binding to and activity on host tissues. Therefore, we investigated which GAGs mediate 
human FH and recombinant human FH complement control protein domains 19 and 20 
(FH19-20) binding to mouse glomerular endothelial cells (mGEnCs) in ELISA. Furthermore, 
we evaluated the functional defects of FH19-20 mutants during complement activation by 
measuring C3b deposition on mGEnCs using flow cytometry. FH and FH19-20 bound dose-
dependently to mGEnCs and TNF-α treatment increased binding of both proteins, whereas 
heparinase digestion and competition with heparin/HS inhibited binding. Furthermore, 2-O-, 
and 6-O-, but not N-desulfation of heparin, significantly increased the inhibitory effect on 
FH19-20 binding to mGEnCs. Compared to wild type FH19-20, atypical hemolytic uremic 
syndrome-associated mutants were less able to compete with FH in normal human serum 
during complement activation on mGEnCs, confirming their potential glomerular 
pathogenicity. In conclusion, our study shows that FH and FH19-20 binding to glomerular 
endothelial cells is differentially mediated by HS but not other GAGs. Furthermore, we 
describe a novel, patient serum-independent competition assay for pathogenicity screening 
of FH19-20 mutants.  
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Introduction 
The complement system, which consists of the classical, lectin, and alternative pathway, 
initiates and amplifies inflammatory responses, including proliferative glomerulonephritis 
(1–3). The three pathways converge in the activation of complement component C3 and lead 
to the formation of membrane attack complexes that lyse affected cells. The alternative 
pathway is initiated by spontaneous hydrolysis of C3 (4), eventually leading to covalent 
attachment of C3b to both adjacent host and non-host cell surfaces (5) and the release of 
the proinflammatory anaphylatoxin C3a (6). Deposited C3b binds complement factor B and, 
after proteolytic cleavage by factor D, forms C3 convertases (C3bBb) on the cell surface, 
providing localized feed-forward amplification of complement activation (7). To protect host 
cells from complement-mediated damage, several regulatory proteins disrupt the 
complement cascade, including the plasma proteins complement factor H (FH) and FH-like 
protein 1, and membrane-bound regulators like complement receptor 1 (CD35), membrane 
cofactor protein (CD46), and decay accelerating factor (CD55) (8–12).  
FH, a 155 kDa glycoprotein, is the major inhibitor of the alternative pathway both in the fluid 
phase and on cellular surfaces (13–15). It competes with factor B for C3b (16), acts as a 
cofactor for complement factor I-mediated proteolytic inactivation of C3b (14), and 
promotes the dissociation of C3bBb convertases (17). FH consists of 20 complement control 
protein (CCP, also called short consensus repeats) domains of ~60 amino acids each (18). The 
N-terminal domains CCP1-4 contain the cofactor and decay accelerating activity (19, 20), 
while CCP7 and CCP19-20 mediate cell surface recognition by binding to sulfated 
glycosaminoglycans (GAGs) on host cells (21–23). Mutations in the two C-terminal surface 
recognition domains can result in the rare renal disease atypical hemolytic uremic syndrome 
(aHUS) (24). Furthermore, a polymorphism in CCP7 (Y402H) has been associated with the 
ocular disease age-related macular degeneration (AMD) as well as the rare renal disease 
dense deposit disease (DDD) (25). In turn, the rare SCR20 mutation R1210C is associated 
with both AMD and aHUS (26). Interestingly, mutations cluster within the cell surface 
recognition domains, and whereas FH systemically controls complement activation, 
complement-mediated damage appears restricted to eyes and kidneys. 
Recent studies (21) provide evidence that the tissue-specific disease manifestation is 
mediated by the differential expression of heparan sulfates (HS), a class of GAGs. HS are 
linear, negatively charged polysaccharides that can be extensively modified by sulfation and 
epimerization to yield highly heterogeneous structures (27). The exact sequence of 
modifications along the carbohydrate backbone, the “HS code”, generates specifically 
sulfated domains that are recognized by proteins with the corresponding HS binding site. 
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This way, endothelial HS plays a crucial role during inflammation by binding to selectins, 
integrins, chemokines, cytokines, inflammatory cells, and complement proteins (28–32). 
Clark et al. (21) recently found that HS-mediated FH binding in the glomerulus is primarily 
mediated by CCP19-20, providing an explanation for the C-terminal localization of aHUS-
related FH mutations. Their observations are supported by earlier evidence from FH knock-
out mouse models. FH-deficient mice display a phenotype reflecting human DDD, which is 
associated with systemic loss of complement control in the fluid phase (33). Recently, the 
model has been refined to a hepatocyte-specific FH knock-out, which results in a phenotype 
even closer to human C3 glomerulonephropathies that include DDD (34). However, if mice 
instead express a FH construct lacking the five C-terminal CCPs, the resulting phenotype 
reflects aHUS, with glomerulospecific, complement-mediated damage despite normal 
plasma C3 concentrations (35). The strong similarities between human and murine disease 
phenotypes lead us to investigate the genotype-phenotype relation of FH19-20 mutants in 
the context of mouse glomerular endothelial cells. 
In a previous study we showed that aHUS-associated FH CCP19-20 (FH19-20) mutants exhibit 
impaired binding to C3b/C3d and impaired or enhanced binding to mouse glomerular 
endothelial cells (mGEnCs) and heparin (36). Our current study aimed to determine the 
functional effects of FH19-20 mutations and evaluate the role of GAGs in binding of FH to 
glomerular endothelium, the clinically affected tissue. We demonstrated that binding of FH 
to mGEnCs is partially mediated by HS, but not chondroitin sulfate, dermatan sulfate or 
hyaluronan. Furthermore, several aHUS-associated FH19-20 mutants were less able to 
compete with full length FH compared to wild type FH19-20 during alternative pathway 
activation on mGEnCs. The obtained results not only confirm the evaluated mutants’ 
potential role in aHUS etiology but illustrate glomerular pathogenicity screening of FH 
mutants under highly controlled experimental conditions without requiring access to patient 
serum.  
 
Methods 
FH, FH19-20 mutants and GAG preparations  
Factor H (FH, Tyr-402 homozygous) was isolated from healthy donors as described (37). 
Recombinant wild type FH19-20 and aHUS-associated FH19-20 mutants (D1119G, W1183L, 
T1184R, E1198A, R1210A, R1215Q) (38) were generated and purified as described (39). GAG 
preparations included heparin, HS from bovine kidney, hyaluronic acid (Sigma), 2-O-
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desulfated heparin, 6-O-desulfated heparin and N-desulfated heparin (Neoparin Inc., 
Alameda, CA). 
 
Cell culture 
Conditionally immortalized mGEnCs with all features of primary glomerular endothelial cells 
were cultured as described (40). Where indicated, cells were activated by incubation with 
tumor necrosis factor (TNF)-α (10 ng/ml; Peprotech, Rocky Hill, NJ) for 18 h.  
 
Binding of FH and FH19-20 to mouse glomerular endothelial cells in enzyme-linked 
immunosorbent assays (ELISAs) 
 mGEnCs were grown in 96-well plates (Corning Life Sciences, Schiphol-Rijk, The 
Netherlands). The cells were washed with phosphate-buffered saline (PBS) and incubated 
with serial dilutions of FH and FH19-20 (0-80 μg/ml) in PBS containing 2% bovine serum 
albumin (2% PBA; w/v; Sigma) for 2 h at 37°C. Binding was detected using polyclonal rabbit 
anti-human FH antiserum (kind gift from Dr. J. Hellwage, Hans Knöll Institute, Jena, 
Germany). The cells were then washed twice with 0.05% Tween 20 in PBS (PBS/Tween; v/v) 
and subsequently incubated with horseradish peroxidase-conjugated F(ab’)2 donkey anti-
rabbit IgG (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA) in 2% PBA for 
1 h at room temperature. Finally, the cells were washed three times with PBS/Tween and 
incubated with tetramethylbenzidine substrate solution (Bio-Rad). The reaction was stopped 
after 15 min with an equal volume 2 M H2SO4, and the absorbance at 450 nm was measured 
using a Bio-Rad Multiplate Reader (Bio-Rad). Full-length FH and wild type FH19-20 were used 
at their 50% effective concentrations (EC50) for the remaining binding assays. 
 
Effect of GAG-degrading enzyme treatment and (modified) heparin/HS competition on 
FH/FH19-20 binding to mGEnCs 
HS on TNF-α-activated mGEnCs was removed by treatment with 0.25 units/ml heparinase I, 
II and III (Sigma-Aldrich) in 0.1 M sodium acetate, 0.2 mM calcium acetate (pH 7.0) for 1 h at 
37°C. Cell surface HS degradation was confirmed by measuring the expression of the HS 
epitope recognized by the antibody AO4B08 (41). Chondroitin sulfate/dermatan sulfate was 
removed by treating mGEnCs with 1 unit/ml chondroitinase ABC (Sigma) in 25 mM Tris/HCl, 
2 mM magnesium acetate (pH 8.0) for 1 h at 37°C. The activity of chondroitinase ABC was 
checked with the anti-chondroitin sulfate antibody IO3H10 (42). Hyaluronic acid was 
50 
 
removed by 0.1% hyaluronidase (w/v; from bovine testes, type I-S; Sigma) in 0.1 M sodium 
acetate (pH 6.0) for 1 h at 37°C, and its activity was confirmed using biotinylated hyaluronic 
acid-binding protein (Sigma). For the competition assays, FH/FH19-20 were preincubated 
with the different GAG preparations or the modified heparinoids (50 μg/ml) before being 
added to the cells. Binding of FH/FH19-20 was then determined using ELISA as described. 
 
Alternative pathway activation on mGEnCs and FH19-20 (mutant) competition  
TNF-α-activated mGEnCs were grown in 48-well plates (Corning Life Sciences). After washing 
twice with PBS, the cells were incubated with 20% pooled normal human serum (NHS; 
Complement Technology, Inc., Tyler, TX) in veronal-buffered saline (15 mM veronal, 145 mM 
NaCl, 3 mM MgCl2, 5 mM EGTA, 0.025% NaN3, pH 7.3) at 37°C. Twenty percent heat-
inactivated NHS (30 min at 56°C) in veronal-buffered saline was used as negative control. 
Convertase formation was stopped after 60 min by adding EDTA to a final concentration of 
10 mM. The cells were then detached by vigorous pipetting, washed with 0.5% PBA and 
incubated with rabbit anti-human C3/C3b (1 μg/ml; clone H-300; Santa Cruz Biotechnology, 
Inc., Santa Cruz, CA) in 0.5% PBA for 30 min at 4°C. After washing and incubating with a goat 
anti-rabbit IgG:Alexa488 (Life Technologies) for 30 min at 4°C, C3b deposition on mGEnCs 
was detected using a Beckman Coulter FC500 flow cytometer and evaluated using CXP2.2 
software. To evaluate the functional effects of aHUS-associated mutations, 10 µg/ml wild 
type or mutant FH19-20 were added to NHS to compete with full-length FH during the 
activation step. 
 
Statistical analysis 
Titration data were fitted using non-linear regression with a “log(agonist) versus response” 
model using GraphPad Prism version 5.03 (GraphPad Software Inc., San Diego, CA). Values 
are expressed as means ± S.E. and significance was evaluated by Student’s t test or analysis 
of variance using GraphPad Prism. Post hoc comparison of individual means was performed 
using Tukey’s method. Binding experiments were performed four times in duplicate. Results 
of the activity assays represent data from three separate experiments. 
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Results 
TNF-α treatment increases full-length FH and FH19-20 binding to glomerular endothelial 
cells 
Complement FH binds endothelial cells (43), and recently, we demonstrated the differential 
binding of FH19-20 and FH19-20 mutants to mGEnCs (36). In the current study, we 
investigated the ability of mGEnCs to bind FH and FH19-20 using ELISA and found that both 
FH and FH19-20 exhibited specific and dose-dependent binding to mGEnCs (Figure 1a). 
Activation of mGEnCs with TNF-α to simulate the inflammatory conditions of aHUS 
significantly increased binding of both full-length FH and FH19-20 ~1.5-fold and ~1.3-fold, 
respectively (Figure 1b). To take advantage of the observed increase in signal, we 
investigated binding of FH and FH19-20 using TNF-α-activated mGEnCs for the subsequent 
experiments. 
 
 
Figure 1 - Full-length FH and FH19-20 bind differentially to mouse glomerular endothelial cells (mGEnCs). (a) 
Serial dilutions of FH and recombinant FH CCP19-20 (FH19-20) were added to mGEnCs, and binding was 
detected using ELISA. Full-length FH bound mGEnCs at a lower EC50 concentration than FH19-20, suggesting the 
presence of additional binding sites for ligands on the cell surface. (b) TNF-α activation of mGEnCs results in an 
increased binding of full-length FH and FH19-20. The results were normalized on binding of the complement 
factors to untreated mGEnCs. **, p < 0.01 versus untreated mGEnCs; ***, p < 0.001 versus untreated mGEnCs. 
 
Binding of full-length FH and FH19-20 to glomerular endothelial cells is differentially 
mediated by HS but not chondroitin sulfate or dermatan sulfate 
Because endothelial glycocalyx composition and modifications differ between different 
tissues, we investigated the role of different types of GAGs in regulating binding of FH and 
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FH19-20 to glomerular endothelium. Therefore, mGEnCs were either treated with a mixture 
of glycosidases to degrade specific GAGs before measuring FH and FH19-20 binding, or the 
proteins were preincubated with soluble GAGs to compete for cell surface GAGs on mGEnCs. 
Although removal of chondroitin sulfate using chondroitinase ABC (CSase ABC) had no effect 
on binding of either full-length FH (Figure 2a) or FH19-20 (Figure 2b), digesting HS with 
heparinase I, II and III (HepI-II-III) significantly reduced binding ~1.7-fold and ~1.2-fold, 
respectively. Treatment with hyaluronidase, which removes hyaluronic acid, decreased 
binding of FH19-20 to TNF-α-activated mGEnCs, whereas the binding of full-length FH was 
unaffected. However, binding of both proteins was significantly decreased after treating 
mGEnCs with both hyaluronidase and HepI-II-III, although not below the observed effect of 
HepI-II-III treatment alone. Accordingly, soluble hyaluronic acid did not effectively compete 
with mGEnC-associated hyaluronic acid for full-length FH and FH19-20 (Figure 3). In contrast, 
pre-incubation with heparin or HS significantly inhibited the binding of full-length FH and 
FH19-20 to TNF-α-activated mGEnCs.  
 
 
Figure 2 - Heparinase treatment reduces the binding of full-length FH and FH19-20 to mGEnCs. Monolayers of 
TNF-α-activated mGEnCs were treated with chondroitinase ABC (CSase ABC), a mixture of heparinase I, II and III 
(HepI-II-III), hyaluronidase (HAase) or a combination of hyaluronidase and heparinase I, II and III (HAase-HepI-II-
III). The binding of full-length FH (a) and FH19-20 (b, both at EC50 concentrations) was measured by ELISA. The 
results were normalized on binding of full-length FH and FH19-20 to untreated mGEnCs. *, p < 0.05 versus 
untreated mGEnCs; **, p < 0.01 versus untreated mGEnCs; ***, p < 0.001 versus untreated mGEnCs; ****, p < 
0.0001 versus untreated mGEnCs. 
 
Because the interaction between HS and FH depends on the sulfation of the GAG backbone, 
we evaluated the effect of several selectively desulfated heparinoids in competition with HS 
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in the glomerular endothelial glycocalyx. None of the modified heparinoids affected the 
binding of full-length FH when compared with heparin as the competitor (Figure 3a). In 
contrast, pre-incubation with 2-O- and 6-O-desulfated heparin significantly reduced the 
binding of FH19-20 to mGEnCs compared with heparin (Figure 3b), indicating that these 
modifications could be involved in the self-recognition of glomerular endothelium by FH19-
20. N-desulfated heparin in turn did not affect binding of FH19-20 to mGEnCs. Thus, 2-O- 
and 6-O-desulfated heparin showed differential inhibitory effects on the binding of full-
length FH and FH19-20 to mGEnCs. Finally, GAG digestion appeared more effective in 
reducing full-length FH binding compared to FH19-20 (Figure 2), whereas the opposite was 
observed during the competition experiments (Figure 3). 
 
 
Figure 3 - Competition with soluble heparin and HS reduces the binding of full-length FH and FH19-20 to 
mGEnCs. FH and FH19-20 were preincubated with 50 μg/ml hyaluronic acid, HS, heparin, or 2-O-, 6-O-, and N-
desulfated (desulf.) heparin before adding the mixtures to monolayers of TNF-α-activated mGEnCs. The binding 
of full-length FH (a) and FH19-20 (b) to the cells was then evaluated by ELISA. Pre-incubation with heparin and 
HS significantly reduced binding of both proteins, whereas 2-O- and 6-O-desulfation selectively increased the 
inhibitory effect compared with heparin on FH19-20 but not FH binding to mGEnCs. The results were 
normalized on binding of full-length FH and FH19-20 to mGEnCs in absence of competitors (Untreated). *, p < 
0.05 versus untreated; **, p < 0.01 versus untreated; ***, p < 0.001 versus untreated; &, p < 0.05 versus 
heparin; &&, p < 0.01 versus heparin. 
 
aHUS-associated FH19-20 mutants are less able to compete with full-length FH for ligands 
on mGEnCs compared to wild type FH19-20 during alternative pathway activation 
We previously identified three types of defects caused by mutations in FH19-20, i.e. 
decreased binding to C3b/C3d and decreased or increased binding to heparin and mGEnCs 
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(36). However, the functional consequences of these mutations for complement control on 
glomerular endothelium were still unexplored. For the current study we selected FH mutants 
to include all defined defects as well as their combinations and evaluated their ability to 
compete with full-length FH on mGEnCs during alternative pathway activation. 
Incubating mGEnCs with normal human serum resulted in significant C3b deposition on the 
cell surface compared to heat-inactivated human serum as measured in flow cytometry 
(Figure 4a). Competing with full-length FH for ligands on mGEnCs using wild type FH19-20 
further increased the observed C3b deposition by ~1.7 fold, suggesting an increased 
susceptibility to alternative pathway activation. Interestingly, several of the screened aHUS-
associated FH19-20 mutants show a decreased ability to compete with full-length FH 
compared with wild type FH19-20 (Figure 4b). The effect is statistically significant for the 
mutants W1183L, E1198A, and R1215Q, which appear unable to compete with full-length FH 
at all, indicating a complete loss of function of the C-terminal cell-surface recognition 
domains. Although the remaining mutants, D1119G, T1184R, and R1210A, are not 
significantly less able to compete with full-length FH compared to wild type FH19-20, they all 
display a trend towards decreased function.  
 
 
Figure 4 - aHUS-associated FH19-20 mutants are less able to compete with full-length FH during alternative 
pathway activation on mGEnCs. (a) TNF-α-activated mGEnCs were incubated with 20% heat-inactivated and 
normal human serum (NHS (h.i.) and NHS, respectively) and C3b deposition on the cell surface was evaluated 
using flow cytometry. (b) Adding 10 µg/ml wild type FH19-20 (WT) to compete with FH for ligands in the 
cellular microenvironment during alternative pathway activation significantly increases C3b deposition 
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compared to incubation with NHS alone. Interestingly, several screened FH19-20 mutants are less able to 
compete with full-length FH during activation, with the mutations W1183L, E1198A, and R1215Q resulting in an 
almost complete loss of competitive ability. (c) Sequence alignment of mammalian FH CCP19-20 amino acid 
sequences. With the exception of D1119G, the loss of inhibitory ability compared with wild type FH19-20 
reflects the conservation of the mutated amino acid in mammalian species (green, highly conserved; red, not 
conserved). **, p < 0.01 versus WT; ***, p < 0.001 versus WT. 
 
Discussion 
Previous in vitro studies on the interaction between FH and endothelium or the effects of FH 
mutations on cell-surface complement control used non-renal endothelial cells, which might 
lack tissue-specific disease-determining factors. Therefore, we characterized the GAG ligands 
for full-length FH and FH19-20 on glomerular endothelial cells. Furthermore, we explored 
the effect of aHUS-associated FH19-20 mutations on alternative pathway inhibition in the 
context of the physiologically affected tissue.  
We found that both full-length complement FH and FH19-20 bound dose-dependently to 
mGEnCs. TNF-α activation of mGEnCs resulted in a significant increase in binding of full-
length FH and FH19-20 to the endothelial monolayer. This might reflect a cellular response 
to provide additional protection from complement-mediated damage during glomerular 
inflammation. We previously showed that TNF-α activation increases the expression highly 
sulfated HS domains (recognized by the antibodies AO4B08, EW3D10, and EW4G2) as well as 
lowly sulfated HS (recognized by 10E4) (29). Total HS expression in the endothelial glycocalyx 
increased ~3-fold in response to TNF-α, which could result in an increased binding of FH and 
FH19-20. 
It is important to note that the interaction studies and pathogenicity screening of FH19-20 
mutants were performed using murine instead of human glomerular endothelial cells. 
However, FH-deficient mouse and pig models suggest that the tissue-specific determinants 
of FH-associated diseases are conserved within mammals (33–35, 44). The animals develop a 
DDD-like renal phenotype, and aged FH-deficient mice have been used as the model for 
AMD (45). Furthermore, the DDD-like phenotype converts to aHUS in FH-deficient mice 
expressing a transgenic FH variant lacking CCP16-20, as model for FH mutants with C-
terminal loss of function (35). The renal disease phenotype can be reversed by injecting FH-
deficient mice with human FH, suggesting cross-reactivity between the human and murine 
factors involved in complement regulation (46).The removal of HS from the endothelial 
glycocalyx significantly reduced binding of both full-length FH and FH19-20, confirming that 
HS mediates FH binding to glomerular endothelium via CCP19-20. In contrast, removal of 
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chondroitin and dermatan sulfate had no effect on the interaction between mGEnCs and 
either of the proteins. Removal of hyaluronic acid by hyaluronidase decreased binding of 
FH19-20, whereas the addition of hyaluronic acid in soluble form had no effect on binding. 
This apparent discrepancy could arise because hyaluronidase treatment disturbs the 
integrity of the endothelial glycocalyx, which includes GAGs and short branched N- and O-
linked oligosaccharides with negatively charged terminal sialic acid residues (47).  
In accordance with the GAG digestion results, competition with soluble heparin and HS 
significantly diminished the interaction between mGEnCs and full-length FH or FH19-20. 
Interestingly, 2-O- and 6-O-desulfated heparin significantly decreased binding of FH19-20 to 
mGEnCs even further. Although this effect is not observed for full-length FH, it could be 
masked by the presence of additional, non-HS ligands on mGEnCs. These results suggest that 
FH19-20 preferentially binds to heparan sulfate with low levels of 2-O- and 6-O-sulfation, 
contradicting previous observations that the interaction between FH19-20 and heparin 
depends on high levels of sulfation (21). However, these experiments either measured 
binding of FH to heparin directly or competed with soluble heparinoids for immobilized 
heparin. Our experiments in turn used modified heparins in solution to compete for HS in its 
physiological environment, the endothelial glycocalyx. Therefore, 2-O- and 6-O-desulfated 
heparin could be more effective in competing for the physiological HS ligands of FH19-20 
compared to unmodified heparin. Both in the GAG digestion and competition experiments, 
complete reduction of FH and FH19-20 binding could not be achieved, suggesting that other, 
non-GAG ligands indeed contribute to the interaction between FH and glomerular 
endothelium. As full-length FH is glycosylated, contrary to FH19-20, interactions between 
cell surface receptors and glycans in FH could contribute to the interaction as well. 
We have previously characterized three different functional defects of FH19-20 mutants, i.e. 
decreased ability to compete with wild type FH19-20 for C3b/C3d (W1183L, T1184R, and 
R1210A), decreased (R1210A and R1215Q), or increased (T1184R and E1198A) binding to 
heparin and mGEnCs (Table 1) (36). Although we originally found none of these defects in 
D1119G, later studies revealed a decreased affinity for C3b/C3d (48). Because the D1119G 
mutant still efficiently competes with wild type FH19-20 for C3b/C3d, the mutation might 
affect the self-association characteristics of the two C-terminal CCPs, preventing binding to 
C3b/C3d. Recently, the aHUS/AMD-associated R1210C mutation has been shown to 
introduce a gain of function defect, as it enables the protein to form covalent bonds with 
serum albumin (49, 50). The R1210A mutant used in the current study lacks the surface-
exposed cysteine; therefore, the observed effects can likely be attributed to a decrease in 
electrostatic interactions with FH19-20 ligands. 
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Table 1 - Functional characterization of aHUS-associated FH19-20 mutants. Arrows indicate an increase (↑), 
decrease (↓), or no signiﬁcant change (↔) in binding/activity. (*conserved amino acid; binding data adapted 
from Lehtinen et al. (36))  
FH19-20 
mutant 
C3b/C3d 
binding 
Heparin 
binding 
mGEnC 
binding 
Functional 
activity 
D1119G* ↔ ↔ ↔ ↔ 
W1183L* ↓ ↔ ↔ ↓ 
T1184R ↓/↔ ↑ ↑ ↔ 
E1198A* ↔ ↑ ↑ ↓ 
R1210A ↓ ↓ ↓ ↔ 
R1215Q* ↔ ↓ ↔ ↓ 
 
However, the influence of these C-terminal FH mutations defects on complement control on 
glomerular endothelium had not yet been explored. Therefore, we designed a competition 
assay to explore the effect of mutations in FH19-20 on glomerular complement control. The 
alternative pathway activated spontaneously on mGEnCs as measured through a significant 
increase in C3b deposition compared with heat-inactivated serum. This represents an 
advantage of using mGEnCs compared with human endothelium, which is protected from 
complement attack from normal human serum. We observed significant functional defects 
in three of the mutants, which are likely caused by altered interactions with both 
complement proteins and cell surface ligands. W1183L has a decreased affinity for C3b/C3d 
and is apparently unable to compete with full-length FH for the protein during complement 
activation. E1198A shows an increased affinity for heparin and mGEnCs, while binding of 
R1215Q to heparin is decreased. The loss of a negatively and positively charged amino acid, 
respectively, likely changes the specificity of the proteins for FH19-20-binding HS domains, 
leaving sufficient HS unoccupied to efficiently inhibit complement activation on mGEnCs 
despite the competition. Note that competition using mutants with two of the defined 
defects (T1184R and R1210A) did not have the largest effect on alternative pathway 
inhibition on mGEnCs. Instead, the observed decrease in competitive ability of the screened 
FH19-20 mutants reflects the conservation of the affected amino acid in mammalian species, 
with the exception of D1119G (Figure 4c). All other mutations in highly conserved amino 
acids (W1183L, E1198A, and R1215Q) completely abolish the protein’s ability to compete 
with full-length FH for ligands on mGEnCs. However, additional FH19-20 mutants will have to 
be screened to expand this observation. 
Because recombinant proteins were used to evaluate the functional effects of mutations in 
FH19-20, the experiments can be performed without access to limited available aHUS 
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patient serum. Therefore, our assay is unaffected by variable complement concentrations in 
patient serum, current disease state, or improper handling of serum samples, since the same 
human serum pool is used as source of complement for all FH19-20 mutants. However, 
potential pathogenic contributions of other serum factors, such as FH-like 1 and FH-related 
proteins 1-5, will not be reflected in the obtained results. 
In conclusion, this study is the first to demonstrate the role of HS in binding of the full-length 
FH and FH19-20 to (TNF-α -activated) glomerular endothelial cells. Furthermore, we showed 
the pathogenic effect of several aHUS-associated FH19-20 mutations on FH-mediated 
complement control on the clinically affected tissue. Finally, we have described a 
competition assay that enables pathogenicity screening of uncharacterized FH mutations 
without requiring access to limited available patient serum.  
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Abstract  
Glycosaminoglycans (GAGs) are linear negatively charged polysaccharides and important 
components of extracellular matrices and cell surface glycan layers such as the endothelial 
glycocalyx. The GAG family includes sulfated heparin, heparan sulfate (HS), dermatan sulfate 
(DS), chondroitin sulfate (CS), keratan sulfate, and non-sulfated hyaluronan. Because relative 
expression of GAGs is dependent on cell-type and niche, isolating GAGs from cell cultures and 
tissues may provide insight into cell- and tissue-specific GAG structure and functions. In our 
objective to obtain structural information about the GAGs expressed on a specialized mouse 
glomerular endothelial cell culture (mGEnC-1) we adapted a recently published GAG isolation 
protocol, based on cell lysis, proteinase K and DNase I digestion. Analysis of the GAGs 
contributing to the mGEnC-1 glycocalyx indicated a large HS and a minor CS content on barium 
acetate gel. However, isolated GAGs appeared resistant to enzymatic digestion by 
heparinases. We found that these GAG extracts were heavily contaminated with RNA, which 
co-migrated with HS in barium acetate gel electrophoresis and interfered with 1,9-
dimethylmethylene blue (DMMB) assays, resulting in an overestimation of GAG yields. We 
hypothesized that RNA may be contaminating GAG extracts from other cell cultures and 
possibly tissue, and therefore investigated potential RNA contaminations in GAG extracts from 
two additional cell lines, human umbilical vein endothelial cells and retinal pigmental 
epithelial cells, and mouse kidney, liver, spleen and heart tissue. GAG extracts from all 
examined cell lines and tissues contained varying amounts of contaminating RNA, which 
interfered with GAG quantification using DMMB assays and characterization of GAGs by 
barium acetate gel electrophoresis. We therefore recommend to routinely evaluate the RNA 
content of GAG extracts and propose a robust protocol for GAG isolation that includes an RNA 
digestion step. 
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Introduction 
Glycosaminoglycans (GAGs) are linear, negatively charged polysaccharides and prominent 
components of extracellular matrices and cell surface glycan layers. GAGs are synthesized 
from repeating disaccharide building blocks and most GAGs, including heparan sulfate (HS), 
heparin, keratan sulfate, chondroitin sulfate (CS) and dermatan sulfate (DS), can be modified 
by sulfation, which renders them strongly negatively charged. For example, HS consists of N-
acetylglucosamine and uronic acid disaccharide building blocks and can be sulfated at the N-, 
2O-, 3O- and 6O-positions of the carbohydrate ring structures. The sequence of modifications 
along the carbohydrate backbone allows sulfated GAGs, particularly HS, to bind growth 
factors, chemokines and cellular adhesion molecules, such as fibroblast growth factors, 
interleukin-8, selectins and the macrophage-1 antigen (Mac-1), thereby regulating various 
physiological processes including cell growth, morphogenesis, coagulation and inflammation 
(1-9).  
GAG expression and modifications are often tissue- and cell type-specific (10,11). Therefore, 
isolation and characterization of GAGs from different tissues or cell cultures is important to 
unravel tissue- and cell type-specific GAG structure and function (12). Previously, we have 
isolated and characterized a unique mouse glomerular endothelial cell line (mGEnC-1) (13) 
and identified specifically sulfated HS domains in the glomerular endothelial glycocalyx that 
mediate chemokine binding and leukocyte trafficking during inflammation in vitro and in vivo 
(13-18). Since the presence of many additional functional GAG domains in the glomerular 
endothelial glycocalyx is presumed, isolation and analysis of intact GAGs, e.g. using mass 
spectrometry, may yield novel structural information about functional GAG domains. 
Described GAG extraction protocols usually involve release of GAGs using chaotropic buffers, 
non-ionic detergents, protease treatment or alkaline β-elimination, followed by removal of 
contaminants by enzymatic or chemical digestion, selective precipitation or chromatography 
(12,19-21). GAG quantification in mGEnC-1 GAG extracts initially suggested high yields, with 
HS as the major component of the mGEnC-1 glycocalyx, as was previously described (22). 
However, the obtained HS fraction appeared largely resistant to digestion with bacterial 
heparinases I, II and III, suggesting that the sugars which co-migrated with HS standards during 
barium acetate agarose gel electrophoresis contained non-HS compounds. Subsequently we 
identified RNA as a major contaminant. Here, we describe a GAG isolation protocol including 
an RNAse treatment that yields GAG extracts that can be reliably visualized by agarose gel 
electrophoresis and quantified by the DMMB method. 
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Methods 
Cell culture and animal tissue  
Conditionally immortalized mouse glomerular endothelial cells (mGEnC-1) were cultured as 
previously described (13). Briefly, mGEnC-1 were grown at the proliferative temperature of 
33°C in 1% gelatin (Sigma-Aldrich)-coated culture flasks (Corning Life Sciences) with 
DMEM/Ham’s F12 medium (3:1; Life Technologies) supplemented with 5% fetal bovine serum 
(FBS; Bodinco), 1% penicillin/streptomycin (PS; Life Technologies) and 20 units (U)/ml 
recombinant mouse interferon-γ (IFN-γ; PeproTech). For differentiation, mGEnC-1 were 
seeded at 25% density in uncoated culture flasks and cultured for 7 days in DMEM/Ham’s F12 
without IFN-γ at the non-permissive temperature of 37°C. Primary human umbilical vein 
endothelial cells (HUVEC) were grown to confluence on 1 µg/cm2 bovine fibronectin (Bio-
Connect)-coated culture flasks in endothelial cell growth medium (EGM)-2 (Lonza). 
Immortalized retinal pigmental epithelial cells (ARPE-19) were grown to confluence in culture 
flasks in DMEM/Ham’s F12 (1:1) supplemented with 10% FBS and 1% PS. All cell lines were 
maintained in T75 culture flasks in a 5% CO2 humidified environment at 37°C.  
Mouse organs were collected from wild-type C57BL/6J mice sacrificed by cervical dislocation. 
Animal experiments were approved by the animal ethics committee of the Radboud 
University.  
 
Isolation of GAGs from cells and tissues 
Original protocol (23,24): Cell monolayers were thoroughly washed with phosphate-buffered 
saline (PBS), and digested overnight at 37°C with 125 µg/ml proteinase K (Merck Millipore) in 
2 ml extraction buffer (50 mM Tris-HCl, 10 mM NaCl, 3 mM MgCl2 and 1% triton X-100, pH7.9) 
per 75 cm2 confluent cell monolayer. The lysate was recovered from the culture flask and 
heated to 95°C for 10 min to deactivate proteinase K before adding 7.5 U/ml DNase-I (Qiagen) 
and incubating overnight at 37°C. The digested lysate was then mixed 1:1 with 4 M sodium 
chloride to dissociate GAG-bound peptides, followed by mixing 1:1 with chloroform and 
centrifugation for 30 min at 4500xg. The top (aqueous) layer containing purified GAGs was 
collected and dialyzed thoroughly against 18.2 MΩ.cm deionized water (MQ). GAG solutions 
were then dried using a SC200 Speed Vac centrifugal evaporator (Savant Instruments). Before 
analysis, GAG preparations were reconstituted in MQ. GAGs from cryosections of C57BL/6J 
mouse tissues (i.e. heart, liver, spleen and kidney) were isolated by the same protocol 
described above. 
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Adapted protocol: An excess of RNase-I (10 U/ml; Thermo Scientific) was added to the DNase 
mixture for subsequent extractions. Where indicated, GAG extracts were treated with a 
mixture of 0.25 U/ml heparinase I, II and III (Sigma). 
 
DMMB analysis of GAGs 
DMMB solution was prepared as previously described (23,25) with minor modifications. Fifty 
mg DMMB (Sigma) were dissolved in 25 ml ethanol, filtered through Whatman filter paper 
and used to prepare a solution containing a final concentration of 0.1 mg/ml DMMB, 5% v/v 
ethanol, 0.2 M guanidine hydrochloride (GuHCl), 0.2% w/v sodium formate and 0.2% w/v 
formic acid. Subsequently, the dye mixture was diluted (1:1) with an identically prepared, 
DMMB-free buffer to create a stable solution. One ml of the prepared DMMB solution was 
added to 100 µL of sample and vortexed for 30 minutes. The GAG:DMMB complex was 
precipitated by centrifugation at 10.000xg for 10 minutes and the supernatant was aspirated 
carefully. The precipitate was then reconstituted by vortexing for 30 minutes in 250 µL 
decomplexant solution (4 M GuHCl, 10% 1-propanol and 50 mM sodium acetate, pH6.8). Two 
hundred µL of dissolved GAG:DMMB mixture was transferred to a 96 wells plate and the 
absorbance at 650 nm was measured using a Bio-Rad Multiplate Reader (Bio-Rad). To quantify 
the GAG concentration, absorbances were compared to different amounts (0 to 40 µg/ml) of 
heparan sulfate from bovine kidney as a standard (HSBK; Sigma). GAG concentrations are 
given as mean ± s.e.m. Significance was determined by ANOVA. 
 
Barium acetate agarose gel electrophoresis and silverstaining of GAGs 
Analysis of obtained GAGs on agarose gel was performed as described previously (26) with 
minor modifications. In short, 500 mg multipurpose agarose (1%; Roche) were dissolved by 
heating in 50 ml 50 mM barium acetate (electrophoresis buffer, pH 5.0), 13 ml were cast on 
the hydrophilic side of a 85 x 100 mm gelbond film (Lonza) placed on a glass slide and wells 
were excised once the gel had set. A mass of 0.5-1 µg of isolated GAGs were diluted 6x in 
electrophoresis buffer containing 20% glycerol and 0.01% bromophenol blue. Five µl/well GAG 
extract were loaded and electrophoresis was performed in electrophoresis buffer at 60V on a 
LKB bromma 2117 multiphor electrophoresis unit (LKB, Bromma, Sweden). Gels were stained 
and fixed overnight with 0.1% w/v Azure A (Sigma) in 50 mM sodium formate (pH 3.5) and 10 
mM magnesium chloride, destained with 10 mM sodium acetate (pH 5.5) and air dried. Gels 
were washed twice for 10 minutes in 1% triton X-100 (Sigma) in MQ and washed again 
thoroughly with MQ to remove residual triton X-100. Silverstaining was performed by adding 
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100 ml freshly prepared silverstaining solution, consisting of a mixture of 60 mM NH4NO3, 30 
mM AgNO3, 3.5 mM tungstosilicic acid and 0.15 mM 37% formaldehyde, 0.47 M Na2CO3 (1:1, 
v/v). The reaction was stopped with 1% acetic acid in MQ and gels were air dried. GAG extracts 
were compared to commercial standards for HS, DS and CS (Sigma). 
 
Ethidium bromide agarose gel electrophoresis  
RNA presence in 0.5-1 µg of isolated GAG extracts was analyzed on 1% agarose gel in Tris-
Boric acid-EDTA (TBE; Invitrogen) with 0.01% ethidium bromide. 
 
Results and discussion 
GAGs in the glomerular endothelial glycocalyx mediate important functions (13-18), therefore 
we aimed to isolate pure GAGs from cultured glomerular endothelium to obtain novel 
information on composition and structure. To isolate and characterize GAGs expressed by 
mGEnC-1, a published protocol for the isolation of GAGs from tissues (23,24) was followed. 
The GAG composition of the mGEnC-1 glycocalyx as assessed by barium acetate agarose gel 
electrophoresis implied a large HS and smaller CS content (Fig 1A), which was in line with the 
previously described HS:CS ratio of 4:1 for endothelium (22). Isolated GAGs were quantified 
by an adapted 1,9-dimethylmethylene blue (DMMB) GAG quantification assay based on the 
Farndale method (23-25), which relies on the formation of a GAG-cationic dye complex. GAGs 
obtained from mGEnC-1 were quantified relative to HSBK, indicating a yield of ~0.12 µg GAGs 
per cm2 cell monolayer (Fig 1B). To confirm the relative contribution of HS or CS to the mGEnC-
1 glycocalyx, GAG preparations were treated with heparinases I, II and III to digest HS. 
However, the glycocalyx-derived GAG spot co-migrating with HS standards was not affected 
by enzymatic degradation with heparinases I, II and III (Fig 1A), suggesting a major impurity 
with an electrophoretic mobility comparable to HS.  
Therefore, the original isolation protocol was re-evaluated for potential sources of 
contamination. We reasoned that RNA may be contaminating the GAG extracts, since a high 
density of negative charges in RNA could result in co-purification and detection by cationic 
dyes. When the purity of GAG extracts was assessed on ethidium bromide agarose gels, a 
significant polynucleotide impurity was found, which could efficiently be removed by RNase-I 
digestion (Fig 2A). Furthermore, when the RNase-I-treated mGEnC-1 GAG extract was re-
evaluated on barium acetate gels these GAG extracts showed a much fainter spot co-migrating 
with the HS standards (Fig 2B). Together, the ethidium bromide and barium  
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Fig 1. Characterization of mGEnC-1 GAGs by barium acetate gel electrophoresis and DMMB analysis. The GAG 
content in extracts from conditionally immortalized mouse glomerular endothelial cells (mGEnC-1) was visualized 
by barium acetate gel electrophoresis (A), and quantified relative to heparan sulfate from bovine kidney using 
1,9-dimethylmethylene blue (B). Analysis of heparinase I, II and III-treated mGEnC-1 GAGs on gel indicated no 
degradation of the spot that co-migrates with the HS standard (C). 
 
acetate gel electrophoresis data suggest that, under the conditions applied, RNA is a major 
contaminant in the GAG extract obtained from mGEnC-1 cells. RNA digestion with RNase-I 
enables determination of the actual GAG composition and the relative contribution of HS and 
CS to the mGEnC-1 glycocalyx. 
To determine whether RNA is a common contaminant in other cell- and tissue-derived GAG 
extracts, and whether this may affect further analysis, GAGs were isolated from HUVECs and 
ARPE-19 cells, and from mouse kidney, heart, liver and spleen, with and without including an 
RNase-I digestion step during purification. Like mGEnC-1 cells, both HUVEC- and ARPE-19-
derived GAGs contained substantial RNA impurities that were detected in the ethidium 
bromide and barium acetate agarose gels (Fig 3A and 4A). Furthermore, analysis of GAG yield 
by DMMB assays suggested about 5-fold higher RNA concentrations in HUVEC and ARPE-19 
GAG extracts compared to mGEnC-1 GAG extracts, whereas the true GAG concentration 
measured by DMMB after RNase treatment was comparable between 40 and 60 ng/cm2 
confluent cell culture (Fig 5A). Kidney, heart, liver and spleen extracts all contained variable 
amounts of RNA impurities, some of which appeared less susceptible to  
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Fig 2. Characterization of mGEnC-1-derived GAGs reveals RNA as a major contaminant. The RNA content in 
extracts from conditionally immortalized mouse glomerular endothelial cells (mGEnC-1) was visualized by 
ethidium bromide agarose gel electrophoresis (A), and barium acetate gel electrophoresis (B) before and after 
RNase treatment. Enzymatic degradation of RNA in mGEnC-1 GAG extracts removes the RNA band observed on 
ethidium bromide gel, and a large spot that appears to co-migrate with HS on the barium acetate gel. 
 
 
Fig 3. Glycosaminoglycans (GAG) extracts contain significant RNA impurities, which can be digested by RNase-
I treatment. Visualizing nucleotide impurities in GAG preparations from conditionally immortalized mouse 
glomerular endothelial cells (mGEnC-1), human umbilical vein endothelial cells (HUVEC), immortalized retinal 
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pigmental epithelial cells (ARPE-19) (A), and mouse kidney, heart, liver and spleen (B) on ethidium bromide 
agarose gels, revealed significant RNA contaminations. RNase-I treatment efficiently removed the contamination 
from mGEnC-1 and ARPE-19 GAGs, though minor impurities remained in HUVEC-, kidney- and spleen-derived 
extracts.  
 
RNase-I treatment, particularly in spleen extracts (Fig 3B and 4B). GAG isolation from some 
tissues, such as the spleen, may therefore require a higher RNase-I concentration for complete 
RNA degradation. In most tissues, except the kidneys, degradation of the RNA contaminant 
also resulted in a pronounced reduction in RNA/GAG yield as determined by DMMB assays 
(Fig 5B).  
 
 
Fig 4. RNA impurities interfere with the analysis of glycosaminoglycans (GAGs) using barium acetate agarose 
gel electrophoresis. Resolving untreated GAG extracts by barium acetate gel electrophoresis suggested relatively 
large amounts of heparan sulfate (HS) and dermatan sulfate (DS) and relatively little chondroitin sulfate (CS) in 
GAGs obtained from mouse glomerular endothelial cells (mGEnC-1), human umbilical vein endothelial cells 
(HUVEC) and immortalized retinal pigmental epithelial cells (ARPE-19) (A). GAG extracts from mouse tissues 
appeared to contain large amounts of DS (heart and liver) and CS (spleen), whereas kidney-derived GAGs were 
enriched in HS, but also contained DS and CS (B). However, the observed staining patterns seemed to result from 
contaminating RNA co-migrating between HS and DS, as RNase-I treatment revealed the actual GAG spots 
corresponding to primarily HS and CS.  
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Fig 5. RNA contamination of glycosaminoglycan (GAG) extracts leads to a significant overestimation of GAG 
yields. The GAG content in extracts from conditionally immortalized mouse glomerular endothelial cells (mGEnC-
1), human umbilical vein endothelial cells (HUVEC), immortalized retinal pigmental epithelial cells (ARPE-19) (A) 
and C57BL/6J mouse kidney, heart, liver and spleen (B) was quantified relative to heparan sulfate from bovine 
kidney using 1,9-dimethylmethylene blue. The apparent yield in untreated GAG samples from cell cultures was 
significantly overestimated 2- to 6-fold compared to RNase-treated samples, indicating that RNA contamination 
interferes with the charge-based DMMB quantification method. RNA also interfered with the quantification of 
GAGs obtained from heart, liver and spleen, but not in kidney cortex extracts. GAG concentrations are presented 
as µg/cm2 confluent cell monolayer or µg/mg wet tissue. Results are given in means ± s.e.m. *P<0.05 by Anova. 
 
The susceptibility of GAG quantification using DMMB to contaminating polyanions has 
recently been discussed in the field of tissue engineering as well (27). Studies on GAGs in 
synovial fluid showed that contaminating RNA and DNA at concentrations above 20 µg/ml 
result in the overestimation of GAG content (28). Accordingly, quantification of cell/tissue-
derived GAG extracts using DMMB assays in our study revealed a major reduction in apparent 
GAG yield from 120 to 280 ng before RNase treatment to between 40 to 60 ng of GAGs per 
square cm of cultured cells after RNase treatment (Fig 5A), and a GAG yield of 500 to 1000 ng 
before RNase treatment to 200 to 300 ng of GAG per mg of tissue after RNase treatment (Fig 
5B). However, the constant yield of GAGs obtained from mouse kidney tissue, may indicate 
that the concentration of contaminating RNA is below the detection threshold for detection 
with DMMB, since analysis on gel did reveal an effect of RNase treatment (Fig 4B). 
The results from our studies thus clearly demonstrate that GAGs extracted from both tissues 
and cell-lines contain varying amounts of RNA (Fig 3), which interfere with identification of 
the GAGs on barium acetate agarose gel electrophoresis (Fig 4), since RNA appeared to co-
migrate in between the HS and DS fraction, and with the quantification of GAGs in DMMB 
assays (Fig 5). We showed that most of these RNA impurities could be efficiently removed by 
overnight incubation with an excess of RNase-I.  
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Since many of the more recent GAG extraction protocols do not include treatments to remove 
RNA contaminants, it was initially hypothesized that the inherent instability of RNA, as well as 
abundant endogenous/exogenous RNases would be sufficient to remove contaminating RNA. 
Many studies have focussed on isolation of GAGs for quantification or structural analysis, 
resulting in a large variety in protocols for GAG extraction. In some of the earliest publications 
describing GAG isolations, DNase and RNase were used to remove contaminating 
polynucleotides from the GAG extracts (29-31). However, more recent publications no longer 
describe (a combination of) these nucleases (23,24,32-38), which will result in the ample 
presence of RNA in GAG extracts. Of course, depending on the specific downstream 
application of the GAG extract and additional purification steps such as ion exchange 
chromatography, not all GAG extractions require RNA digestion (39-41). For example, when 
incorporating radioactive sulfate into GAGs for the quantification of GAG synthesis in cultured 
cells, the presence of RNA in the GAG extract may be neglected (42-44). But also in these 
settings RNA impurities can become highly relevant during functional assays, because of the 
similar physical characteristics between GAGs and RNA. Monitoring the RNA content of GAG 
extracts on ethidium bromide agarose gels or by measuring the absorbance at 260 nm during 
purification can reveal contamination, particularly when combined with high resolution 
techniques such as capillary electrophoresis (45). Furthermore, several protocols use alkaline 
treatment to release GAGs into solution. RNA is highly susceptible to alkaline hydrolysis (46), 
and protocols including alkaline treatment are therefore less likely to contain significant RNA 
impurities (47-51). A drawback of this method however is that both depolymerisation of GAGs 
and loss of functional groups, including sulfates, can occur during the incubation of GAGs in 
basic solutions (52,53). Alkaline treatment may therefore not be an ideal approach when the 
goal is to obtain more specific structural information about the GAGs expressed in tissues or 
on cultured cells.  
Thus, the adaptation of a protocol for GAG extraction must be chosen carefully, since the 
application described in the original article may require a lesser degree of purity of the final 
GAG extract, as in our studies we experienced problems with the RNA impurity that is not 
described in the source of our GAG isolation protocol (23,24). In theory, this may lead to false 
detection of GAGs after barium acetate gel electrophoresis or DMMB analysis, e.g. when HS 
presence is concluded from azure A staining on agarose gels based on a “known” band position 
compared to DS and CS (54) and may therefore be wrongfully assigned. Since polynucleotides 
are often not considered as potential contaminants in GAG extracts, the complexation with 
cationic dyes that occurs in DMMB assays may result in overestimated GAG yields and wrong 
assignment of relative GAG compositions (23,24,32-38). It is difficult to discern from the 
results of studies that lack controls for RNA content whether GAG extracts were contaminated 
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by RNA. However, excessively high GAG yields and intense GAG spots on barium acetate 
agarose, which cannot be removed by digestion with GAG-specific glycosidases, can suggest a 
contamination with polynucleotides.  
In conclusion, the similar physical characteristics of GAGs and nucleic acids can result in 
significant RNA contamination of GAG extracts, which interferes with GAG compositional 
analysis on agarose gels and charge-based quantification. We therefore recommend to 
routinely evaluate the RNA content of GAG extracts and propose a robust protocol for GAG 
isolation that includes an RNA digestion step (Fig 6). 
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Fig 6. Schematic workflow for glycosaminoglycan (GAG) extraction including RNase treatment Cell/tissue 
lysates are treated overnight with proteinase K (Prot. K), followed by DNase-I and RNase-I treatment and finally 
chloroform extraction and dialysis to remove contaminating proteins/DNA/RNA. After drying/concentration of 
GAG extracts, the purity of the preparations is assessed using ethidium bromide (EtBr) agarose gels, or by 
measuring the absorbance at 260 nm (A260).  
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Abstract 
Unregulated complement activation is characteristic of the renal diseases atypical hemolytic 
uremic syndrome (aHUS) and C3 glomerulopathy (C3G). The complement inhibitor factor H 
(FH) and FH-related proteins (FHRs) without inhibitory activity regulate activation by 
competing for host cell glycans, particularly heparan sulfate (HS). HS is extensively modified 
by acetylation, sulfation and epimerization by HS biosynthesis enzymes, which determines 
specific protein binding. Competition-increasing mutations in FH and FHRs or disturbed 
glomerular HS biosynthesis could reduce binding of FH, resulting in aHUS/C3G. Therefore, 
FHR-mediated deregulation on human glomerular endothelial cells (ciGEnCs) and HS 
biosynthesis enzymes and sulfate modifications which determine FH/FHR binding were 
investigated. FH, FHR1, FHR2 and FHR5 binding to and complement deregulation on ciGEnCs 
in C3G patient and FHR-supplemented sera were evaluated using ELISA and flow cytometry. 
The role of HS biosynthesis enzymes in FH/FHR binding to ciGEnCs was determined using 
RNA interference. Relevant HS modifications were analyzed by competing with selectively 
desulfated heparin for binding to purified ciGEnC HS (HSGlx). Finally, 2-O-desulfated heparin 
oligosaccharides were generated and the reversal of FHR-mediated deregulation on ciGEnCs 
by 2-O-desulfated heparin was evaluated. FH, FHR1 and FHR5 binding to glomerular 
endothelial cells in vitro was significantly increased by the presence of C3b, whereas FHR2 
barely bound to the cells. Silencing HS biosynthesis enzymes, particularly 2-O- and 6-O-
sulfotransferases, differentially reduced ciGEnC binding of FH, FHR1 and FHR5. FH binding to 
HSGlx depended on N-, 2-O- and 6-O-sulfation, whereas FHR1 and FHR5 binding was primarily 
mediated by N-sulfation and inhibited by short oligosaccharides (<hexasaccharides). FHR1 
and FHR5 inhibited FH binding to HSGlx and significantly deregulated complement activation 
on ciGEnCs, which was reversed by incubation with 2-O-desulfated heparin. Although 
complement appeared deregulated in individual patient sera, average activities did not differ 
between healthy controls and C3G patients. In conclusion, FH/FHR binding to HS was 
differentially mediated by sulfation, which was applied to reverse complement deregulation 
on ciGEnCs, offering a novel approach for treating C3G. 
 
 
 
 
 
 
87 
 
Introduction 
The complement system serves an important role in immunity by removing pathogens and 
apoptotic debris. Three distinct pathways can induce complement activation, with the 
alternative pathway (AP) targeting both pathogens and host tissues. Activation results in the 
cleavage of complement component C3 to C3b, which attaches covalently to cell surfaces 
and extracellular membranes. C3b recruits complement factor B to form an autocatalytic C3 
convertase complex, resulting in feed-forward amplification of complement activation, 
which culminates in formation of a lytic pore by formation of the C5b-9 complex (1). 
Failure to control AP activation on host tissues can lead to disease, including the glomerular 
diseases C3 glomerulopathy (C3G) (2) and atypical hemolytic uremic syndrome (aHUS) (3). 
C3G and aHUS have been associated with genetic variations in various complement proteins, 
including complement factor H (FH), the main inhibitor of the AP (4). FH consists of 20 
homologous complement control protein (CCP) domains and binds to C3b (5), thereby 
displacing factor B (6). It also acts as cofactor for complement factor I, which cleaves C3b 
into inactive iC3b (7). FH differentiates between host tissues and pathogens by binding to 
heparan sulfate (HS) on host tissues using CCP7 (8, 9) and CCP20 (10), as well as sialic acid 
using CCP20 (11). FH-mediated complement control is further regulated by five FH-related 
proteins (FHR1-5), which contain CCPs with high homology to CCP7 and CCP19-20 and have 
been shown to bind to FH ligands, including HS and C3b (12–14). FHRs have therefore been 
proposed to compete with FH for ligands on (pathogenically altered) host tissues such as 
glomerular endothelial cells and the glomerular basement membrane, leading to local 
deregulation of AP activation and tissue damage (15). FHRs can be divided into type 1 FHRs 
(FHR1, FHR2 and FHR5), which occur as homo- and heterodimers, and type 2 FHRs (FHR3, 
FHR4), which are monomeric in plasma (16, 17). Type 1 FHRs, particularly FHR1 and FHR5, 
are prominently found in renal biopsies of C3G patients (18) and FHR gene rearrangements 
have been described which result in FHRs with multiple dimerization domains and oligomeric 
type 1 FHR complexes with increased competitive abilities (15, 19, 20). Additionally, 
pathogenic changes in glomerular tissues, e.g. deviations in the biosynthesis of HS, might 
affect the balance between FH and FHR binding and further contribute to disease 
development.  
HS is a linear polysaccharide from the glycosaminoglycan family, which is particularly 
prominent in the endothelial glycocalyx, a thick glycan layer which lines the inside of blood 
vessels (21). In humans, HS is synthesized by a complex biomachinery of >30 enzymes (22). 
Initially, the carbohydrate backbone is generated by the exostosin 1/exostosin 2 (EXT1/2) 
copolymerase complex from up to 200 repeating N-acetylglucosamine/glucuronic acid 
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(GlcNAc/GlcA) disaccharides. Subsequently, N-deacetylase/N-sulfotransferases (NDSTs) 
substitute acetyl groups in GlcNAc for sulfates, the first of several sulfate modifications. GlcA 
can be converted to iduronic acid (IdoA) by glucuronic acid epimerase (GLCE), introducing 
additional structural variability (23). Finally, the remaining sulfate modifications are added at 
the 3-O- and 6-O-positions of GlcNAc and 2-O-position of GlcA/IdoA, respectively, by 2-O-, 3-
O- and 6-O-sulfotransferases (HS2STs, HS3STs and HS6STs). Most HS biosynthesis enzymes 
have multiple isoforms with varying substrate specificities and activities, resulting in 
substantial structural diversity of HS depending on HS biosynthesis enzyme expression and 
activity. Based on the sequence of modifications along the carbohydrate backbone, HS acts 
as specific receptor for a variety of proteins, including complement regulators (24, 25).  
The cell surface recognition domains of FH and FHRs are highly homologous, but not 
identical. Since small changes in the HS binding domains of FH can significantly affect the 
protein’s specificity for certain sulfate modifications (26), similar differences in specificity 
might exist between FH and FHRs. Theoretically, this would enable selective inhibition of 
FHR binding to host tissues by HS oligosaccharides containing the correct sequence of sulfate 
modifications. Therefore, the relevant HS modifications for binding of FH and type 1 FHRs to 
glomerular endothelial HS were investigated. Binding of FH, FHR1 and FHR5 to glomerular 
endothelial HS was found to be differentially mediated by 2-O- and 6-O-sulfation. 
Importantly, 2-O-desulfated heparin reduced FHR-mediated AP deregulation on glomerular 
endothelial cells in vitro, offering a novel approach to treating C3G. 
 
Methods 
Cell culture 
Conditionally immortalized human glomerular endothelial cells (ciGEnCs) were cultured as 
previously described (27) on 1.0 µg/cm2 bovine fibronectin (Bio-Connect BV, Huissen, The 
Netherlands) coating. For proliferation, cells were cultured at 33°C in endothelial cell basal 
medium (EGM-2 MV; Lonza, Verviers, Belgium). For experiments, ciGEnCs were seeded at 
25% confluence at 37°C and grown to confluent monolayers. Human umbilical vein 
endothelial cells (HUVECs) were cultured as previously described (28). Media were refreshed 
every two days.  
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RNA interference using small interfering RNA (siRNA) 
ciGEnCs were detached using 0.05% (w/v) trypsin/ethylenediaminetetraacetic acid (EDTA; 
Thermo Scientific, Waltham, MA, USA) and resuspended at 4x104 cells/ml in EGM-2 MV. 
DharmaFECT1 (GE Healthcare, Eindhoven, The Netherlands) was diluted in serum-free EGM-
2 MV (1:200) and siGENOME SMARTpool siRNA (50 nM final concentration; GE Healthcare) 
in Opti-MEM 1 (Thermo Scientific). Equal volumes of DharmaFECT1 and siRNA solutions 
were mixed and incubated for 20 minutes at room temperature (RT). The mixture was then 
5x diluted in ciGEnC suspension and cells were seeded at 10000 cells/cm2 in 6 or 96 well 
plates (Corning Life Sciences, Schiphol-Rijk, The Netherlands) for evaluation of knockdown 
efficiencies and FH, FHR1 and FHR5 binding to silenced ciGEnCs, respectively. After 24 hours, 
silencing solutions were replaced by EGM-2 MV and effects of silencing were determined 
after 96 hours. 
 
RNA isolation, cDNA synthesis and quantitative real-time PCR 
For evaluation of HS biosynthesis enzyme expression and knockdown efficiencies, ciGEnC 
mRNA was extracted using RNeasy mini kit (Qiagen, Venlo, The Netherlands) and 1.0 µg 
mRNA was transcribed into cDNA using RevertAid First strand cDNA synthesis kit (Thermo 
Scientific). The obtained cDNA was used at 50x dilution in SYBR Green SuperMix (Roche 
Diagnostics, Mannheim, Germany) containing 10 µM forward/reverse primer (Table 1; 
Isogen Life Science, De Meern, The Netherlands). Target gene expression was quantified 
with the delta-delta CT method relative to glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) using a CFX real-time PCR system (Bio-Rad Laboratories BV, Veenendaal, The 
Netherlands). 
 
Evaluation of FH/FHR ciGEnC binding using ELISA 
ciGEnCs were grown in 96 well plates for five days. After differentiation, cells were washed 
twice using Hank's balanced salt solution including Mg2+/Ca2+ (HBSS) and incubated for 30 
minutes at RT with two-fold dilution series of serum-purified FH (Complement Technologies 
Inc., Tyler, TX, USA) or recombinant 6xHis-tagged FHR1, FHR2 and FHR5 (Novoprotein, 
Summit, NJ, USA) in 2% (w/v) bovine serum albumin (BSA; Sigma-Aldrich Chemie, 
Zwijndrecht, The Netherlands) in HBSS. Binding was detected using monoclonal anti-FH 
antibody (Clone: Ox24; Bio-Rad Laboratories BV) followed by goat anti-mouse 
IgG1:horseradish peroxidase (HRP) conjugate (Sanbio BV, Uden, The Netherlands) or mouse 
anti-6xHis antibody (Sigma-Aldrich) followed by goat anti-mouse IgG:HRP conjugate (Jackson 
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ImmunoResearch, West Grove, PA, USA). Assays were developed using 3, 3', 5, 5' 
tetramethyl benzidine substrate A+B (Biolegend, London, UK). Based on the titrations, FH, 
FHR1, FHR2 and FHR5 were used at a concentration of 100, 70, 50 and 10 µg/ml, 
respectively, for all subsequent assays unless stated otherwise.  
 
Table 1 – HS biosynthesis enzyme primer sequences 
Target 
gene 
Sequence (5’3’) 
EXT1 
(F) ACCAGGAATGCCTTATATCAC 
(R) TTGTGTCTGCTGTCTAAGTG 
EXT2 
(F) GGAAGTATGAGTCTGAGTGG 
(R) TGGGGTTACCTTGATAACTG 
NDST1 
(F) GTTGGTCAGTGGACGATTC 
(R) ATCTCTGTGCGGTATTTGAAG 
NDST2 
(F) GTGGACTCTGTATAGTTGCC 
(R) TGGTGGACACATAATAAGCC 
NDST3 
(F) TGAGCCGATGGTAACGAG 
(R) TTGATATGGTAGGTGTTGGAG 
NDST4 
(F) ACTATGGCACTTTAGGAAACG 
(R) GACCGAGTTGAGAGTATTGG 
GLCE 
(F) GTTCCAGTGACAAAGCAATC 
(R) GAGCCCTAACACCTTACTTC 
HS2ST 
(F) GGTGCTTCTCCTTTATGATTTG 
(R) GTGGATTTGAAACAGGGTTG 
HS6ST1 
(F) ATCATTGAGAAGTGGTAGTGG 
(R) CGTCTGTCCTGTTTTATCCC 
HS6ST2 
(F) CAGCAAGTAAGGATAAACGG 
(R) TTGTTGGCTAGATTGTAGGG 
HS6ST3 
(F) GCAGGAGCATAGAATAGTTTG 
(R) GAGACCCCTTTAGGCATTAG 
GAPDH 
(F) GAAGGTGAAGGTCGGAGT 
(R) AGATGGTGATGGGATTTC 
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Binding of FH, FHR1 and FHR5 to ciGEnCs treated with siRNA was determined as described 
above. Effects of silencing on HS modifications in the ciGEnC glycocalyx were measured using 
VSV-G-tagged HS-specific glycoprobes AO4B08 and EW4G2 (29, 30), followed by mouse anti-
VSV-G:HRP conjugate (Sigma-Aldrich Chemie). 
For evaluation of FH and FHR binding to C3b-labeled ciGEnCs, cells were cultured in 96 well 
plates for five days at 37°C, washed twice with HBSS and sensitized with anti-
Jurkat/Ramos/THP-1 antiserum (1:30 in HBSS) (31). Classical pathway activation was then 
induced by incubation with 3.60 µg/ml C1, 1.00 µg/ml C2, 6.00 µg/ml C4 and 130 µg/ml C3 
(Complement Technologies Inc.) in HBSS for 20 minutes at 37°C. C3b labeling was confirmed 
using polyclonal sheep anti-C3 antibody (Immunology Consultants Laboratory Inc., Portland, 
OR, USA) followed by rabbit anti-sheep IgG:HRP conjugate (Sanbio BV). For competition 
assays between FH and FHRs on C3b-labeled ciGEnCs, ciGEnCs were preincubated with FHRs 
for 10 minutes before addition of FH for 20 minutes at RT. Binding of FH and FHRs to C3b-
labeled ciGEnCs was determined as described above.  
 
Alternative/terminal pathway activation assays 
ciGEnCs and HUVECs were cultured in 24 or 48 well plates as described above. After 
differentiation, cells were washed twice with 0.2% (w/v) BSA in phosphate-buffered saline 
(PBS) and incubated for 30 minutes at 37°C with 20% (v/v) normal human serum (NHS; 
Complement Technologies Inc.) in veronal-buffered saline (15 mM barbitone, 145 mM NaCl, 
5 mM MgCl2, 5 mM EGTA, 0.025% NaN3 (pH 7.3)) or 20% NHS supplemented with 35 µg/ml 
FHR1, 25 µg/ml FHR2 or 5 µg/ml FHR5. 20% NHS supplemented with 10 mM EDTA was used 
to correct for cell surface binding of C3 in absence of complement activation. Monoclonal 
antibodies specific for decay-accelerating factor (Bio-Rad Laboratories BV; clone: BRIC-216) 
or membrane cofactor protein (Santa Cruz Biotechnology, Santa Cruz, CA, USA; clone: M177) 
were included to sensitize ciGEnCs to AP activation. To determine AP activity deregulation 
on ciGEnCs using patient serum, cells were incubated with C3G patient sera including 
patients with 3 to 4 copies of the CFHR1 gene or the CFHR1 and CFHR3 gene deletion 
(ΔCFHR3-1). Since no C3 deposition was observed when using C3G patient sera (not shown), 
most likely due to C3 consumption by fluid phase activation, 20% NHS or C3G patient sera 
were supplemented with active AP components C3 (130 µg/ml), factor B (21 µg/ml) and 
factor D (0.2 µg/ml) (Complement Technologies Inc.) before addition to the cells. Patient 
sera which did not exceed the C3 signal of NHS supplemented with EDTA (MFI: 54819 ± 
6202) by at least 2.5-fold after AP supplementation were rejected from analysis. To 
determine potential therapeutic effects, FHR-supplemented sera were spiked with 2-O-
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desulfated heparin before addition to the cells. Cells were detached by incubation with 1% 
(w/v) BSA in non-enzymatic cell dissociation solution (Sigma-Aldrich Chemie) and gentle 
scraping, centrifuged at 500 g and resuspended in 0.5% (w/v) BSA in ice-cold PBS. C3 and C9 
deposition was detected using polyclonal sheep anti-C3 antibodies and goat anti-C9 
antiserum (Quidel, San Diego, CA, USA). Antibody binding was quantified with Alexa 488-
labeled donkey anti-sheep IgG and donkey anti-goat IgG (Life Technologies, Breda, The 
Netherlands) using a Beckman Coulter CytoFLEX flow cytometer with Kaluza 2.1 software. To 
determine if the classical pathway contributes to the observed C3 deposition, cells were 
sensitized with anti-Jurkat/Ramos/THP-1 antiserum and incubated with 20% NHS in either 
veronal-buffered saline or HBSS (Supplementary figure 1). 
 
HS purification using low melting agarose barium acetate gel electrophoresis 
Glycosaminoglycan extractions were performed as described previously (32). GAGs were 
loaded on 1% (w/v) low-melting agarose gel (Boehringer Mannheim, Mannheim, Germany), 
and resolved by gel electrophoresis in 50 mM barium acetate buffer, pH5.0 (Sigma-Aldrich 
Chemie). Gels were stained using Azure A (Sigma-Aldrich Chemie) and ciGEnC glycocalyx-
derived HS (HSGlx) bands were collected and melted at 65°C for 10 minutes. After extraction 
using an equal volume basic phenol (Boom BV, Meppel, The Netherlands), the aqueous 
phase was collected and HSGlx was precipitated by addition of 0.24 µl 27% (w/v) sodium 
acetate (Sigma-Aldrich Chemie) and 3.72 µl ethanol (Merck, Darmstadt, Germany) per µl 
aqueous phase, followed by overnight incubation at -20°C. Precipitates were collected by 
centrifugation at 15700 g for 10 minutes and resuspended in H2O. Three consecutive 
precipitations were performed per HSGlx extract. 
 
2-O-desulfated heparin oligosaccharide library generation 
2-O-desulfated heparin was generated from 100 mg heparin (Aspen Oss BV, Oss, The 
Netherlands) as described previously (33). A 5% (w/v) solution of heparin in H2O was 
alkalized by adding sodium hydroxide (Merck) to 0.5 M concentration, snap-freezing and 
lyophilization. 1% (w/v) sodium borohydride (Sigma-Aldrich Chemie) was included to 
minimize degradation by β-elimination. The resulting product was dissolved and neutralized 
by adding 5% (v/v) acetic acid and dialyzed extensively against H2O. Selective 2-O-desulfation 
was confirmed by disaccharide analysis of 4 mg heparin or 2-O-desulfated heparin as 
described previously (34). 2-O-desulfated heparin oligosaccharide libraries were generated 
following the protocol described by Powell et al. (35). 40 mg 2-O-desulfated heparin were 
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digested overnight at 37°C using 1.0 mU/mg heparinase II (Iduron, Macclesfield, UK) in 2.0 
ml 100 mM sodium acetate (pH 7.0), 1.5 mM calcium chloride. 5.00 to 8.75 mg/run of 2-O-
desulfated heparin digest were resolved by size exclusion chromatography in 0.25 M 
ammonium bicarbonate at 0.22 ml/min flow speed over a BioGel P10 column (75x1.6 cm; 
Bio-Rad Laboratories BV) while monitoring the absorbance at 232 nm and collecting 1.0 ml 
fractions. Fractions corresponding to defined peaks were pooled, dialyzed against H2O using 
100-500 Da molecular weight cut-off Float-A-Lyzers (Repligen, Breda, Netherlands) and 
concentrated by centrifugal evaporation. 2-O-desulfated heparin oligosaccharides were 
quantified using a Smart-Spec Plus spectrophotometer (Bio-Rad Laboratories BV) to measure 
the absorbance 232 nm and an extinction coefficient of 5500 M-1cm-1 (36). Successful 
digestion and size separation were confirmed using polyacrylamide gel electrophoresis 
compared to size-defined heparin oligosaccharide standards (GlaxoSmithKline, Brentford, 
UK; Iduron) (35), Alcian blue staining and silver-staining following Morrissey (37). 
 
Competition assays using selectively desulfated heparin (oligosaccharides)  
Since HSGlx yields were too low to allow quantification by weighing, HSGlx was immobilized on 
microtiter plates (NUNC, Roskilde, Denmark) at a concentration which resulted in ~70% of 
the EW4G2 signal obtained from 2.0 µg/well of HS from bovine kidney (Sigma-Aldrich 
Chemie). Plates were washed using PBS containing 0.05% (v/v) Tween-20 and blocked using 
2% (w/v) BSA in HBSS for 2 hours at RT. Binding of FH, FHR1, FHR2 and FHR5 after 1 hour 
incubation at RT was determined as described for cell surface binding assays. For 
competition between FH and FHRs, plates were preincubated with FHR1 or FHR5 in 2% BSA 
in HBSS for 1 hour at RT before incubation with FH. The role of HS modifications was 
evaluated by preincubating FH, FHR1 and FHR5 with 100 µg/ml heparin, N-, 2-O- and 6-O-
desulfated heparin (Iduron) for 1 hour at RT before addition to immobilized HSGlx. To 
determine the minimum oligosaccharide size required for inhibition of FHR1 and FHR5 
binding to HSGlx, proteins were preincubated with 10 µM each of the different size exclusion 
chromatography fractions. 
 
Statistics 
Experiments were performed at least in triplicate and values are given as mean ± standard 
error of the mean unless stated otherwise. Groups were compared with Student's t-test or 
ANOVA (>2 groups) using GraphPad Prism 5.03 (GraphPad Software Inc., San Diego, CA). 
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Results 
FH and type 1 FHRs bind to (C3b-labeled) glomerular endothelial cells in vitro 
To investigate the role of specific sulfate modifications in the interaction between FH, type 1 
FHRs and HS in the glomerular endothelial glycocalyx in vitro, FH and FHRs were first titrated 
on ciGEnCs. All proteins except FHR2 bound to the cell surface within their reported 
physiological concentrations (13, 38, 39) (Figure 1a and 1b). Depositing C3b on antibody-
sensitized ciGEnCs using classical pathway proteins (Figure 1c) significantly increased binding 
of FH (Figure 1d) and FHRs (Figure 1e), though FHR2 binding remained relatively weak 
compared to FHR1 and FHR5.  
 
 
Figure 1 – Factor H and recombinant FHR1 and FHR5 bind to glomerular endothelial cells in vitro. Factor H (a) 
and factor H-related proteins (FHRs) 1, 2 and 5 (b) were titrated on conditionally immortalized glomerular 
endothelial cells (ciGEnCs) and binding was determined using ELISA. Labeling antibody-sensitized ciGEnCs with 
C3b using classical pathway proteins (c) significantly increased binding of factor H (d) and FHR1, FHR2 and FHR5 
(e). (OD450, optical density at 450 nm; *p<0.05, **p<0.01, ***p<0.001 vs C1/C2/C4) 
 
FHR1 and FHR5 deregulate complement on glomerular endothelium in vitro 
Since type 1 FHRs bound to (C3b-labeled) glomerular endothelial cells in vitro, their effect on 
complement regulation in the glomerular endothelial microenvironment was determined 
using complement activity assays. Supplementing human serum with FHR1, FHR2 or FHR5 
before incubation with ciGEnCs and quantifying complement activation products on the cell 
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surface revealed a significant deregulation of AP activity in the case of FHR1 and FHR5 
(Figure 2a), and the terminal pathway in the case of FHR1 (Figure 2b). No significant AP 
activity deregulation compared to healthy control serum was observed when ciGEnCs were 
incubated with serum from C3G patients (p=0.19), although individual patients showed up to 
1.5-fold increased C3 deposition (Supplementary figure 2). To determine if the observed 
deregulation results from decreased FH binding to ciGEnCs, FH was added to cells 
preincubated with type 1 FHRs. While no significant inhibition of FH binding was observed on 
untreated ciGEnCs, FHR5 significantly reduced cell surface binding of FH after ciGEnCs were 
labeled with C3b using the classical pathway (Fig. 2c). Thus, HS-binding type 1 FHRs 
deregulate complement activity on ciGEnCs, although deregulation might depend on C3 
deposition in the cellular microenvironment.  
 
 
Figure 2 – Factor H-related proteins 1 and 5 deregulate alternative pathway activation on glomerular 
endothelial cells in vitro. Conditionally immortalized glomerular endothelial cells (ciGEnCs) were incubated 
with 20% normal human serum (NHS) in veronal-buffered saline including EGTA, which prevents classical/lectin 
pathway activation. Serum was supplemented with factor H-related proteins (FHRs) 1, 2 or 5 and effects on 
alternative pathway (a) and terminal pathway (b) activity were evaluated using flow cytometry. To determine 
the effect of FHR competition on FH binding, unlabeled or C3b-labeled ciGEnCs were pre-incubated with buffer 
(Control) or FHRs 1, 2 or 5, after which FH binding was detected using ELISA (c). Potential therapeutic 
applications of 2-O-desulfated heparin were investigated by incubating (FHR-supplemented) serum with 
increasing concentrations of 2-O-desulfated heparin before addition to the cells (d). (**p<0.01, ***p<0.001 vs 
NHS; #p<0.05 vs Control) 
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Silencing HS biosynthesis enzymes in ciGEnCs alters the expression of specific HS epitopes 
and differentially reduces binding of FH, FHR1 and FHR5 
To identify relevant targets for silencing, the expression of HS biosynthesis enzymes in 
ciGEnCs was evaluated (Figure 3a). Glomerular endothelial cells expressed both EXT1 and 
EXT2, i.e. the components of the EXT copolymerase complex, as well as GLCE and HS2ST at 
high levels in vitro. NDST isoforms were expressed at variable levels, with NDST2 being most 
prominent, followed by NDST1, whereas NDST3 and NDST4 were not detected. Similarly, 
HS6ST1 was the most abundant 6-O-sulfotransferase isoform, while expression of HS6ST2 
and HS6ST3 was comparatively low. Therefore, EXT1, NDST1, NDST2, GLCE, HS2ST and 
HS6ST1 were selected as targets for silencing.  
 
 
Figure 3 – Factor H and Factor H-related protein 1 binding to glomerular endothelium in vitro is differentially 
reduced by silencing of HS biosynthesis enzymes. Expression of HS biosynthesis enzymes exostosin (EXT) 1 and 
2, N-deacetylase/N-sulfotransferase (NDST) 1-4, glucuronic acid epimerase (GLCE), 2-O-sulfotransferase 
(HS2ST) and 6-O-sulfotransferase (HS6ST) 1-3 in conditionally immortalized glomerular endothelial cells 
(ciGEnCs) was determined using quantitative real-time PCR. Expression was quantified as the difference in PCR 
amplification cycles (ΔCT) between the target gene and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 
i.e. lower values indicate higher expression. NDST3 and NDST4 transcripts were not detected within forty 
amplification cycles (a). Short interfering RNA was used to silence the expression of HS biosynthesis enzymes in 
conditionally ciGEnCs and binding of glycoprobes AO4B08 (b) and EW4G2 (c) with specificities for highly 
sulfated HS structures as well as factor H (d), and factor H-related proteins 1 (FHR1, e) and 5 (FHR5, f) was 
evaluated using ELISA. (*p<0.05, **p<0.01, ***p<0.001 vs Control). 
 
97 
 
RNA interference using siRNA reduced mRNA expression of all targets except NDST2 by ~80-
90% (Table 2), which significantly altered the expression N-, 2-O- and 6-O-sulfated HS 
domains recognized by the HS-specific antibodies AO4B08 (Figure 3b) and EW4G2 (Figure 
3c). FH, FHR1 and FHR5 binding to ciGEnCs after silencing was determined (Figure 3d-f), 
whereas FHR2 was excluded due to its comparatively weak ciGEnC binding. Silencing NDST2, 
HS2ST and HST6ST1, i.e. the enzymes catalyzing N-, 2-O- and 6-O-sulfation of HS, 
respectively, significantly decreased ciGEnC binding of FH. FHR1 binding in turn appeared to 
be primarily dependent on NDST activity, as only NDST1 and NDST2 knockdown resulted in 
significant decreases in binding. GLCE knockdown reduced ciGEnC binding of both proteins, 
whereas EXT1 silencing did not reduce binding of any of the proteins. Notably, FHR5 binding 
to ciGEnCs was unaffected by silencing of any of the enzymes. In conclusion, NDST1, HS2ST 
and HS6ST1 differentially regulate FH and FHR1 binding in the glomerular endothelial 
microenvironment. 
 
Table 2 – HS biosynthesis enzyme mRNA expression knockdown efficiencies. Exostosin (EXT) 1, N-
deacetylase/N-sulfotransferase (NDST) 1 and 2, glucuronic acid epimerase (GLCE), 2-O-sulfotransferase (HS2ST) 
and 6-O-sulfotransferase 1 (HS6ST1) expression in conditionally immortalized glomerular endothelial cells was 
knocked down using short interfering RNA. Knockdown efficiencies were determined using quantitative real-
time PCR. 
Target 
gene 
mRNA expression (%, 
mean ± standard 
deviation) 
EXT1 19.3 ± 4.4 
NDST1 11.9 ± 4.2 
NDST2 37.5 ± 9.5 
GLCE 8.8 ± 1.4 
HS2ST 14.0 ± 3.9 
HS6ST1 23.7 ± 9.8 
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Desulfated heparins selectively compete for FHR, but not for FH binding to ciGEnC HS 
To investigate FH/FHR binding to HSGlx under conditions where HS is the only ligand available 
and to further define the role of distinct sulfate modifications, FH and type 1 FHR binding to 
purified and immobilized HSGlx was determined using ELISA. As observed for ciGEnCs, FH, 
FHR1 and FHR5 bound to HSGlx, contrary to FHR2, which was therefore excluded from 
subsequent experiments (Figure 4a). In absence of other ligands on the glomerular 
endothelial cell surface, FHR1 and FHR5 efficiently competed for FH binding to HSGlx (Figure 
4b). To confirm the relevant HS modifications suggested by RNA interference, competition 
assays were performed using heparin, which structurally reflects heparan sulfate domains 
rich in N-, 2-O- and 6-O-sulfation, and N-, 2-O- or 6-O-desulfated heparin. Unmodified 
heparin blocked HS binding sites on FH, FHR1 and FHR5, thereby preventing their binding to 
HSGlx, although removing any of the sulfates from heparin abolished competition for FH 
binding (Figure 4c). In contrast, 2-O- and 6-O-desulfated, and to a lesser degree N-desulfated 
heparin were still able to compete for FHR1 (Figure 4d) and FHR5 (Figure 4e). Accordingly, 
adding 2-O-desulfated heparin to type 1 FHR-supplemented serum during AP activation 
assays concentration-dependently reversed the deregulation caused by the competition 
with FH on ciGEnCs (Figure 2d) as well as HUVECs (Supplementary figure 3). Thus, 2-O- and 
6-O-desulfated heparins were identified as highly selective competitors for FHR1 and FHR5, 
but not FH binding to HSGlx, and have therapeutic potential in treating C3G. 
 
 
Figure 4 – O-desulfated heparin (oligosaccharides) are highly selective inhibitors of FHR1 and FHR5, but not 
FH binding to glomerular endothelial heparan sulfate (HS). HS was purified from conditionally immortalized 
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glomerular endothelial cells (HSGlx) and immobilized on microtiter plates. Binding of factor H (FH) and factor H-
related proteins (FHRs) was measured using ELISA (a). For competition assays, HSGlx was incubated with FHR1 
or FHR5 before binding of FH was determined (b). The contribution of specific sulfate modifications to FH (c), 
FHR1 (d) and FHR5 (e) binding to HSGlx was evaluated by preincubating proteins with heparin or selectively 2-O-
, 6-O- and N-desulfated (deS) heparin before addition to microtiter plates. To determine the minimal 
oligosaccharide size required for FHR1 and FHR5 competition, proteins were preincubated with equimolar 
amounts of 2-O-desulfated heparin digest size exclusion chromatography fractions (f). (OD450, optical density 
at 450 nm; **p<0.01, ***p<0.001 vs Control; ##p<0.01, ###p<0.001 vs Heparin) 
 
Short 2-O-desulfated heparin oligosaccharides are selective inhibitors of FHR1 and FHR5 
binding to HSGlx 
The reversal of FHR-mediated deregulation of AP activity on ciGEnCs following the addition 
of 2-O-desulfated heparin indicates a potential for treating C3G. However, its size and 
structural heterogeneity may cause unwanted side effects during clinical application, which 
could be reduced by using size- and possibly structurally defined oligosaccharides to 
minimize interactions with other heparin-binding proteins. Therefore, a 2-O-desulfated 
heparin oligosaccharide library was generated to determine the minimal oligosaccharide size 
required for competing with FHR1 and FHR5 for HSGlx. Alkaline lyophilization of 100 mg 
heparin yielded ~70 mg product after dialysis, which corresponded to the commercially 
available 2-O-desulfated heparin in both size and selective competition for FHR, but not FH 
binding (Supplementary figure 4). The relative amount of 2-O-sulfated disaccharides in 2-O-
desulfated heparin was selectively reduced from 81% to 4% compared to the original 
material, whereas N- and 6-O-sulfates were essentially unaffected (91% to 91% and 85% to 
84%, respectively (Table 3). Gel electrophoresis of the 2-O-desulfated heparin digest 
revealed distinct oligosaccharide bands ranging down to at least tetrasaccharides based on 
comparison with Fondaparinux (Arixtra®), a clinically applied pentasaccharide (Figure 5a). 
Separation of 2-O-desulfated heparin oligosaccharides using size exclusion chromatography 
(Figure 5b) yielded seven fractions enriched for distinct oligosaccharide sizes ranging down 
from dodecasaccharides (FR3 to FR9) as well as two fractions corresponding to barely 
digested (FR1) and unresolved oligosaccharides (FR2) (Figure 5c). Importantly, the selectivity 
of 2-O-desulfated heparin was retained even in the smallest oligosaccharide fractions (Figure 
4f), as all tested fractions inhibited FHR1 and FHR5, but not FH binding to HSGlx, supporting 
their potential application in novel C3G therapies.  
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Table 3 – Alkaline lyophilization selectively reduces 2-O-sulfation of heparin. Disaccharide profiles of 2-O-
desulfated (2-O-desulf.) heparin and the original heparin preparation. (Orange: 2-O-sulfated disaccharides, 
Green: Disaccharides lacking 2-O-sulfates; ΔUA: unsaturated uronic acid, GlcNAc: N-acetylglucosamine, GlcNS: 
N-sulfoglucosamine, 2S: 2-O-sulfation, 6S: 6-O-sulfation)  
 Heparin (%) 
2-O-desulf. 
 heparin (%) 
ΔUA,2S-GlcNS,6S 69.65 2.87 
ΔUA,2S-GlcNAc,6S 1.69 0.24 
ΔUA-GlcNS,6S 11.01 76.09 
ΔUA-GlcNAc,6S 2.93 4.49 
ΔUA,2S-GlcNS 7.47 0.67 
ΔUA,2S-GlcNAc 1.79 0.15 
ΔUA-GlcNS 2.88 11.31 
ΔUA-GlcNAc 2.58 4.19 
 
 
Figure 5 – 2-O-desulfated heparin oligosaccharide library generation. 2-O-desulfated heparin was digested 
into oligosaccharides by heparinase II (a) and the oligosaccharides were separated into different size fractions 
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(FR1-9) using size exclusion chromatography (SEC) (b, representative SEC chromatogram of digested 2-O-
desulfated heparin. AU, absorbance units). Size range and resolution of SEC fractions were resolved by gel 
electrophoresis and visualized by Alican blue and silver staining compared to commercial heparin-derived 
pentasaccharides (Arixtra®, dp5), decasaccharides (dp10) and docosasaccharide (dp22) (c). 
 
Discussion 
The pathogenesis of C3G is associated with the deregulation of FH-mediated complement 
inhibition in the glomerulus by type 1 FHRs, which have been proposed to compete with FH 
for host tissue-associated ligands, such as HS in the glomerular endothelial glycocalyx or 
glomerular basement membrane. Although binding of FH, FHR1 and FHR5 to ciGEnCs 
reflected the proteins’ HS binding ability (38, 39), a contribution of other cell surface ligands, 
such as sialic acid, cannot be excluded. Binding of all proteins was increased by depositing 
C3b on ciGEnCs, suggesting that type 1 FHR-mediated deregulation could be affected by an 
immunological insult which results in glomerular C3b deposition. The presence of C3b in the 
glomerular microenvironment appears particularly relevant for FHR5-mediated AP activity 
deregulation, which showed the largest relative increase in binding to C3b-labeled ciGEnCs 
among the type 1 FHRs and significantly reduced FH binding to C3b-labeled ciGEnCs. 
Notably, CFHR5 nephropathy is frequently preceded by respiratory and other infections 
which might result in accumulation of C3b-containining complement deposits in the 
glomerular microenvironment (40), facilitating competition with FH and thus AP activity 
deregulation. 
Contrary to FHR5, FHR1 did not inhibit FH binding to ciGEnCs, but strongly deregulated AP 
activity on ciGEnCs, resulting in terminal pathway activation and C9 deposition. FHR1-
mediated deregulation might therefore differ on cell surfaces which have been C3b-labeled 
by AP activation compared to classical pathway activation, e.g. through interactions with the 
AP C3 convertase (C3bBb) rather than C3b alone. Notably, the classical pathway does not 
contribute to the C3 deposition observed on ciGEnCs in vitro (Supplementary figure 1). 
Alternatively, FHR1-mediated AP activity deregulation on ciGEnCs could result from C3 
convertase assembly on cell surface-attached FHR1 (41), as has been described for properdin 
(42, 43). Although FHR5-mediated AP activity deregulation on ciGEnCs did not lead to 
terminal pathway activation in vitro, AP deregulation is likely to proceed into terminal 
pathway activation in vivo over time if C3b deposits are not cleared up. The absence of 
significant AP deregulation by FHR2 on ciGEnCs matches its low overall binding to unlabeled 
and C3b-labeled cell surfaces.  
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No significant AP deregulation was observed in C3G patient sera even after supplementation 
with active AP components and sensitization of ciGEnCs to AP activation by inhibiting decay-
accelerating factor and membrane cofactor protein using monoclonal antibodies. However, 
the trend in average C3 deposition indicates an increased AP activity in the glomerular 
microenvironment for C3G patients, including patients with 3 to 4 copies of the CFHR1 gene. 
The increase in AP activity appears absent in C3G patients with ΔCFHR3-1 deficiency, 
suggesting that the glomerular AP activity deregulation is affected by the presence of FHR1. 
The largest deregulation (~1.5-fold increased C3 deposition) was found for a patient with 
multiple copies of the CFHR1 gene, matching the strong deregulation observed with FHR1-
supplemented serum. Expanding the group sizes might further solidify the observed trends. 
Alternatively, larger amounts of active complement might be required to detect significant 
deregulation on the cell surface, especially if AP components are quickly consumed by 
activation in the fluid phase. 
ciGEnCs show a specific expression pattern of HS biosynthesis enzyme isoforms, with NDST3 
and NDST4 being not detected, as previously observed for mouse glomerular endothelial 
cells (44). Silencing highly expressed genes, with the exception of HS2ST, significantly 
reduced binding of glycoprobes AO4B08 and EW4G2, which specifically recognize highly 
sulfated HS structures. However, an increase in N- and 6-O-sulfation has been described in 
mice lacking 2-O-sulfotransferase (45), which might also compensate for the reduction in 2-
O-sulfation due to RNA interference in vitro. Furthermore, decreases in AO4B08 and EW4G2 
binding are relatively larger than decreases observed for FH, FHR1 and FHR5, suggesting that 
non-HS ligands for FH/FHRs can at least partially compensate for the loss of HS. This 
redundancy appears particularly prominent for FHR5, which has been shown to bind 
additional ligands such as laminin-521 in the extracellular matrix (46, 47), and was 
unaffected by RNA interference.  
When the interaction between FH, FHRs and HS was investigated using purified HSGlx, i.e. in 
absence of other cell surface ligands, the observed effects of FHR competition and removing 
specific HS modifications were increased significantly. Unmodified heparin competed more 
efficiently for FHR1 and FHR5 than for FH binding to HSGlx. Heparin has successfully been 
used in the treatment of C3G patients (48), suggesting that the observed effects could have 
been partially mediated by competition of FHR1 and FHR5 from glomerular endothelial HS. 
FH binding to HSGlx depended on N-, 2-O- and 6-O-sulfation, supporting the results of the 
silencing assays and matching previously published FH competition experiments with 
selectively desulfated heparin (9, 49). In contrast, N-, 2-O- and 6-O-desulfated heparin were 
efficient inhibitors of FH binding to mouse glomerular endothelial cells in vitro (50), 
suggesting that desulfated heparins might interfere with FH binding to ligands other than HS 
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in the microenvironment of mouse glomerular endothelial cells. As observed for FH, 
selectively desulfated heparin competition for FHR1 binding to HSGlx supports the silencing 
results, as binding was primarily mediated by N-sulfation. Although the interaction between 
FHR5 and ligands in the glomerular endothelial microenvironment in vitro was unaffected by 
silencing of HS biosynthesis enzymes, FHR5 binding was strongly dependent on N-, but not 2-
O- and 6-O-sulfation in context of purified HSGlx. Since silencing of HS2ST and HS6ST1 
significantly decreased binding of FH, but not FHR1 and FHR5 in the glomerular endothelial 
microenvironment, a reduction in the activity of these enzymes could shift the balance of FH 
and type 1 FHRs to favor complement activation. These enzymes are therefore promising 
candidates for targeted genetic analysis in C3G patients, particularly patients without C3G-
associated mutations in complement genes (51). 
Notably, although FHR5 bound more strongly to HSGlx compared to FHR1, FHR1 was the more 
potent competitor for FH binding to HSGlx, reflecting the close homology between the HS 
binding domains of the two proteins. Nevertheless, the difference in heparin/HS binding 
characteristics between FH and FHR1 is striking considering the 97% identity between FH 
CCP20 and FHR1 CCP5. The two altered amino acids (S1191/L290 and V1197/A296) in 
FH/FHR1 are buried and unlikely to interact directly with HS. They do however affect the 
structure of a surface-exposed loop containing the HS-binding amino acids K1186/K285 and 
K1188/K287 in FH/FHR1 (52), possibly altering the surface charge distribution and 
consequently the HS binding characteristics of the domain. Similarly, the age-related 
macular degeneration-associated Y402H polymorphism in the N-terminal HS binding site of 
FH has been shown to significantly affect the domains affinity for specific HS modifications 
(53). Interestingly, both S1191L and V1197A mutations have been described in patients with 
aHUS (54, 55), suggesting a pathogenic mechanism in which CCP20 of FH approximates the 
structure of FHR1 CCP5, leading to increased competition. 
Finally, the ability of 2-O-desulfated heparin (oligosaccharides) to selectively compete for 
FHR, but not FH binding to HSGlx and reverse FHR-mediated AP deregulation on glomerular 
endothelial cells in vitro provides a novel approach for treating C3G. 2-O-desulfation by 
alkaline lyophilization is not only remarkably selective and simple, it also removes the rare 
glucosamine 3-O-sulfate modification, significantly reducing the anticoagulant activity of 2-
O-desulfated heparin (56) and thus potential adverse effects. Importantly, selective 
competition was retained in short 2-O-desulfated oligosaccharides (<hexasaccharides), 
potentially enabling the synthesis of therapeutically active oligosaccharides by 
chemoenzymatic methods (57). The short 2-O-desulfated heparin oligosaccharides 
generated in this study are therefore prominent candidates for detailed structural 
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characterization by e.g. mass spectrometry (58, 59) and ultimately therapeutic application in 
C3G. 
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Supplementary figures 
 
Supplementary figure 1 – The classical pathway does not contribute to C3 deposition in the alternative 
pathway activity assays. Conditionally immortalized glomerular endothelial cells were either left untreated 
(Untr.) or sensitized with anti-Jurkat/Ramos/THP-1 antiserum (AB) to induce classical pathway activation. Cells 
were incubated with 20% human serum in veronal-buffered saline supplemented with containing EGTA (EGTA) 
or Hank's balanced salt solution including Mg2+/Ca2+ (HBSS), i.e. buffers which prevent and enable classical 
pathway activation, respectively. C3 deposition was compared to determine if the classical pathway 
contributes significantly to the C3 deposition observed in the AP activity assays (***p<0.001 vs Untr./EGTA; 
MFI: Mean fluorescence intensity). 
 
 
Supplementary figure 2 – No significant alternative pathway deregulation is observed in sera obtained from 
C3G patients. Conditionally immortalized glomerular endothelial cells were incubated with normal human 
serum (NHS) or C3G patient sera, including patients with 3 to 4 copies of the FHR1 gene (red) and patients with 
the FHR1 and FHR3 deletion (ΔCFHR3-1). Sera were supplemented with C3, factor B and factor D to ensure the 
presence of active AP components. Serum samples which did not exceed the C3b signal observed for NHS 
supplemented with ethylenediaminetetraacetic acid to prevent complement activation by at least 2.5-fold 
were excluded from the analysis. 
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Supplementary figure 3 – 2-O-desulfated heparin reverses FHR1- and FHR5-mediated alternative pathway 
deregulation on human umbilical vein endothelial cells. Human umbilical vein endothelial cells were 
incubated in 20% normal human serum (NHS) in veronal-buffered saline including EGTA, which prevents 
classical/lectin pathway activation. Serum was supplemented with factor H-related proteins (FHRs) 1, 2 or 5, or 
FHR proteins including 2-O-desulfated (2-O-des.) heparin before addition to the cells. Effects on alternative 
pathway activity were evaluated using flow cytometry. (***p<0.001 vs Untreated) 
 
 
Supplementary figure 4 – 2-O-desulfated heparin matches commercially available 2-O-desulfated heparin in 
size and selectivity. 2-O-desulfated heparin (2-O-deS. heparin) was compared to the original heparin 
preparation and commercially available 2-O-desulfated heparin (Iduron) using polyacrylamide gel 
electrophoresis (a). Similar to the commercially available product, 2-O-desulfated heparin selectively reduces 
FHR1 and FHR5, but not FH binding to HSGlx (b).  
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Abstract 
Choroidal endothelial cells play a central role in the pathogenesis of age-related macular 
degeneration (AMD). Protocols for the isolation of primary choroidal endothelial cells have 
been described, but require access to human donor eyes, which is a limiting factor. 
Therefore, a conditionally immortalized choroidal endothelial cell (ciChEnC) line has been 
established. Choroidal endothelial cells were selected by magnetic-activated cell sorting and 
conditionally immortalized using temperature-sensitive simian virus 40 large T antigen and 
human telomerase. The cell line obtained was characterized based on expression of 
endothelial marker proteins and endothelial cell-specific responses to various stimuli. 
Binding of AMD-associated and non-AMD variants of complement factor H in context of a 
recombinant CCP6-8 (complement control protein domains 6-8) construct was determined 
using ELISA. ciChEnCs maintained morphology and von Willebrand factor and vascular 
endothelial cadherin expression for up to 27 passages. The cells internalized acetylated low-
density lipoprotein, formed tubes on Matrigel, and increased intercellular adhesion 
molecule-1 expression in response to tumor necrosis factor-α. Cells grew into dense 
monolayers with barrier function and showed characteristics of choriocapillary cells, such as 
expression of plasmalemma vesicle-associated protein, human leukocyte antigen ABC, 
carbonic anhydrase IV, and membrane indentations reflecting fenestrations. ciChEnCs 
synthesized glycosaminoglycans chondroitin sulfate and the complement factor H ligand 
heparan sulfate. Interestingly, binding of the AMD-associated 402H variant of factor H to 
ciChEnC was significantly decreased compared to the 402Y variant. A novel ciChEnC cell line 
with choriocapillary characteristics has successfully been established and should greatly 
facilitate investigation of the pathogenesis of AMD in context of the choriocapillary 
microenvironment. 
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Introduction 
Age-related macular degeneration (AMD) is the major cause of blindness in the elderly, with 
an estimated 300 million people worldwide to suffer from the disease by 2040 (1). In the 
early stages of AMD, electron-dense deposits called drusen accumulate in the central retina 
(the macula), where these form within the Bruch’s membrane, the basal extracellular matrix 
separating the retinal pigment epithelium (RPE), and choriocapillary vessels. In the advanced 
stage the disease progresses into two clinical phenotypes: The “dry” form of AMD is 
characterized by geographic atrophy of photoreceptor and RPE cells, which is often 
preceded by pathogenic changes in the underlying choroidal vasculature (2–6). In the “wet” 
form AMD, aberrant neovascularization of the choriocapillaris across the Bruch’s membrane 
and RPE leads to retinal fluid leakage and severely impaired central vision (7). Clinically 
proven effective treatments for "dry" AMD have not yet been described, whereas 
monoclonal antibodies inhibiting vascular endothelial cell growth factor (VEGF) signaling 
have shown promise in the treatment of "wet" AMD (8).  
Unregulated activation of the complement system, particularly the alternative pathway, has 
been strongly implicated in the etiology of AMD. Drusen contain complement components 
(9, 10), while mutations and AMD-associated polymorphisms have been identified in several 
proteins of the complement system, including the alternative pathway inhibitor complement 
factor H (11–14). In particular, a common factor H polymorphism (Y402H) confers an 
increased risk for developing AMD (15–17) and has been shown to impair the protein's 
interaction with Bruch's membrane and choroidal vessels (18). 
Therefore, choroidal endothelial cells (chEnCs) likely play a central role in both the "dry" and 
"wet" form of AMD. Investigation of their response to angiogenic stimuli as well as 
complement regulation in the choriocapillary microenvironment could reveal novel 
treatment targets for AMD. While protocols for the isolation and culture of primary human 
chEnCs have been described (19, 20), they require a steady source of donor eyes, as cell 
viability in culture is limited. Conditional immortalization of (human) endothelial cells, which 
proliferate when cultured at 33°C and redifferentiate to primary-like cells during culture at 
37°C, has proven successful for the culture of endothelial cells which were previously 
difficult to obtain and maintain in culture (21–23).  
We describe here the generation and characterization of a novel, conditionally immortalized 
choroidal endothelial cell line (ciChEnC). The ciChEnC cell line has multiple phenotypic and 
functional features of choroidal endothelial cells, which will facilitate mechanistic research 
aimed at AMD, including complement regulation in the microenvironment of the 
choriocapillaris. 
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Methods 
Isolation and conditional immortalization of primary choroidal endothelial cells 
Primary chEnCs were isolated based on published protocols (19, 20). A ~1 cm2 tissue section 
around the macula was excised from the enucleated eye bulb of a 63-year-old female donor 
with ocular melanoma that did not affect the macula. There were no signs of macular 
degeneration in the unaffected or enucleated eye. Informed consent was obtained following 
the tenets of the Declaration of Helsinki. Following removal of the neuroretina, the RPE in 
the macula area was carefully brushed from Bruch’s membrane using a sterile cotton swap. 
Bruch's membrane and the underlying choroid were peeled from the sclera and digested 
using 200 U/ml collagenase II (Life Technologies, Breda, The Netherlands) in sterile Hank's 
balanced salt solution (HBSS) for 3 hours at 37°C. The released cells were then filtered 
through 70-µm nylon filters (VWR International, Radnor, PA, USA), seeded in bovine 
fibronectin (1 µg/cm2; Bio-Connect, Huissen, The Netherlands)-coated culture flasks (Corning 
Inc., Corning, NY, USA) containing microvascular endothelial cell growth medium (EGM-2 
MV; Lonza, Verviers, Belgium) and grown to confluence. Monolayers were detached using 
0.0125% (wt/vol) trypsin (Life Technologies) in 10 mM ethylenediaminetetraacetic acid and 
endothelial cells were selected using 2.0 µg mouse anti-platelet endothelial cell adhesion 
molecule (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and 0.5 µg mouse anti-vascular 
endothelial cadherin (BD Pharmingen, San Diego, CA, USA) antibodies per 106 cells, followed 
by incubation with goat anti-mouse IgG-coated magnetic beads (Dynabeads; Life 
Technologies; 5 beads/cell) and magnetic-activated cell sorting. Cells were then 
immortalized by transduction with temperature-sensitive Simian virus 40 large T antigen and 
human telomerase and selected as described previously (24), followed by subcloning from 
single cells by limiting dilution. 
 
Cell culture 
Conditionally immortalized choroidal endothelial cells (ciChEnCs) were maintained in 
fibronectin-coated culture flasks containing EGM-2 MV at 33°C and split 1:3 every 4 days. For 
differentiation, cells were seeded 1:3 at 37°C and cultured for 4 to 5 days, refreshing the 
growth medium every other day. For tube formation assays, 3 x 105 ciChEnCs were seeded in 
EGM-2 MV in 6 well plates (Corning Inc.) precoated with 600 µl/well Matrigel (Sigma-Aldrich 
Chemie, Zwijndrecht, The Netherlands) and tube formation was evaluated after 18 hours. 
Pictures of tube formation and cell morphology were taken at x40 and x200 total 
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magnification, respectively, using a Nikon Coolpix 990 camera (Nikon, Tokyo, Japan). The RPE 
cell line ARPE-19 was cultured in DMEM/F12 (Life Technologies) as described previously (25). 
 
Immunocytochemistry 
Cells were cultured in slide flasks, washed twice in phosphate-buffered saline (PBS) and fixed 
for 10 minutes using 90% ice-cold acetone, or 2% paraformaldehyde for plasmalemma 
vesicle-associated protein (PLVAP), human leukocyte antigen (HLA)-ABC, and carbonic 
anhydrase IV staining. Cell monolayers were blocked for 1 hour at room temperature (RT) 
with 1% (wt/vol) bovine serum albumin (BSA, Sigma-Aldrich Chemie) in PBS. Cells were 
stained using goat anti-vascular endothelial cadherin antibody (Santa Cruz Biotechnology), 
rabbit anti-von Willebrand factor antibody (DAKO, Glostrup, Denmark), rabbit anti-PLVAP 
(Atlas Antibodies, Bromma, Sweden), mouse anti-HLA-ABC (ITK Diagnostics, Uithoorn, The 
Netherlands) or rabbit anti-carbonic anhydrase IV (Life Technologies) in 1% BSA in PBS for 1 
hour at RT. Antibodies were detected using fluorescently-labeled donkey anti-goat IgG:Alexa 
594 or goat anti-rabbit IgG:Alexa 488 (Life Technologies) in 1% BSA in PBS for 1 hour at RT. 
For internalization of acetylated low-density lipoprotein (LDL), unfixed ciChEnCs or ARPE-19 
cells were incubated with Alexa 488-labeled acetylated LDL (Life Technologies) in EGM-2 MV 
for 4 hours at 37°C. Stained cells were postfixed using 1% paraformaldehyde in PBS for 15 
min at RT and embedded in Vectashield H-1000 mounting medium (Brunschwig Chemie, 
Amsterdam, The Netherlands) containing 4',6-diamidino-2-phenylindole. Pictures were 
taken at x200 total magnification, or 400x total magnification for PLVAP, HLA-ABC and 
carbonic anhydrase IV using a Zeiss Axio Imager.M1 microscope (Zeiss, Jena, Germany). 
 
Analysis of ciChEnC activation by flow cytometry 
ciChEnCs were cultured at 37°C and activated using 10 ng/ml recombinant tumor necrosis 
factor-α (eBioscience, Vienna, Austria) in EGM-2 MV for 18 hours before measuring 
intercellular adhesion molecule-1 (ICAM-1) expression. Cells were detached in enzyme-free 
cell dissociation buffer (Sigma-Aldrich Chemie) for 30 minutes at RT, centrifuged at 570g for 
5 minutes, and resuspended in ice-cold 0.5% (wt/vol) BSA in PBS. ICAM-1 expression was 
detected using a mouse monoclonal anti-human ICAM-1 antibody (Clone HA58, 
eBioscience), followed by goat anti-mouse IgG:Alexa 488 conjugate (Life Technologies). 
Fluorescence was quantified using a FC500 flow cytometer with CXP2.2 software (Beckman 
Coulter, Miami, FL, USA) and mean fluorescence intensities were corrected for background 
staining of murine IgG1 isotype control antibody (Sigma-Aldrich Chemie). 
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Scanning electron microscopy (SEM) 
ciChEnCs were grown at 37°C for 5 days on glass coverslips coated with 1 µg/cm2 bovine 
fibronectin. After washing with serum-free EGM-2 MV at RT, the cell monolayer was prefixed 
with a 1:1 mixture of ice-cold serum-free EGM-2 MV and 2% glutaraldehyde (Sigma-Aldrich 
Chemie) in 0.1 M sodium cacodylate buffer (pH7.3) for 3 minutes. Subsequently, the mixture 
was exchanged against ice-cold 2% glutaraldehyde in 0.1 M sodium cacodylate buffer and 
the cells fixated over night at 4°C. Fixed cells were washed 3x with 0.1 M sodium cacodylate 
buffer for 10 minutes, followed by sequential incubation with 1% (wt/vol) osmium tetroxide 
in 0.1 M sodium cacodylate buffer, 1% (wt/vol) thiocarbohydrazide in deionized water (MQ) 
and 1% osmium tetroxide in 0.1 M sodium cacodylate buffer for 15 minutes each at RT. The 
cells were then washed in MQ and dehydrated by sequential incubation with 30%, 50%, 70% 
and 90% ethanol in MQ for 5 minutes, followed by 100% ethanol and zeolite-dehydrated 
100% ethanol for 15 minutes. Afterwards, the cells were dried using hexamethyldisilazane 
(Sigma-Aldrich Chemie) and gold-coated using a 208HR sputter coater (Cressington, Redding, 
CA, USA). Pictures were taken using a SEM6340F electron microscope (JEOL, Tokyo, Japan). 
 
Glycosaminoglycan isolation and gel electrophoresis 
Glycosaminoglycan (GAG) isolation from ciChEnC monolayers and analysis by gel 
electrophoresis was performed as described previously (26). GAGs from ~8-cm2 monolayer 
were loaded on agarose gels and electrophoretic mobilities of the observed GAG spots were 
compared to 0.5 µg/each of commercial standards for heparan, dermatan and chondroitin 
sulfate (Sigma-Aldrich Chemie). The identity of ciChEnC GAGs was confirmed by digestion 
with 1.0 U/ml chondroitinase ABC (Sigma-Aldrich Chemie) in 50 mM Tris-acetate pH 8.0, 60 
mM sodium acetate or 0.1 U/ml heparinases I, II and III (IBEX Technologies, Montreal, 
Canada) in 20 mM Tris-HCl pH 7.0, 100 mM sodium chloride, and 1.5 mM calcium chloride 
for 1 hour at 37°C. 
 
Transendothelial electrical resistance (TEER) measurement 
TEER measurements were performed essentially as described previously (27). Briefly, 
ciChEnCs were seeded in polyester transwell inserts (0.4-µm pore size; Corning Inc.) and 
cultured for 5 days at 37°C. Control wells were incubated with EGM-2 MV and refreshed 
simultaneously with the ciChEnC cultures. TEER was determined using a Millicell-ERS Volt-
Ohm meter (EMD Millipore, Billerica, MA, USA). After measurement, ciChEnC monolayers 
were fixed using 1% paraformaldehyde and stained with 0.1% (wt/vol) crystal violet in 10% 
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ethanol in MQ for 15 minutes to evaluate the presence of an intact monolayer. Pictures 
were taken at x40 total magnification. 
 
Recombinant factor H CCP6-8 binding in ELISA 
ciChEnCs were seeded in 96-well tissue culture plates (Corning Inc.) and cultured for 5 days 
at 37°C. Recombinant 402H and 402Y variants of factor H complement control protein 
domains 6-8 (CCP6-8) were expressed and purified as described previously (28). Cells were 
washed with HBSS, followed by incubation with 2-fold dilution series of 20 µg/ml CCP6-8 
402Y and 402H in 2% BSA in HBSS for 20 minutes at room temperature. Protein binding was 
detected using polyclonal goat anti-human factor H antibody (Quidel, San Diego, CA, USA) 
followed by incubation with donkey anti-goat IgG:horseradish peroxidase conjugate (Jackson 
ImmunoResearch, West Grove, PA, USA). Assays were developed using 3, 3', 5, 5' 
tetramethyl benzidine substrate A+B (Biolegend, London, UK). Specificity of the antibody 
was confirmed by immobilizing 0.5 µg/well recombinant CCP6-8 proteins in microtiter plates 
(NUNC, Roskilde, Denmark) followed by incubation with a 2-fold dilution series of anti-factor 
H antibody (Supplementary figure 1). 
 
Statistics 
Experiments were performed at least in triplicate and values are given as mean + standard 
error of the mean. Groups were compared with Student's t-test or ANOVA (>2 groups) using 
GraphPad Prism 5.03 (GraphPad Software Inc., San Diego, CA, USA). 
 
Results 
Choroidal endothelial cells have successfully been immortalized 
Conditionally immortalized and differentiated choroidal endothelial cells (ciChEnCs) grew 
into "cobblestone" monolayers comparable to primary chEnCs, with cell morphology being 
unaffected up to 27 passages (Figure 1a, c, d). ciChEnC expression of vascular endothelial 
cadherin (VE cadherin) and von Willebrand factor (vWF), both marker proteins for an 
endothelial phenotype, mirrors the expression by primary choroidal endothelial cells and 
remained unchanged during prolonged cell culture as well (Figure 1e, g, h). Culture at the 
proliferative temperature of 33°C resulted in significantly reduced VE cadherin expression 
and general absence of vWF-positive cells indicating de-differentiation (Figure 1b, f). 
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Figure 1 - Conditionally immortalized choroidal endothelial cells maintain morphology and endothelial 
marker expression up to 27 passages. (a) Primary human choroidal endothelial cells passage (P)5; (b-d) 
ciChEnC at P10, 33°C (b), P10, 37°C (c), and P27, 37°C (d). (f-g) ciChEnCs express endothelial markers vascular 
endothelial cadherin (VE cadherin) and von Willebrand factor (vWF) up to 27 passages (ciChEnC P10, 37°C (g) 
and P27, 37°C (h)) at levels comparable to primary cells (P5 (e)). Expression of VE cadherin and vWF is reduced 
at 33°C (P10 (f)). DAPI, 4',6-diamidino-2-phenylindole. 
 
ciChEnCs show endothelial cell-characteristic responses to various stimuli 
To further investigate the endothelial phenotype, ciChEnCs were exposed to a number of 
stimuli that result in endothelial cell-specific responses. Endothelial cells express a 
scavenging receptor for acetylated LDL (29). Therefore, the ability of ciChEnCs to internalize 
fluorescently labeled acetylated LDL was investigated. ciChEnCs ingested acetylated LDL 
(Figure 2a), whereas no uptake was observed for ARPE-19 cells, a RPE cell line (Figure 2b). 
When cultured on Matrigel, a sarcoma-derived extracellular matrix rich in angiogenesis-
promoting factors including VEGF (30), ciChEnCs formed intricate tubular networks, 
mimicking the formation of new blood vessels in vivo (Figure 2c). In response to 
inflammatory stimuli, endothelial cells increase the expression of cellular adhesion 
molecules such as ICAM-1, allowing leukocytes to adhere to the blood vessel wall and 
extravasate towards the site of inflammation (31). Accordingly, ciChEnCs increasingly 
expressed ICAM-1 after exposure to tumor necrosis factor-α (TNF-α) (Figure 2d).  
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Figure 2 - Conditionally immortalized choroidal endothelial cells show endothelial cell-characteristic 
responses to various stimuli. ciChEnCs internalize acetylated low-density lipoprotein (acetylated LDL) (a), 
whereas no internalization is observed for the RPE cell line ARPE-19 (b). Culturing ciChEnCs on Matrigel results 
in the formation of intricate tubular networks (c). Activation using TNF-α significantly increases the expression 
of ICAM-1 (d); ***p<0.001 vs untreated control, n=6). DAPI, 4',6-diamidino-2-phenylindole; MFI, mean 
fluorescence intensity. 
 
ciChEnCs share characteristics with choriocapillary cells 
The choriocapillaris is a highly polarized, attenuated and fenestrated endothelial tissue (32). 
Choriocapillary fenestrations are generated in response to locally produced growth factors, 
particularly RPE cell-derived VEGF (33, 34), which is also present in the cell culture medium. 
Scanning electron microscopy of ciChEnCs reveals oval membrane indentations of 50- to 
100-nm diameter consistent with fenestrations within the ciChEnC membrane (Figure 3a, b). 
ciChEnCs stained strongly positive for HLA-ABC (Figure 3c) and showed granular membrane 
staining for carbonic anhydrase IV (Figure 3e), which are enriched (35) and exclusively 
expressed (36), respectively, in the choriocapillaris. Similarly, PLVAP, which is contained in 
fenestral diaphragms (37), has been found to be selectively expressed in the choriocapillaris 
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but not larger choroidal vessels (38). Probing ciChEnCs with antibodies specific for PLVAP 
(Figure 3d) resulted in pronounced granular membrane staining, whereas the isotype-
matched rabbit IgG controls revealed no staining (Figure 3f).  
 
 
Figure 3 - Conditionally immortalized choroidal endothelial cells contain membrane indentations consistent 
with fenestrations and express choriocapillary cell-specific proteins. Scanning electron microscopy of 
conditionally immortalized choroidal endothelial cells (ciChEnCs) reveals oval membrane indentations (a, 
arrowheads, scale bar: 1 µm) which are approximately 100 nm in diameter (b. scale bar: 0.1 µm) and 
reminiscent of fenestrae. ciChEnCs stain strongly positive for human leukocyte antigen (HLA)-ABC (c). Staining 
of ciChEnCs for plasmalemma vesicle-associated protein (PLVAP) (d) and carbonic anhydrase IV (e) results in 
granular membrane staining, whereas staining with isotype-matched rabbit IgG control is negative (f). 
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ciChEnCs express endothelial glycocalyx components heparan sulfate and chondroitin 
sulfate 
In vivo, endothelial cells are covered by a thick glycan layer called glycocalyx, which contains 
among others the glycosaminoglycan (GAG) heparan sulfate (HS) (39). Since HS plays a 
central role in controlling complement activation in the cellular microenvironment by 
binding to the alternative pathway inhibitor complement factor H (14, 40–42), the 
expression of GAGs in ciChEnCs was evaluated. After resolving extracted GAGs by agarose 
gel electrophoresis, two distinct GAG spots were observed, which co-migrated with 
commercial standards for HS and chondroitin sulfate, and which were efficiently degraded 
by incubation with the GAG-specific glycosidases heparinase I, II and III, and chondroitinase 
ABC (Figure 4). 
 
 
Figure 4 - Conditionally immortalized choroidal endothelial cells express the endothelial glycocalyx 
components heparan sulfate and chondroitin sulfate. ciChEnC glycosaminoglycans (GAGs) were resolved on 
barium acetate agarose gels. GAGs co-migrated with commercial standards for heparan sulfate (HS) and 
chondroitin sulfate (CS), with CS being more prominent. Treatment with chondroitinase ABC (CSase ABC) and 
heparinases I, II and III (Hep. I/II/III) confirmed the identity of the GAG spots. DS, dermatan sulfate. 
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ciChEnCs form dense endothelial monolayers with barrier function in vitro 
In glomerular and other endothelial cells, the glycocalyx provides a selective barrier against 
leakage of plasma proteins through endothelial fenestrations (43). Since the choriocapillaris 
is fenestrated and ciChEnCs express glycocalyx components in vitro, cells were cultured in 
transwell insert and the TEER was determined as model for endothelial barrier function. 
Crystal violet staining revealed dense monolayers (Figure 5a), which increased TEER over the 
transwell insert by approximately 20 Ω*cm2 compared to empty control wells (Figure 5b). 
 
Figure 5 - Conditionally immortalized choroidal endothelial cells grow to dense monolayers with endothelial 
barrier function. Trans-endothelial electrical resistance (TEER) of ciChEnC monolayers was determined as 
measure of endothelial barrier function. Staining ciChEnCs with crystal violet revealed dense monolayers (a), 
which significantly increased TEER compared to empty control wells (b, ***p<0.001). 
 
AMD-associated 402H polymorphism reduces ciChEnC binding of factor H CCP6-8 
The common Y402H polymorphism in the CCP7 domain of complement factor H, 402H, 
confers an increased risk for AMD and alters the protein's specificity for HS compared to the 
non-disease-associated 402Y variant (28). Since ciChEnCs were found to express HS, binding 
of both the non-AMD (402Y) and AMD-associated (402H) variant of factor H in context of the 
recombinant CCP6-8 construct to ciChEnCs was determined. While both proteins showed a 
concentration-dependent increase in signal, binding of the AMD-associated 402H variant of 
CCP6-8 was significantly reduced by ~40% compared to the non-AMD 402Y variant. 
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Figure 6 - The age-related macular degeneration-associated Y402H polymorphism reduces factor H CCP6-8 
binding to conditionally immortalized choroidal endothelial cells. Recombinant factor H CCP6-8 402H bound 
significantly less well to ciChEnCs in ELISA compared to the non-disease-associated 402Y variant. Signals were 
normalized based on the maximum signal obtained in the assays (*p<0.05, ***p<0.001). 
 
Discussion 
The current study describes the successful conditional immortalization of human chEnCs, as 
cells could be maintained in culture at the permissive temperature of 33°C for up to 27 
passages without signs of senescence. Cell morphology reflected primary choroidal 
endothelial cells (19, 20), as well as other conditionally immortalized human microvascular 
endothelial cells (22). ciChEnCs expressed the endothelial marker proteins vWF and VE 
cadherin at stable levels up to 27 passages at the non-permissive temperature, whereas the 
reduced expression of these markers at 33°C suggests de-differentiation during culture at 
the permissive temperature. The endothelial phenotype of ciChEnCs is further confirmed by 
their ability to internalize acetylated LDL, tube formation on Matrigel, and increased ICAM-1 
expression in response to TNF-α. Angiogenesis inhibitors targeting VEGF have shown 
promise in treating the "wet" form of AMD (8). The strong response to angiogenic stimuli in 
Matrigel suggests that ciChEnCs can be applied in the screening of novel antiangiogenic 
drugs in a choriocapillary context. 
The choriocapillaris consists of endothelial cells which express fenestrations in response to 
VEGF produced by retinal pigment epithelial cells (33). The EMG-2 MV cell culture medium 
used in the current study is supplemented with VEGF and, accordingly, ciChEnC membranes 
were found to contain membrane indentations ~100 nm in diameter that resemble fenestral 
openings. While the density and symmetric distribution of ciChEnC fenestrations is reduced 
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compared to human choroidal endothelium in vivo (44), the scattered presence of 
fenestrations in endothelial cell membranes has also been described for primary choroidal 
microvascular endothelial cells when grown on fibronectin (19). However, the low density of 
fenestrations, as well as the low probability of capturing one complete, cytosol traversing 
fenestration in a single cut, makes confirmation of the cells’ choriocapillary origin by 
electron microscopy almost impossible. Therefore, the microvascular phenotype was 
additionally evaluated through the expression of choriocapillaris-associated protein markers. 
ciChEnCs stain positive for PLVAP, which has been shown to be selectively expressed in the 
choriocapillaris, but not larger choroidal vessel in vivo (35, 36, 38). Together, these results 
suggest that ciChEnCs have characteristics of choriocapillary endothelial cells in vitro. 
ciChEnCs expressed the glycosaminoglycans HS and chondroitin sulfate in vitro. Both 
components constitute the endothelial glycocalyx and have previously been detected in 
choroidal vessels using macular tissue sections (45). Since HS has been found to determine 
complement activation on self-surfaces by binding the complement inhibitor factor H (40, 
42), ciChEnCs could provide a suitable substrate for investigating complement control within 
the choriocapillary microenvironment. The endothelial glycocalyx furthermore impedes 
vascular permeability (39). Although the choriocapillaris is generally considered highly 
permeable to small molecules in order to supply the retina with nutrients and oxygen, early 
and current studies indicate a selective barrier function of choriocapillary vessels (46–49). 
Accordingly, ciChEnC monolayers were found to increase TEER across transwell inserts by 
~20 Ω*cm2 in vitro, matching reported TEER ranges (13.4 - 26.5 Ω*cm2) for other human, 
non-brain-derived microvascular endothelial cells (50). 
Finally, ciChEnCs show a significantly reduced affinity for the AMD-associated 402H variant 
of recombinant factor H CCP6-8 compared to the non-AMD 402Y variant, reflecting earlier 
results obtained using human retinal tissue (18). Since the disease-associated polymorphism 
alters the protein's specificity for heparin and HS (18, 28, 51), and the CCP6-8 region of 
factor H has been reported to be the primary binding site for HS in macular tissue (52), the 
reduced affinity of factor H for choroidal endothelium could result in unregulated alternative 
pathway activation in the choriocapillary microenvironment. 
In conclusion, a ciChEnC line with choriocapillary characteristics has successfully been 
established and should contribute to unraveling the pathogenic mechanisms of AMD within 
the choriocapillary microenvironment. 
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Supplementary figures 
 
Supplementary figure 1 - The factor H-specific antiserum has equal affinities for recombinant factor H CCP6-
8-402Y and -402H. Equal amounts of recombinant factor H complement control domains 6-8 (CCP6-8) 402H 
and 402Y were immobilized on microtiter plates and detected using a dilution series of factor H-specific 
antiserum. No difference in signal was observed between the two CCP6-8 variants at all antiserum dilutions. 
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Summary 
Failure to properly regulate the alternative pathway (AP) of complement activation on host 
tissues can result in the renal diseases atypical hemolytic uremic syndrome (aHUS) and C3 
glomerulopathy (C3G), as well as the ocular disease age-related macular degeneration 
(AMD). Endothelial cells play a central role in the pathogenesis of these diseases, as 
activation occurs in the endothelial microenvironment, i.e. on the endothelial glycocalyx, a 
thick carbohydrate layer which covers endothelial cells, and the underlying basal 
membranes. As introduced in chapter 1, malfunctioning of the factor H protein family, which 
includes complement factor H (FH), the main inhibitor of the AP on host tissues, and five 
factor H-related proteins (FHR1-5), has been strongly associated with disease development. 
Mutations in FH can interfere with FH binding to complement proteins and host-specific 
ligands such as the glycosaminoglycan heparan sulfate (HS) in the endothelial glycocalyx, or 
generate pathogenic FHR fusion proteins which compete with FH for ligands on host tissues, 
resulting in complement deregulation. HS can be extensively modified by sulfation, thereby 
generating specific binding sites for a large variety of proteins, and is an integral part of both 
the endothelial glycocalyx and basal membranes, i.e. the affected host tissues in aHUS, C3G 
and AMD. Although the involvement of HS in FH-mediated AP inhibition has been 
established, the structural heterogeneity of the glycosaminoglycan has so far prevented a 
detailed characterization of the interaction between HS and members of the FH protein 
family. Furthermore, the reason for the tissue-specific disease manifestation of aHUS, C3G 
and AMD is yet unexplained. In this thesis, complement regulation by the FH protein family 
was investigated in vitro in the context of the clinically affected tissues, i.e. the endothelial 
microenvironment of the glomerulus in the kidney and the choriocapillaris in the eye. Novel 
assays and in vitro models were developed and applied to study the functional effects of FH 
mutations and competition by FHRs, as well as relevant HS modifications for FH-mediated AP 
inhibition on endothelial cells. 
Previous studies of the interaction between FH protein family members and HS on host cell 
surfaces in vitro utilized surrogate tissues such as human umbilical vein endothelial cells or 
red blood cells. However, aHUS, C3G and AMD specifically manifest in kidneys and eyes, 
even though the entire vascular system is exposed to AP activation in the plasma, suggesting 
a tissue-specific determinant of disease manifestation. As reviewed in chapter 2, HS 
modifications and the resulting structural domains are frequently distinct between different 
organs and even different tissues within the same organ (1). Furthermore, binding of FH in 
the macula and the glomerulus has been shown to be differentially mediated by the N- and 
C-terminal HS binding sites within FH, supporting the importance of investigating FH-
mediated AP inhibition in the context of the clinically affected tissue. In chapter 3, the 
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interaction between full-length FH, a recombinant protein construct comprised of the two C-
terminal FH domains (FH19-20), and glycosaminoglycans (GAGs) in the endothelial glycocalyx 
was therefore studied using conditionally immortalized mouse glomerular endothelial cells 
(mGEnCs) (2). Both FH and FH19-20 bound to mGEnCs and their binding increased 
significantly after exposing the cells to inflammatory stimuli. By digesting different GAGs 
using specific glycosidases, the interaction was found to be partially mediated by HS, but not 
other GAGs in the endothelial glycocalyx. The contribution of HS to cell surface recruitment 
of FH was confirmed by competition using HS and heparin, which partially reduced mGEnC 
binding of full-length FH and FH19-20. The interaction between FH and FH19-20 and HS was 
differentially mediated by 2-O- and 6-O-sulfation. The observation that HS and heparin could 
not completely reduce FH and FH19-20 binding to mGEnCs suggested the presence of 
additional, compensating ligands in the mGEnC microenvironment, such as sialic acid and 
potentially murine von Willebrand factor (vWF). Since aHUS is a rare disease, making patient 
serum a scarce resource, a patient serum-independent assay was developed to quantify AP 
deregulation in the glomerular microenvironment due to aHUS-associated mutations. FH19-
20 was used to compete with FH in serum for ligands on mGEnCs, resulting in an increase in 
AP activity. Recombinant FH19-20 protein constructs containing aHUS-associated mutations 
lost their competitive ability to a degree which generally reflected the conservation of the 
mutated amino acid in FH. In conclusion, the study confirms the relevance of HS for FH 
binding to endothelial cells originating from the clinically affected tissue and describes a 
novel assay for pathogenicity screening of aHUS-associated FH mutations. 
The identification of FH ligands such as sialic acid or vWF, as well as the moderate decreases 
in FH and FH19-20 binding to mGEnCs after HS digestion and competition with (selectively 
desulfated) heparin suggested a redundancy of FH ligands in the glomerular endothelial 
microenvironment. To investigate the interaction between the FH protein family and HS 
without interference from other ligands, a protocol was adapted from the literature to purify 
GAGs from endothelial cells in vitro. Chapter 4 describes the observation that the obtained 
GAG extracts from cell monolayers and tissues contained a significant RNA contamination 
(3). Therefore, an adapted protocol including an RNase digestion step was developed, which 
efficiently removed the nucleic acid contaminants and enabled accurate quantification of 
GAG yields using cationic dyes and analysis of GAG composition by barium acetate agarose 
gel electrophoresis followed by visualization with Alcian blue and silver staining. Obtaining 
pure GAGs was particularly relevant for studying the interaction between FH and HS in 
absence of other ligands, as FH has been described to interact with several other ligands, 
including oligonucleotides (4, 5).  
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As models for the human glomerular endothelial microenvironment became available in the 
form of conditionally immortalized human glomerular endothelial cells (ciGEnCs), they were 
utilized in chapter 5 to investigate complement regulation by FH and type 1 FHRs (FHR1, 
FHR2 and FHR5) on glomerular endothelium in vitro. FH, FHR1 and FHR5 bound to ciGEnCs, 
whereas FHR2 barely interacted with the cells. However, binding of all tested FH protein 
family members was increased by covalent attachment of complement C3b in the 
glomerular endothelial microenvironment, suggesting a change in complement regulation 
which might follow an immunological insult in vivo. While the HS-binding FHR1 and FHR5 
deregulated the AP activity on ciGEnCs, FHR1 appeared to be more potent and increased 
terminal pathway activation on the cell surface. Furthermore, the role of specific HS 
biosynthetic enzymes in mediating the interaction between ciGEnCs and FH, FHR1 and FHR5 
was determined by RNA interference followed by binding assays. It appeared that FH and 
FHR1 binding was differentially reduced by silencing N-deacetylase/N-sulfotransferase 
(NDST) 1, 2-O- and 6-O-sulfotransferase, while HS domains generated by glucuronic acid 
epimerase and NDST2 activity mediated binding of both proteins. Binding of FHR5 to ciGEnCs 
was unaffected by RNA interference, possibly due to compensating interactions between 
FHR5 and non-HS ligands in the glomerular endothelial microenvironment, such as sialic 
acid, vWF and laminin-521 (6). Therefore, relevant HS modifications for FH, FHR1 and FHR5 
binding were investigated in the absence of non-HS ligands by competing for HS purified 
from the ciGEnC glycocalyx with selectively desulfated heparin. N-, 2-O and 6-O-desulfated 
heparin were unable to compete for FH binding to immobilized ciGEnC-derived HS, 
indicating that these sulfate modifications mediate the interaction between FH and HS. In 
contrast, N-, 2-O- and 6-O-desulfated heparin were found to compete for FHR1 and FHR5 
binding to immobilized ciGEnC HS, with 2-O- and 6-O-desulfated heparin being the most 
effective competitors. Importantly, 2-O-desulfated heparin reversed FHR1- and FHR5-
mediated AP activity deregulation on ciGEnCs and human umbilical vein endothelial cells. 
The ability of 2-O-desulfated heparin to compete for FHR1 and FHR5, but not FH binding to 
glomerular endothelial HS was preserved in smaller 2-O-desulfated heparin oligosaccharides 
(<hexasaccharides), thereby potentially enabling the exact structural characterization of 
competing oligosaccharides and facilitating a clinical application in treating C3G. 
The majority of research presented in this thesis focused on the interaction between the FH 
protein family and HS in the glomerular endothelial microenvironment, for which murine 
and human in vitro models were available as represented by conditionally immortalized cell 
lines. To enable investigation of FH-mediated complement regulation in another clinically 
affected tissue, the macula of the eye, a comparable in vitro model was generated by 
conditional immortalization of human choroidal endothelial cells (ciChEnCs) and 
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characterized in chapter 6 (7). ciChEnCs stably expressed endothelial cell marker proteins 
vascular endothelial cadherin and vWF in vitro, formed monolayers with barrier function and 
showed endothelial cell-specific responses to various stimuli, including acetylated low 
density lipoprotein internalization, upregulation of intercellular adhesion molecule-1 
expression and tube formation on Matrigel. Cells stained positively for plasmalemma vesicle-
associated protein, carbonic anhydrase IV and human leukocyte antigen class I proteins, 
which are associated with microvascular choroidal endothelium in vivo, suggesting that the 
cell line assumes characteristics of the choriocapillaris in vitro. GAG extractions from cell 
monolayers confirmed the expression of endothelial glycocalyx components chondroitin 
sulfate and HS. Finally, an AMD-associated FH polymorphism (Y402H) significantly decreased 
binding of a recombinant FH fragment containing the N-terminal HS binding site to ciChEnCs, 
thereby providing a potential mechanism for disease development. In conclusion, a novel in 
vitro model of the choriocapillary endothelium was successfully generated, which can be 
applied to investigate FH-mediated AP inhibition in the microenvironment of the clinically 
affected tissue in AMD. 
 
Future perspectives 
In addition to HS, FH has been found to interact with various other glycan and non-glycan 
ligands. Results obtained in chapters 3 and 5 indeed suggest that non-HS ligands in the 
endothelial microenvironment can at least partially compensate for the reduction in FH 
binding due to digestion of HS by glycosidases or manipulation of HS biosynthesis enzyme 
expression. The presence of multiple different glycan and protein ligands for FH binding in 
the endothelial microenvironment poses a number of questions: Which FH ligands can 
compensate for the loss of another, which are most relevant for AP inhibition and how many 
interactions have to fail to result in complement deregulation on host tissues?  
The interaction between FH and HS or sialic acid is particularly interesting. Both ligands are 
part of the endothelial glycocalyx and interact with several of the same amino acids within 
the C-terminus of FH (8, 9), suggesting that HS and sialic acid could compete with each other 
in the microenvironment of host cells. Many aHUS-associated FH mutants show impaired 
interactions with both heparin/HS and sialic acid (9–11). Although the affinity of FH for sialic 
acid is relatively weak (dissociation constants in the micro- to millimolar range), sialic acid 
contributes to complement regulation as FH domains 19 and 20 can simultaneously bind to 
both C3b and sialic acid (9). The presence of an additional, carbohydrate ligand on host 
tissues increases the avidity of the interaction between FH and C3b, which has also been 
suggested for HS (12). However, the size and density of the glycocalyx on endothelial cells, as 
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well as the location of AP activation within the endothelial microenvironment questions the 
relevance of sialic acid for complement regulation in a healthy glycocalyx. Sialic acids cap the 
branches of N- and O-linked glycans and glycosphingolipids (13), i.e. they are found in close 
proximity to the cell membrane. The glycocalyx can reach a thickness of several hundred 
nanometers and impedes the diffusion of large proteins across the (glomerular) endothelium 
(14–16). If AP activation occurs in the upper layers of the endothelial glycocalyx, HS may be 
the only ligand in sufficiently close proximity to allow simultaneous interaction with C3b. 
However, if glycocalyx components are degraded, e.g. due to increased expression of 
heparanase in response to (glomerular) inflammation (17, 18), the endothelial cell surface 
will be exposed and consequently sialoglycans and membrane-bound complement inhibitors 
will become more accessible for binding of complement factors. Therefore, the interaction 
between FH and sialic acid might provide a backup mechanism to ensure complement 
regulation following excessive damage to the endothelial glycocalyx.  
So far, very little is known about the interaction between FHRs and sialic acid, and further 
investigation of their ability to compete with FH for glycan ligands other than HS is 
warranted. The in vitro models and assays utilized and developed in this thesis can be 
applied to further dissect the relevance of sialic acid for complement regulation by the FH 
protein family. Sialic acid synthesis (SAS) inhibitors have been described (19), which similarly 
to the RNA interference approach used in chapter 5 could reduce sialic acid expression in the 
endothelial glycocalyx. Measuring FHR binding to SAS inhibitor-treated endothelial cells 
could determine the contribution of sialic acid to FHR binding in the endothelial 
microenvironment, especially if potential interference by HS is minimized by treating 
endothelial cells with heparinases. The AP activation assays described in chapter 5 using 
FHR-supplemented serum could then be performed on SAS inhibitor-treated endothelial 
cells to address whether interactions between FHRs and sialic acid contribute to AP 
deregulation on endothelial cells. 
The results presented in this thesis have been obtained using in vitro models of the 
endothelial microenvironment in the affected tissues, i.e. the glomerulus and the macula. 
While these models are most suitable for mechanistic studies, translation to the clinic will 
require reproduction of the results in an in vivo setting. While mouse models for aHUS and 
C3G have been described (20–22), the disease phenotypes occur due to deletion of the host 
tissue recognition domains of FH or deletion of the FH gene. Therefore, these mouse models 
cannot be directly applied to investigate complement regulation by HS and the FH protein 
family or screen novel HS-based drugs for their efficacy in vivo. However, since pathogenic 
FHR fusion proteins have been suggested to cause C3G through increased avidity for ligands 
on host tissues and thus increased competition with FH (23, 24), injection of these fusion 
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proteins in normal mice could result in novel models for human C3G. These models could 
then be used to screen novel HS-based drugs for their ability to restore AP regulation in the 
glomerular microenvironment in vivo. If human FHRs fail to compete with murine FH, the 
model could be further humanized by co-injecting pathogenic FHR fusion proteins with 
human FH into FH-deficient mice. Notably, human FH has previously been shown to restore 
the renal disease phenotype in FH-deficient mice (25, 26).  
In chapters 3 and 5, the interaction between FH, FHRs and HS as well as the effect of aHUS-
associated FH mutations on complement regulation on glomerular endothelial cell surfaces 
were investigated. Although the functional consequences of C-terminal FH mutations were 
originally determined using murine cells, the assay appears easily translatable to human 
endothelial cells (11) and could be performed using ciGEnCs to increase the diagnostic value. 
With the generation of the novel choroidal endothelial cell line described in chapter 6, 
analyses and assays described in this thesis can now also be performed in context of the 
choriocapillary microenvironment, i.e. the clinically affected tissue in AMD. Since the N- and 
C-terminal HS binding sites in FH mediate binding to ocular and renal tissues, respectively, 
and have different specificities for HS modifications (27), it will be interesting to determine 
which HS biosynthesis enzymes mediate FH binding to ciChEnCs. Furthermore, pure HS can 
now easily be obtained from ciGEnCs, ciChEnCs as well as non-renal, non-ocular 
microvascular endothelial cells using the adapted extraction protocol described in chapter 4. 
Evaluating the interaction with the N- and C-terminal HS binding sites of FH could easily 
support the role of HS as tissue-specific determinant of aHUS, C3G and AMD manifestations 
as proposed in chapter 2. Finally, recent studies point towards a crucial role of Bruch’s 
membrane and the choriocapillaris in controlling access and diffusion of complement 
proteins and inhibitors in Bruch’s membrane. To illustrate, factor H-like 1, the truncated 
splice variant of FH, can diffuse through Bruch’s membrane, whereas diffusion of full-length, 
glycosylated FH is impeded (28). Although Clark et al. focused on diffusion of complement 
proteins across Bruch’s membrane, choroidal endothelial cells also actively regulate the 
transport of serum proteins into Bruch’s membrane (29, 30). Since ciChEnCs have barrier 
function as indicated by the transendothelial electrical resistance, they could serve as a 
novel in vitro model for complement protein transport across the choriocapillary 
microenvironment.  
The results presented in this thesis underline the importance of interactions between the FH 
protein family and HS in the endothelial glycocalyx for complement regulation within the 
(glomerular) microenvironment. Importantly, the differential inhibition of FH and FHR 
binding to ciGEnC HS by 2-O- and 6-O-desulfated heparin observed in chapter 5 creates new 
approaches for treating C3G by selectively competing for FHR binding to the glomerular 
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endothelial glycocalyx. Particularly, competition with 2-O- or 6-O-desulfated heparin could 
improve the outcome of kidney transplantation in C3G patients with pathogenic FHR 
mutations, as complement activation contributes to acute transplant rejection and 
influences the adaptive immune response against the donor organ (31). Additionally, aHUS 
patients with mutations in the CFHR5 gene (32) might benefit from treatment with 2-O- or 6-
O-desulfated heparin as well. With the generation and screening of a 2-O-desulfated heparin 
oligosaccharide library, the first steps towards the development of novel HS-based drugs for 
treating C3G have been taken. Using 2-O-desulfated oligosaccharides to selectively compete 
pathogenic FHRs from glomerular endothelium while retaining FH binding in C3G patients 
will however require further characterization of the specific HS structures which bind to 
FHRs but not FH. The generated small oligosaccharide fractions provide a convenient starting 
point for structural analysis. Recent developments in the analysis of HS using mass 
spectrometry could assist in the structural characterization of these HS oligosaccharides (33, 
34).  
Although relevant HS modifications for FH, FHR1 and FHR5 binding to glomerular endothelial 
HS have originally been identified in the context of C3G, deletions in FHR proteins have been 
shown to be protective against diseases such as AMD (35) or IgA nephropathy (36). 2-O-
desulfated heparin also reversed FHR-mediated deregulation on non-renal endothelial cells 
in vitro, suggesting that these novel drugs might not be exclusive to treating glomerular 
complement-mediated diseases. Targeted manipulation of the FH/FHR balance on host 
tissues might therefore be beneficial in non-renal diseases such as AMD as well. 
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Samenvatting 
Disregulatie van de alternatieve route (AR) van complementactivatie kan leiden tot de 
nierziekten atypisch hemolytisch uremisch syndroom (aHUS) en C3 glomerulopathie (C3G), 
en de aan leeftijd gerelateerde oogziekte maculadegeneratie (LMD). Endotheelcellen staan 
centraal in de pathogenese van deze ziekten, omdat activatie plaatsvindt in de micro-
omgeving van het endotheel, voornamelijk in de glycocalyx, een dikke suikerlaag op 
endotheelcellen, en de onderliggende basaalmembranen. Zoals geïntroduceerd in hoofdstuk 
1, zijn disfuncties van de factor H eiwitfamilie, inclusief complement factor H (FH), de 
belangrijkste regulator van de AR op lichaamseigen weefsels, en vijf factor H-gerelateerde 
eiwitten (FHR1-5), sterk geassocieerd met het ontstaan van aHUS, C3G en LMD. Mutaties in 
FH kunnen interfereren met de binding van FH aan complement eiwitten en andere 
lichaamseigen liganden zoals het glycosaminoglycaan (GAG) heparansulfaat (HS). Andere 
mutaties kunnen leiden tot ziekteverwekkende FHR fusie–eiwitten die met FH concurreren 
voor liganden op lichaamseigen weefsel, wat vervolgens leidt tot complement deregulatie. 
HS kan extensief worden gemodificeerd door sulfatering, wat bindingsplaatsen genereerd 
voor een groot aantal verschillende eiwitten, en is een belangrijk onderdeel van de 
glycocalyx en basaalmembranen, de getroffen structuren in aHUS, C3G en LMD. Hoewel de 
rol van HS in FH-gemedieerde AR inhibitie al lang bekend is, wordt een gedetailleerde 
karakterisering van de interactie tussen HS en leden van de FH eiwitfamilie tot nu toe 
bemoeilijkt door de structurele heterogeniteit van de GAGs. Verder is de reden voor de 
weefselspecifieke manifestatie van aHUS, C3G en LMD nog onbekend. In dit proefschrift 
werd complement regulatie door de FH eiwitfamilie onderzocht in vitro in de context van de 
klinisch aangedane weefsels, dat wil zeggen de micro-omgeving van glomerulaire- en 
oculaire endotheelcellen. Nieuwe methoden en in vitro modellen zijn ontwikkeld en 
toegepast om de functionele gevolgen te bestuderen van FH mutaties en competitie door 
FHRs, alsmede de relevantie van HS modificaties voor FH-gemedieerde AR regulatie op 
endotheelcellen. 
Eerdere studies over de interactie tussen de FH eiwitfamilie en HS op lichaamseigen 
celoppervlaktes in vitro maakten gebruik van minder relevante modellen zoals humaan 
navelstreng endotheel of rode bloedcellen. aHUS, C3G en LMD ontstaan echter specifiek in 
de nieren en ogen, hoewel het hele vasculaire systeem is blootgesteld aan plasma en dus AR 
activatie, hetgeen een weefselspecifieke oorzaak van de ziekteontwikkeling suggereert. 
Zoals besproken in hoofdstuk 2, zijn HS modificaties en de resulterende structurele HS 
domeinen vaak verschillend, wanneer verschillende organen en zelfs verschillende weefsel 
in hetzelfde orgaan worden vergeleken (1). Verder is de binding van FH in de macula en de 
glomerulus differentieel gemedieerd door de N- en C-terminale HS bindingsplaatsen in FH, 
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hetgeen het belang benadrukt om FH-gemedieerde AR inhibitie te onderzoeken in de 
context van het klinisch aangedane weefsel. Daarom is in hoofdstuk 3 de interactie tussen 
FH, een recombinant eiwit bestaande uit de twee C-terminale FH domainen (FH19-20), en 
GAGs in de glycocalyx onderzocht op muis glomerulaire endotheelcellen (mGEnCs) (2). FH en 
FH19-20 bonden aan mGEnCs, en de binding nam significant toe na blootstelling van de 
cellen aan inflammatoire stimuli. Door GAGs op het celoppervlak af te breken met specifieke 
glycosidases, werd aangetoond dat FH en FH19-20 binding aan mGEnCs gedeeltelijk is 
gemedieerd door HS, en niet door andere GAGs in de glycocalyx. De bijdrage van HS aan 
mGEnC binding werd bevestigd door competitieproeven met HS en heparine, waardoor 
binding van FH en FH19-20 gedeeltelijk werd gereduceerd. De interactie tussen FH of FH19-
20 en HS werd differentieel gemedieerd door 2-O- en 6-O-sulfatering van HS. De observatie 
dat HS en heparine niet in staat zijn om binding van FH en FH19-20 aan mGEnCs volledig te 
reduceren, wijst op de aanwezigheid van andere FH liganden in de micro-omgeving van 
mGEnCs, zoals siaalzuur en mogelijk von Willebrand factor (vWF). Omdat aHUS een 
zeldzame ziekte is en aHUS patiëntenserum weinig beschikbaar is, werd een 
patiëntenserum-onafhankelijke assay ontwikkeld om AR deregulatie in de glomerulaire 
micro-omgeving te kwantificeren. FH19-20 werd gebruikt om FH te verdringen van liganden 
op mGEnCs, hetgeen leidde tot een toegenomen AR activiteit. Recombinante FH19-20 
eiwitten, die aHUS-geassocieerde mutaties bevatten, verloren hun competitief vermogen 
waarbij het gemuteerde aminozuur in FH geconserveerd is wanneer verschillende soorten 
worden vergeleken. Concluderend, het onderzoek in dit proefschrift bevestigt de rol van HS 
in FH binding aan endotheelcellen normaliter aanwezig in klinisch aangedaan weefsel en 
beschrijft een nieuwe assay waarmee de pathogeniciteit van onbekende aHUS mutanten 
bestudeerd kan worden. 
De binding van FH aan liganden zoals siaalzuur of vWF, en de matige vermindering van FH en 
FH19-20 binding aan mGEnCs na digestie van HS of competitie met (selectief 
gedesulfateerde) heparine, wijst op een redundantie van FH liganden in de micro-omgeving 
van glomerulair endotheel. Om de interactie tussen de FH eiwitfamilie en HS te kunnen 
onderzoeken, in afwezigheid van voornoemde interfererende liganden, is een protocol uit de 
literatuur toegepast om GAGs op te zuiveren van gekweekte endotheelcellen. Hoofdstuk 4 
beschrijft de observatie dat GAGs verkregen via het gepubliceerde protocol uit gekweekte 
cellen en weefsels, zijn gecontamineerd met RNA (3). Daarom werd naast de enzymatische 
afbraak van DNA ook de enzymatische afbraak van RNA toegevoegd in een aangepast 
protocol , resulterend in volledige verwijdering van nucleïnezuur verontreinigingen, 
waardoor een nauwkeurige kwantificering van GAG-opbrengsten en analyse van GAG 
composities mogelijk werden met behulp van bariumacetaat gel-elektroforese gevolgd door 
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kleuring met Alcian blue en zilver. Het verkrijgen van zuivere GAGs was bijzonder belangrijk 
om de interactie tussen FH en HS in afwezigheid van andere liganden te kunnen bestuderen, 
omdat zoals gezegd, FH ook bindt aan niet-HS liganden, inclusief nucleïnezuren (4, 5). 
Zodra modellen voor de humane glomerulaire micro-omgeving beschikbaar kwamen in de 
vorm van conditioneel geïmmortaliseerde humane glomerulaire endotheelcellen (ciGEnCs), 
werden deze gebruikt in hoofdstuk 5 om complementregulatie door FH en type 1 FHRs 
(FHR1, FHR2 en FHR5) te bestuderen. FH, FHR1 en FHR5 bonden aan ciGEnCs, terwijl FHR2 
nauwelijks bond aan deze cellen. Binding van FH en FHRs nam toe nadat C3b covalent werd 
gebonden in de glomerulaire micro-omgeving, wat mogelijk wijst op een verandering in 
complementregulatie na een immunologische insult dat leidt tot C3b binding aan 
glomerulair endotheel in vivo. FHR1 en FHR5 dereguleerden beide de AR activiteit op 
ciGEnCs, waarbij FHR1 ook leidde tot deregulatie van de terminale route op het 
celoppervlak. Verder werd de rol bepaald van specifieke HS-modificerende enzymen in de 
interactie tussen ciGEnCs en FH, FHR1 en FHR5 door te interfereren met de mRNA expressie 
van deze enzymen en vervolgens de binding van FH, FHR1 en FHR5 aan ciGEnCs te meten. 
Het bleek dat FH en FHR1 binding differentieel werd gereduceerd door silencing van N-
deacetylase/N-sulfotransferase (NDST)- 1, 2-O- en 6-O-sulfotransferase mRNA expressie. HS 
domeinen gegenereerd door glucuronzuur epimerase en NDST2 activiteit droegen bij aan 
binding van beide FH en FHR1. Binding van FHR5 werd niet gereduceerd door RNA-
interferentie van HS-modificerende enzymen, waarschijnlijk omdat niet-HS liganden in de 
glomerulaire endotheliale micro-omgeving, zoals siaalzuur, vWF en laminin-521 (6), kunnen 
dienen als alternatieve liganden voor FHR5 na veranderingen in de HS domeinen. Daarom 
werden de belangrijke HS modificaties voor binding van FH, FHR1 en FHR5 onderzocht in 
afwezigheid van niet-HS liganden zoals siaalzuur, vWF en laminins, door de FH en FHR 
eiwitten te verdringen van opgezuiverde HS uit de ciGEnC glycocalyx door competitie met 
selectief gedesulfateerd heparine. N-, 2-O- of 6-O-gedesulfateerde heparine was niet in staat 
om FH te verdringen van ciGEnC HS, wat erop wijst dat deze modificaties belangrijk zijn voor 
de interactie tussen HS en FH. Tegenovergesteld blokkeerde N-, 2-O- of 6-O-gedesulfateerde 
heparine de interactie tussen FHR1 of FHR5 met HS afkomstig van ciGEnC, waarbij 2-O- en 6-
O-gedesulfateerde heparine het meest effectief was. Van bijzonder belang is de waarneming 
dat 2-O-gedesulfateerd heparine de FHR1- en FHR5-gemedieerde AR deregulatie 
(gedeeltelijk) kon herstellen op ciGEnCs en humane navelstreng endotheelcellen. Korte 2-O-
gedesulfateerde oligosacchariden (<hexasacchariden) waren ook in staat om FHR1 en FHR5, 
echter niet FH, te verdringen van HS afkomstig van ciGEnC. De beperkte grootte van deze 
oligosacchariden maakt hun structurele karakterisering en eventuele klinische toepassing 
mogelijk. 
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Het grootste deel van het onderzoek dat in dit proefschrift is beschreven, is gericht op de 
interactie tussen FH en HS in de micro-omgeving van glomerulaire endotheel, waarvoor 
muis- en humane in vitro modellen beschikbaar waren in de vorm van conditioneel 
geïmmortaliseerde cellen. Om FH-gemedieerde complement regulatie te kunnen bestuderen 
in een ander klinisch aangedaan weefsel, de retinale macula, werd er een vergelijkbaar in 
vitro model ontwikkeld door choroïdale oogendotheelcellen conditioneel te immortaliseren 
(ciChEnCs) en te karakteriseren in hoofdstuk 6 (7). ciChEnCs behielden een stabiele expressie 
van de endotheelcel marker vascular endothelial cadherin en vWF in vitro, vormden 
monolagen met barrièrefunctie en lieten endotheelcel-specifieke reacties zien op diverse 
stimuli, zoals internalisering van geacetyleerd “low density lipoprotein”, opregulatie van 
“intercellular adhesion molecule-1” en buisjesvorming op Matrigel. De cellen kleurden 
positief voor “plasmalemma vesicle-associated protein”, carbonzuur anhydrase IV en 
humaan leukocyt antigeen klasse I-eiwitten, welke geassocieerd zijn met microvasculair 
choroïdaal endotheel in vivo, hetgeen erop wijst dat de cellen in vitro lijken op de 
choriocapillaris. GAG opzuivering van ciGEnCs monolagen bevestigde de expressie van de 
glycocalyx componenten chondroïtine sulfaat en HS. Een LMD-geassocieerd FH 
polymorfisme (Y402H) reduceerde significant de ciChEnC binding van een recombinant FH 
fragment van de N-terminale HS bindingsplaats in FH, wat mogelijk een mechanistische 
verklaring geeft voor het ontstaan van LMD. Concluderend, er is een nieuwe in vitro model 
gegenereerd van de choriocapillaris, waarmee FH-gemedieerde AR inhibitie kan worden 
onderzocht in de micro-omgeving van het klinisch aangedaan weefsel in LMD. 
 
Toekomstperspectieven 
Naast HS gaat FH ook interacties aan met andere suiker en eiwitliganden. De resultaten in 
hoofdstuk 3 en 5 wijzen er inderdaad op dat niet-HS liganden in de micro-omgeving van 
endotheel voor een deel kunnen compenseren voor de afname in FH binding als gevolg van 
digestie van HS met glycosidases of manipulatie van de expressie van HS modificerende 
enzymen. De aanwezigheid van meerde suiker- en eiwitliganden in de micro-omgeving van 
endotheel roept een aantal vragen op: Welke liganden kunnen compenseren voor het verlies 
van een ander, welke liganden zijn het meest belangrijk voor inhibitie van de AR en hoeveel 
interacties moeten falen voordat deregulatie van de AR ontstaat op lichaamseigen weefsels? 
De interactie tussen FH en HS of siaalzuur is bijzonder interessant. Beide liganden zijn 
onderdeel van de glycocalyx en binden aan dezelfde aminozuren in de C-terminale 
bindingsplaats van FH (8, 9), waardoor HS en siaalzuur waarschijnlijk met elkaar concurreren 
voor FH binding in de micro-omgeving van lichaamseigen cellen. Meerdere aHUS-
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geassocieerde FH mutanten laten een zwakkere interactie zien met zowel heparine/HS als 
siaalzuur (9–11). Hoewel de affiniteit van FH voor siaalzuur relatief zwak is (met 
dissociatieconstanten op micro- tot millimolair niveau), speelt siaalzuur een rol in 
complement regulatie omdat FH domeinen 19 en 20 tegelijk kunnen binden aan zowel C3b 
als siaalzuur (9). De aanwezigheid van een additionele suikerligand op lichaamseigen 
weefsels verhoogt de aviditeit van de interactie tussen FH en C3b, wat ook is beschreven 
voor HS (12). De grootte en dichtheid van de glycocalyx op endotheelcellen en de locatie van 
AR activatie in de micro-omgeving van endotheel zou echter het belang van siaalzuur voor 
complementregulatie kunnen beïnvloeden. Siaalzuur zit aan het eind van sommige vertakte 
N- of O-gebonden suikers en glycosphingolipides (13), waardoor ze zich dicht bij het 
celoppervlak bevinden. De glycocalyx kan een dikte bereiken van meer dan 100 nanometer 
en vertraagt daardoor de diffusie van grotere eiwitten over het (glomerulaire) endotheel 
(14–16). Wanneer AR activatie bovenop de glycocalyx plaatsvindt, zal HS waarschijnlijk de 
enige ligand zijn die tegelijkertijd C3b en FH kan binden. Wanneer echter de glycocalyx 
wordt afgebroken, bijvoorbeeld door heparanase als reactie op glomerulaire ontsteking (17, 
18), wordt het celoppervlak blootgesteld, waardoor siaalzuur en complement inhibitors op 
het celoppervlak beschikbaar komen voor binding van complementfactoren. De interactie 
tussen FH en siaalzuur zou dus kunnen compenseren voor schade aan de glycocalyx en 
verlies van HS tijdens complementactivatie en ontsteking. 
Tot nu toe is er weinig bekend over de interactie tussen FHRs en siaalzuur en is er verder 
onderzoek vereist. De in vitro modellen en assays die in dit proefschrift zijn beschreven 
zouden gebruikt kunnen worden om de rol van siaalzuur in complementregulatie door de FH 
eiwitfamilie te onderzoeken. Siaalzuur synthese (SAS) remmers zijn beschreven (19), die 
vergelijkbaar met de RNA interferentie in hoofdstuk 5 gebruikt zouden kunnen worden om 
de siaalzuurexpressie in de glycocalyx te reduceren. Door FHR binding te meten aan 
endotheelcellen die behandeld zijn met deze SAS remmers, zou de bijdrage van siaalzuur aan 
FHR binding in de micro-omgeving van endotheel bepaald kunnen worden. Vooral als 
mogelijk interferentie door HS vooraf wordt gereduceerd door de cellen te incuberen met 
heparinases. De in hoofdstuk 5 beschreven AR activiteitsassays met FHR-gesupplementeerd 
humaan serum zouden dan kunnen worden toegepast op met SAS remmer-behandelde 
endotheelcellen om te bepalen of siaalzuur bijdraagt aan AR deregulatie op endotheelcellen. 
De resultaten van dit proefschrift zijn behaald door gebruik te maken van (nieuwe) in vitro 
modellen voor de micro-omgeving van endotheel in normaliter aanwezig in klinisch 
aangedane weefsels, dat wil zeggen de glomerulus in de nier en de macula in het oog. 
Hoewel deze modellen geschikt zijn voor mechanistische studies, zullen de resultaten eerst 
gereproduceerd moeten worden in een in vivo omgeving voordat ze klinisch kunnen worden 
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toegepast. Alhoewel muismodellen zijn beschreven voor aHUS en C3G (20–22), ontstaan de 
ziektebeelden in deze modellen omdat of het FH gen, of de C-terminale HS 
herkenningsdomeinen in FH zijn verwijderd. Daardoor kunnen deze muismodellen niet 
worden gebruikt om complementregulatie door HS, FH en FHRs, of nieuwe op HS-
gebaseerde drugs te testen. Er zijn echter FHR fusie eiwitten beschreven, die een verhoogde 
aviditeit tonen voor liganden op het celoppervlak en dus versterkt kunnen concurreren met 
FH (23, 24). Door deze mutanten te injecteren in normale muizen zou een nieuw model voor 
humaan C3G kunnen worden opgezet. Dit model zou vervolgens gebruikt kunnen worden 
om op HS-gebaseerde drugs te testen op hun vermogen om inhibitie van AR te herstellen op 
glomerulair endotheel in vivo. Als humane FHRs niet kunnen competeren met muis FH, zou 
het model verder gehumaniseerd kunnen worden door FHR fusiemutanten samen met 
humaan FH te injecteren in FH-deficiënte muizen, omdat eerder is aangetoond dat humaan 
FH het ziektebeeld in FH-deficiënte muizen kan herstellen (25, 26). 
In hoofdstukken 3 en 5 zijn de interacties tussen FH, FHRs en HS en het effect van met aHUS-
geassocieerde FH mutaties op complementregulatie op glomerulair endotheel onderzocht. 
Hoewel de functionele gevolgen van C-terminale FH mutaties oorspronkelijk zijn bepaald op 
muiscellen, blijkt de assay gemakkelijk vertaalbaar te zijn naar humane endotheelcellen (11) 
en zou daarom ook op ciGEnCs toegepast kunnen worden om de diagnostische waarde te 
verhogen. Door de ontwikkeling van een nieuwe choroïdale endotheelcellijn, zoals 
beschreven in hoofdstuk 6, kunnen de analyses en assays zoals beschreven in dit proefschrift 
worden toegepast in de context van de micro-omgeving van de choriocapillaris, het klinisch 
aangedaan weefsel in LMD. Omdat de N- en C-terminale bindingsplaatsen in FH de binding 
mediëren aan respectievelijk oog- en nierweefsel en specifiek zijn voor verschillende HS 
modificaties (27), zal het interessant zijn om te bepalen welke HS modificerende enzymen 
van belang zijn voor de binding van FH aan ciChEnCs. Verder kan nu zuiver HS worden 
verkregen van ciGEnCs, ciChEnCs en microvasculair endotheel uit andere weefsel dan nier en 
oog met behulp van het in hoofdstuk 4 beschreven nieuwe extractieprotocol. Door de 
binding van de N- en C-terminale HS indingsplaatsen in FH aan ciGEnC en ciChEnC te bepalen 
zou de rol van HS als weefselspecifieke determinant van aHUS, C3G en LMD zoals 
voorgesteld in hoofdstuk 2 bevestigd kunnen worden. Ten slotte wijzen recente studies op 
een centrale rol van Bruch’s membraan en de choriocapillaris in het bepalen van 
beschikbaarheid en diffusie van complementeiwitten en remmers in Bruch’s membraan. 
Bijvoorbeeld, factor H-like 1, de splice-variant van FH, kan diffunderen door Bruch’s 
membraan, terwijl geglycosileerd FH wordt tegengehouden (28). Hoewel Clark et al. zich in 
hun studies richtten op diffusie in Bruch’s membrane, spelen choroïdale endotheelcellen ook 
een belangrijke rol door actief het transport van serumeiwitten naar Bruch’s membraan te 
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reguleren (29, 30). Omdat ciChEnCs een barrièrefunctie hebben, zoals aangetoond door de 
transendotheliale electrische weerstand, zouden deze cellen kunnen worden gebruikt als 
nieuw in vitro model voor complementeiwit transport door de choriocapillaris. 
De resultaten beschreven in dit proefschrift bevestigen de belangrijke rol van interacties 
tussen FH en HS in de glycocalyx in complementregulatie in de (glomerulaire) micro-
omgeving. Van bijzonder belang voor een potentiële nieuwe behandeling van C3G is de 
observatie in hoofdstuk 5 dat 2-O- of 6-O-gedesulfateerde heparines specifiek FHR1 en 
FHR5, maar niet FH, kunnen verdringen van ciGEnC HS. Verder zou competitie met 2-O- of 6-
O-gedesulfateerde heparines de uitkomst van niertransplantatie in C3G patiënten met 
pathogene FHR mutaties kunnen verbeteren, omdat complementactivatie bijdraagt aan 
acute rejectie en de adaptieve immuunrespons kan beïnvloeden (31). 2-O- of 6-O-
gedesulfateerde heparines zouden ook kunnen worden gebruikt om aHUS patiënten te 
behandelen met mutaties in het CFHR5 gen (32). Met de identificatie van 2-O-
gedesulfateerde heparine oligosacchariden die specifiek FHR1 en FHR5, maar niet FH, 
kunnen verdringen, zijn de belangrijke eerste stappen genomen op weg naar een nieuwe 
behandeling voor C3G. Klinische toepassing van deze oligosaccharides vereist echter een 
uitgebreide karakterisering van de specifieke HS structuren die binden aan FHRs maar niet 
FH. De opgezuiverde korte oligosaccharide-fracties vormen door hun beperkte grootte een 
goed begin voor structurele analyse en later klinische toepassing. Recente ontwikkelingen in 
HS analyse met massaspectroscopie zouden de structurele karakterisering van 2-O-
gedesulfateerde oligosacchariden verder kunnen ondersteunen (33, 34).  
Hoewel de relevante HS modificaties voor FH, FHR1 en FHR5 binding aan glomerulair 
endotheel HS oorspronkelijk zijn bepaald in de context van C3G, zijn deleties van FHR eiwit 
als beschermend aangetoond in ziekten zoals LMD (35) of IgA nefropathie (36). 2-O-
gesulfateerd heparine herstelde ook complementregulatie op niet-nierafkomstige 
endotheelcellen in vitro, waardoor de potentiële therapie niet specifiek lijkt te zijn voor 
glomerulaire ziekten. Doelgerichte manipulatie van de FH/FHR balans op lichaamseigen 
weefsels zou dus ook bevorderlijk kunnen zijn bij de behandeling van niet-nier geassocieerde 
ziekten zoals AMD. 
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